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ABSTRACT
A series of studies are presented which attempt to answer specific
questions concerning the androgen-behaviour relationship in the adult
human male.
A critical review of the literature revealed that the
androgen-behaviour relationship in the human male has been poorly
researched. In particular, unsatisfactory experimental methodology and
inexact operational definitions of behaviour have been employed. In
the studies presented in this thesis an attempt was made to
specifically define dysfunctional states and to carefully monitor the
resultant behavioural effects of androgen administration.
In the hypogonadal man, a dose-dependent relationship was
demonstrated for specific aspects of sexual functioning, in particular
self-rated interest in sex and frequency of morning erections appeared
to vary with androgen replacement dose.
In the eugonadal man, intramuscular depot injections of
testosterone were shown to be the best method of overcoming the
homeostatic mechanisms and increasing circulating androgen levels in
the blood.
High dosage testosterone administration acted to increase the
level of sexual interest of a group of men whose presenting complaint
was loss of libido. This treatment, however, did not result in an
increased frequency of sexual activity. High dosage testosterone
administration had no behavioural effect, compared with placebo, in a
group of eugonadal men presenting with erectile dysfunction.
Androgen administration appeared to have a stimulatory effect on
the nocturnal erections of a group of hypogonadal men, although
xiii
androgen withdrawal resulted in differing rates of diminution of
nocturnal erectile response. In contrast, androgen administration had
no effect on the nocturnal erections of a group of eugonadal men
presenting with erectile dysfunction.
Androgen administration to hypogonadal and eugonadal men had a
general lack of effect on a series of psychometric test scores, which
measure various aspects of cognitive functioning and personality.
(Previous investigators had proposed that these test scores were
correlated with circulating androgen levels).
A case study is presented, reporting the lack of behavioural
effect of oral testosterone undecanoate administration in an
institutionalised hypogonadal man who had previously responded very
aggressively to testosterone injections.
The implications of these experimental findings are discussed in
relation to the results of previous studies.
xiv
CHAPTER 1
GENERAL INTRODUCTION AND LITERATURE REVIEW
1
1.1 HISTORICAL INTRODUCTION
For centuries, the products of the testes have been thought to
play an important functional role in the genesis and maintenance of
behavioural masculinity. Radical reduction of circulating androgen
levels, i.e. castration, has been carried out on man and animals since
pre-historic times (Medvei, 1982). However, to this day, the exact
behavioural effects of circulating androgens in man remains to a large
extent a mystery.
Animal evidence (see reviews by Davidson, 1972; Davidson and
Levine, 1972) suggest that androgens are necessary at critical periods
in development in order to organise the central nervous system in a
manner conducive to later adult male behaviour, which is in turn
dependent on circulating androgen levels in adulthood. The exact
behavioural functions of circulating androgens in adult men, however,
have yet to be elucidated. Historically, behavioural observations have
been confined largely to the effects of castration.
Castration of male animals has been carried out for four main
reasons:-
(a) for gastronomic purposes, as gelded animals tend to put on fat and
give a more tender meat (Needham Ft Gwei-Djen, 1968)
(b) to induce sterility
(c) to curb aggression, e.g. in the horse
(d) in order to use the testicular tissue for pharmaceutical
preparations (see below).
The behavioural effects of this operation, principally diminished
sexual behaviour and increased passivitiy, have been known to students
of animal husbandry since described by Aristotle (384-322 BC).
Ken have been castrated for a variety of medical and social
reasons:-
(a) as a form of punishment for criminals (Heim and Hursch, 1979)
(b) as a form of psychiatric treatment with the aim of reducing
aggressiveness or deviant sexual behaviour, e.g. as recently as this
century, castration was claimed to be effective in the "treatment" of
masturbation in adolescent boys (Flood, 1901)
(c) as a means of ensuring lack of potency, e.g. the eunuchoid
guardians of the harem in ancient Rome and Egypt
(d) as a form of surgical therapy, e.g., in the treatment of testicular
carcinoma
(e) as a means of preventing development of the secondary sex
character!stics, e.g. the castrati singers of 18th and 19th century
Italy.
The loss of sexual potency often displayed by castrated men led
Susruta as long ago as 1400 BC to recommend the eating of animal
testicular tissue as a treatnent for sexual impotence (Newarla, 1943).
Pliny the Flder made the same recommendation, though much later in tine
(23-79 AD) and Kesue the Elder (777-837 AO) prescribed testicles as an
aphrodisiac (both cited in Kedvei , 1982). Surprisingly it was not
until 1132 AD that Hsu Shu-Wei proposed the use of testicular extracts
as replacement therapy for male hypogonadism (Needham and Gwei-Djen,
1968). These testicular preparations were unlikely to have had any
more than a placebo effect, principally because the oral route leads to
inactivation of the bio-active testicular products (principally
testosterone) by the liver. However, Needham and Gwei-Pjen (19G8)
suggested that the administration of animal testicular tissue by the
mouth, if in significant quantity, could have had reasonably
significant effects. This is extremely unlikely, as Nieschlag and
Freischem (1982) have calculated that approximately 3 kg of animal
testes would have to be consumed in order to equal the daily
testosterone production of a normal adult male; even then the steroid
would be completely and rapidly inactivated in the liver.
As Newarla (1943) points out, from the middle ages until the turn
of the century, little progress was made in our understanding of the
behavioural effects of androgens in man. This field of research,
however, received much attention in 1889 when Brown-Sequard published
his famous and controversial work on the effects of self-administered
injections of testicular extract. He claimed, at the age of
seventy-two, an improvement in general health, muscular strength and
appetite, as well as improvement in his mental facilities.
Unfortunately, this uncontrolled study, together with subsequent
extravagant claims for the rejuvenative effects of testicular extract
injections led many to try Brown-Sequard's treatment. As this
"therapy" was almost certainly useless, this led to many seekers of
perpetual youth being extremely dissapointed with the results. In
reviewing the effects of the Brown-Sequard (1889) study, Newarla (1943)
states "The susceptibility of many minds in matters pertaining to sex
and the false hopes raised by extravagant claims led inevitably in a
pendulum fashion to a viewpoint strongly antagonistic to the acceptance
of the efficacy of any testicular substances".
This negative attitude, reinforced by the lack of therapeutic
success reported for testosterone treatment in men complaining of
erectile impotence (see section 1.4) has persisted over the last
century and has resulted in a lack of properly controlled experiments
designed to investigate the role androgens play in the regulation and
expression of behaviour in the adult human male. To quote Davidson and
Levine (1972) "One cannot fail to note in current and past literature
the impressive dearth of definitive studies on the endocrinology of
human sexual behaviour. In this vacuum, inadequate clinical
impressions and pseudodata often masquerade as well established
phenomena. There is a great need for large scale investigations of
endocrine-sexual behaviour relationships in human males and females
using acceptably objective behavioural criteria and the appropriate
controls".
Some progress has been made in the last decade to fill the gap
indicated by Davidson and Levine (1972), but it is fair to say that the
precise relationships between androgens and behaviour in man are still
unknown. In this thesis an attempt is made to address some of the
outstanding questions.
1.2 ANDROGEN-BEHAVIOUR RELATIONSHIPS TO BE INVESTIGATED
As will become apparent in the review of the literature that
follows (1.3-1.8), there are many hypothesised relationships between
androgens and behaviour in men. It was therefore necessary to select
out what were, in the author's opinion, the most theoretically
important and promising topics for investigation. In general, the
approach taken by the author has been an experimental rather than a
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correlational one, in that behavioural response to endocrine
manipulation in the hypogonadal and eugonadal man has been studied. In
particular, the studies have focused on the effect (or lack of effect)
of androgen administration on sexual behaviour (i.e. sexual activity,
sexual interest and erectile function), mood state, personality and
cognitive functioning.
The specific questions which the author has attempted to answer in
this thesis are:-
(1) Is there a relationship between androgen replacement dose and
behavioural response in the hypogonadal man, and what aspects of
behaviour are affected by androgen replacement? (Chapter 3)
(2) In the eugonadal man, what is the best method of overcoming the
gonadal steroid homeostatic control mechanisms in order to raise
circulating androgen levels so that behavioural responses to endocrine
manipulation can be studied? (Chapter 4)
(3) Is high dosage testosterone administration an effective form of
treatment for eugonadal men complaining of reduced sexual interest?
(Chapter 5)
(4) Is high dosage testosterone administration an effective form of
treatment for eugoriadal men complaining of erectile dysfunction?
(Chapter 6)
(5) Does androgen administration have an effect on nocturnal erectile
function in hypogonadal and eugonadal men? (Chapter 7)
(6) Does androgen administration have an effect on personality measures
and cognitive functioning in hypogonadal and eugonadal men? (Chapter 8)
(7) Does androgen administration have an effect on aggressive behaviour




1.3 HYPOGONADISM IN THE MALE-BEHAVIOURAL EFFECTS OF ANDROGEN
REPLACEMENT
Hypogonadism in the male (i.e. a marked reduction or absence of
normal levels of circulating androgens) is a well documented clinical
phenomenon (Nieschlag and Freischem, 1982). Uncontrolled clinical
reports have suggested that the most common behavioural consequences of
male hypogonadism are a reduction in the level of sexual interest, an
increased incidence of erectile difficulties and a marked reduction in
the frequency of overt sexual activity, all of which can be improved
following androgen replacement therapy (Whitelaw, 1958; Beumont et
al., 1972; Franchimont _et _al_., 1978; Maisey et al., 1981).
Surprisingly, it is only in the last four years that
methodologically acceptable studies have been carried out which have
conclusively demonstrated that exogenous androgen administration is
superior to placebo with respect to beneficial effects on the sexual
behaviour of the hypogonadal man (Davidson et _al_., 1979; Skakkebaek
et al., 1981).
1.3.1 Androgen Effects on Sexuality-Behavioural Mechanism of Action
"No clinician or researcher who has observed a hypogonadal patient
begin his transformation from a eunuchoid state to renewed sexuality at
the touch of a needle containing testosterone can fail to experience
considerable wonder over how the hormone works" (Davidson et al.,
To date, there have been three major hypotheses presented
concerning the mechanisms underlying the behavioural effect of androgen
replacement in hypogonadal men.
1.3.1.1 Androgens Act Primarily on General Metabolism and Mood?
Kinsey and his colleagues proposed (without supplying supportive
evidence) that androgens act primarily to enhance general metabolism
and mood in a relatively non-specific way, and hence influence
sexuality, among other behaviours, as part of a general activational
effect (Kinsey et al ♦, 1953). Evidence to test the Kinsey hypothesis
dervived from hypogonadal studies is conflicting. While Davidson
_et aj_. (1979) and Salmimies _et _al_. (1982) reported a lack of effect of
testosterone replacement on mood, Luisi and Franchi (1980) claimed that
"mental state" (as assessed using an unpublished mood questionnaire)
was markedly improved following androgen replacement therapy.
Similarly, Skakkebaek _et aj_. (1981) found that fatigue and
tension/anxiety were reduced and vigour increased during active
treatment as compared with placebo. However, in neither study did the
mood change precede the androgen effect on sexual behaviour.
Data from the eugonadal man is equally conflicting. Results of
longitudinal studies correlating fluctuations in endogenous
testosterone level with self-rated mood state have been shown positive
(Mazur and Lamb, 1980), negative (Houser, 1979), and no association
(Doeri ng et _al_., 1974).
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1.3.1.2 Androgens Act to Enhance Mental and Sexual Imagery?
In attempting to account for the fascinating finding that the
ability to produce erections in response to erotic film appears to be
relatively independent of androgen status (Bancroft _et _al_., 1974)
whereas the ability to produce erections in response to sexual fantasy
does appear to be dependent on an adequate androgen level in men
(Bancroft & Wu, 1983), Bancroft (1980) formulated a hypothesis which
suggested that one of the effects of androgen replacement may be to
facilitate mental imagery in a relatively non-specific manner.
Bancroft (1980) suggests that the well documented visuo-spatial
superiority of the male from puberty onwards (i.e. when marked sex
differences in circulating androgen levels appear, see section 1.6)
lends support to his hypothesis. Also anecdotal clinical reports have
been published which suggest that some hypogonadal men report a reduced
incidence of erotic imagery and daydreams (Money, 1961). However,
preliminary evidence suggests that androgen replacement therapy does
not act to improve the spatial ability of hypogonadal men (Hier and
Crowley, 1982).
Bancroft (1980) also claimed that the observation that
testosterone administered to chickens acted to increase their
"persistence of attention" as assessed by the length of pecking runs on
preferred as opposed to non-preferred food (Andrew and Rogers, 1972)
lends additional support to his hypothesis in that testosterone is
acting to facilitate this active cognitive process. Equating feeding
behaviour in chickens with mental imagery and sexual fantasy in the
human male is a conceptual and phylogenetic leap open to criticism.
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In fairness, recent evidence has suggested that androgens may act to
improve performance on stereotyped repetitive tasks, e.g. serial
subtraction in the human (Broverman et al., 1980) but it must be stated
that this simple repetitive type of task appears far removed from the
cognitive sophistication required for the generation and maintenance of
visual imagery and sexual fantasy in man.
1.3.1.3 Androgens Act to Increase the Pleasurable Awareness of Sexual
Response?
The most recent hypothesis which attempts to explain the
behavioural mechanism of action of androgens in man was proposed by
Davidson et al. (1982). These authors suggest that androgens may act
to facilitate sensitivity to, or pleasurable awareness of, both sexual
thoughts and actions. This intriguing hypothesis postulates that
testosterone administration may act:-
(a) to increase the awareness of sexual response, presumably by
reducing thresholds of genital sensitivity, and
(b) to make this increased genital awareness more pleasurable, possibly
via androgen mediated effects on "pleasure centres" in the central
nervous system (Olds & Milner, 1954). This hypothesis that androgens
act to alter neural thresholds has recently received support from work
carried out on the rat. Bermond et _al_. (1982) demonstrated that
androgen administration acts to reduce the hypothalamic theshold at
which electrical stimulation induces aggressive behaviour in the
castrate male.
Davidson et _al_. (1982) suggest that their hypothesis could account
for all the observed changes in sexual behaviour which occur during
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androgen replacement and withdrawal in the hypogonadal nan. They state
"The behaviour-reinforcing properties of sexual pleasure could suffice
to explain all effects of androgen on sexuality through a domino
process involving increased sexual thoughts or fantasies, spontaneous
erections (including nocturnal ones), coitus or masturbation,
satisfaction and even ejaculation". As yet, supportive evidence for
this hypothesis is lacking.
In this thesis an attempt is made to shed light on the validity of
each of the hypotheses outlined above which claim to provide the
mechanism underlying what has been described as the most
phylogenetically stable, biologically important known action of a
hormone on behaviour.
1.3.2 Androgen Replacement in the Hypogonadal Kan - Relationship
Between Dose and Behavioural Response
Dose-response relationships between testosterone replacement and
sexual behaviour have been reported in the rat (Damassa et _al_., 1977)
and in the ram (D'Occhio and Brooks, 1982). The situation in the human
male is less clear. Davidson _et _al_ (1979) claimed to have demonstrated
a dose-response relationship in six hypogonadal men. These authors
reported that in a blind design, injections of 400 mg of testosterone
enanthate consistently produced superior results as compared with
100 mg injections or with placebo injections. This evidence in support
of a dose-response effect was criticised by Bancroft (1980) who pointed
out that following the 100 mg injection, circulating plasma
testosterone levels were maintained within the normal range for less
than half of the four week behavioural assessment period, in contrast
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to the four weeks following the 400 mg injection of testosterone.
Bancroft argues that "in averaging the behavioural scores for the whole
four-week period, the difference between the two regimens could be
accounted for simply by a shorter duration of hormone effect with the
lower dose rather than a true dose-response relationship". Davidson
_et aj_. (1982) answered this criticism by re-analysing the data from
their 1979 paper, this time comparing the frequency of sexual events
involving erection during the first two weeks following each injection.
For each of the six subjects the frequency of erections v/as
significantly higher in the two weeks following the 400 mg injection as
compared with the two weeks following the 100 mg dose. Similarly
there was a significantly higher frequency of erections during the
100 mg testosterone administration phase as compared with matched
placebo. This evidence is suggestive of the existence of a
dose-response relationship in the human male, but firm conclusions
cannot be drawn from a study using only two different doses of
androgen.
Recently the results of a more extensive study investigating the
dose-dependent effects of testosterone replacement on the sexual
behaviour of hypogonadal men were presented (Salmimies et al., 1982;
Pirke & Kockott, 1982). In this single-blind study, fifteen male
hypogonadal patients were administered injections of testosterone,
25 mg for the first month followed by successive one month periods on
placebo, 50 mg, 100 mg and 250 mg doses of testosterone (injections
were administered every two weeks throughout the study).
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The authors reported that four out of'the fifteen patients exhibited a
marked degree of sexual activity while receiving placebo. However,
when the data from the remaining eleven men was analysed, a
dose-dependent relationship was observed during administration of the
50 mg, 100 mg and 250 mg dose regimes (the 25 mg injections of
testosterone did not significantly affect the reported frequency of
erections or ejaculations as compared with placebo). This study is
open to criticism on three counts:-
(a) all the men received gradually increasing doses of testosterone,
and it is possible that the subjects may have expected gradual
increments in their replacement dosage and consequently their
behavioural changes may have been more due to expectation, rather than
because of a genuine hormone mediated effect
(b) the study was not double blind
(c) the four hypogonadal men whose behavioural response did not conform
to the dose-dependent hypothesis were excluded from the analysis.
Taken together the data from the Davidson et _al_. ( 1979) and the
Salmimies et jil_. (1982) studies are suggestive of a possible
dose-response relationship existing between androgen replacement and
the sexual behaviour of the hypogonadal man. However, studies
utilising better experimental design, with better control over androgen
dosage (e.g. oral as opposed to intra-muscular route of administration)
would provide more conclusive evidence.
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1.3.3 Behavioural Effects of Different Androgens
Very little research has been carried out looking at the relative
behavioural efficacy of different androgens in the human male. The few
studies that have been carried out have produced contrary findings.
Bancroft, Wu A Davidson (unpublished data) found rectal
suppositories of DHT to be less effective than T.U. in the treatment of
male hypogonadism (however the plasma levels of DHT achieved following
DHT treatment were modest). Luisi and Franchi (1980) similarly
reported that treatment with mesterolone, which like DHT is
non-aromatizable, was without significant effect comparied with
testosterone undecanoate (T.U.) in a group of hypogonadal men. Gooren
(1982), however, switched six hypogonadal men from their existing
androgen replacement regime of T.U. 120 mg/day to DHT undecanoate 120
mg/day for twelve weeks and observed no deterioration in sexual
functioning.
Further research is obviously required to clarify the relative
behavioural efficacy of these different androgen preparations. As
Davidson _et _al_. (1982) state, "It remains important that further
adequate research be done on the relationship between molecular
structure and sexual function of androgens in humans, in order to
clarify the question of what molecular transformatins androgen might
undergo prior to its action on sexuality".
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1.4 ANDROGENS AND IMPOTENCE
1.4.1 Androgen Levels in Impotent Men
As a result of the clinical evidence suggesting that androgen
deficiency is often associated with sexual dysfunction in the male, a
number of studies have been carried out over the past few years
evaluating the androgen status of men complaining of erectile
impotence.
In one of the first studies to be published, Ismail et _al_. ( 1970)
reported that the urinary excretion of testosterone metabolites was
reduced in impotent men as compared with controls. With the
development of accurate radioimmunoassay techniques, researchers
continued the pioneering work of Ismail et _al_ (1970) and attempted to
correlate plasma androgen levels with sexual dysfunction in the male.
Legros _et _al_. (1973) claimed that mean plasma testosterone levels
were reduced in impotent men compared with normal controls. However,
the authors did not specify the number of blood samples taken from each
subject. This is an important methodological point, as rapid episodic
fluctuations in plasma testosterone levels have been shown to occur in
the normal man (Doering et _al_., 1974; Murray and Corker, 1973; Rowe
et _aj_, 1974).
Racey et al (1974) were the first investigators to carry out a
study which controlled for this intra-individua! variation in androgen
levels. The authors obtained three morning and three afternoon blood
samples from each subject and found that the mean testosterone level of
a group of impotent men did not differ from that obtained from a normal
control group. Similar negative findings were reported by
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Lawrence and Swyer (1974 ), Arisari ( 1975) and Conhaire & Vermeulen
(1975).
More recently Pirke _et _al_. ( 1979) and Schwartz et al (1980) have
carried out more detailed endocrinological investigations of men
presenting with sexual dysfunction. Again, circulating testosterone
levels were not significantly different when the patient group was
compared with controls. However, when Schwarz et al. (1980) divided
their rather heterogenous patient group into specific diagnostic
categories, they found that men with primary impotence had
significantly higher testosterone levels than men with secondary
impotence. Pirke and Kockott (1982) failed to replicate this finding.
The Schwartz _et _al_. (1980) study can be criticised as can most of the
studies in this area, in that only one blood sample was taken from each
subject. Interestingly, Schwartz and his colleagues defend their
sampling regime by stating "Variation in a large group due to
oscillation is random and therefore tends to cancel itself out;
furthermore, recent data show that single blood samples of testosterone
are good estimates of the 24 hour plasma integrated concentration
(Urban et _ajL , 1979)". However, the Urban et _al_ (1979) study deals
solely with the problems associated with gonadotrophin measurement -
testosterone measurement is not mentioned in the entire paper!
Three additional studies have recently been reported where the
investigators determined the endocrine status of consecutive clinic
presenters complaining of sexual dysfunction. In the U.S.A. Spark
et _al_ (1980) screened one hundred and five consecutive male patients
presenting at an endocrine clinic complaining of erectile impotence.
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Of these, thirty-seven men were found to have some degree of
hypogonadism, eight were hyperprolactinaemic and two had evidence of
hyperthyroidism. Nahoum (1982), working in Brazil, similarly
determined the endocrinological status of two hundred and five
consecutive impotent patients. Nahoum reported that seventy-two men
(35.1% of the sample) were shown to have reduced testosterone levels.
This figure agrees well with that of 29.7% of impotent men who were
also shown to have reduced testosterone levels by Spark _et _al_. (1980).
Combining the data from these two studies, approximately one third of
the impotent men investigated demonstrated signs of androgen
deficiency. This is a surprisingly high proportion, (a) in light of
the previous negative reports in the literature and (b) given the
widely held view that 90-95% of all cases of impotence are
psychological in origin. (Although as Bancroft (1982) states "where
this figure came from was never clear, but it has entered into medical
folklore". Spark _et aj_. (1980) suggest that this greater than 90%
estimate originated from Strauss (1950) who maintained, without
providing supportive evidence that "impotence was psychic in
considerably more than 90% of the cases"). Contrary data, however, was
supplied by Batrinos et _al_. (1981) who investigated the testosterone
levels of fifty-seven consecutive Greek men presenting with impotence
at an endocrine clinic. Of these, only six (10.5%) were subsequently
shown to have reduced testosterone levels.
When one attempts to weigh up the evidence for and against
functional androgen deficiency in men complaining of impotence, one is
forced to conclude that the case remains "not proven". As Schiavi and
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White (1976) point out "Methodological differences in number, frequency
and time of blood samplings and inadequate matching of control groups
may account for some of the discrepancies in findings". It is also of
crucial importance to note that in most of the studies carried out to
date, investigators have generally not provided detailed clinical
information regarding their patient sample. In particular operational
definitions of dysfunctional states have been lacking, all disorders
being grouped together under the global term "impotence". For example,
men with erectile difficulties but with a normal degree of interest in
sex, and men whose primary problem is one of loss of libido have often
been combined and studied as one group. Only three studies have been
published which have specified loss of libido in the impotent group
under investigation. Interestingly, all three provided evidence of
reduced testosterone levels in such individuals when compared with
normal controls or with men with erectile dysfunction who had a normal
degree of interest in sex (Cooper _et aj_., 1981; Raboch et aj_. 1975;
Batrinos _et _al_. 1981). The results of these studies appear to be
suggestive of a possible relationship between androgen defecit and loss
of sexual appetite. However, further research is necessary before any
firm conclusions can be made.
1.4.2 Androgen Administration in the Treatment of Impotence
Androgens have been used extensively with varying degrees of
therapeutic success in the treatment of disorders of male sexual
functioning (for review, see Kilmann and Auerbach, 1979). This field
of research has been particularly lacking in well controlled,
methodologically sound experiments. For example, several authors have
claimed testosterone administration to be beneficial in the treatment
19
of erectile impotence, yet have not compared the androgen with placebo.
One such study was reported by Maddison (1973). The author found
testosterone treatment to be behaviourally effective in the treatment
of a group of men complaining of impotence, but stated that cross-over
trials could not be carried out for ethical reasons. "I could not
give dummy preparations to men who expected active treatment"
(Maddison, 1973). With this attitude by no means uncommon, the
scientific assimilation of knowledge in this area has progressed
extremely slowly. To the present author's knowledge, there have been
only four controlled studies published which have compared the efficacy
of testosterone versus placebo in the treatment of impotence in the
eugonadal man.
The first of these studies was carried out by Bruhl and Leslie
(1963), who compared the efficacy of a methyl testosterone preparation
against placebo in a double blind design. The authors claimed a
significant drug effect; however, the clinical and endocrine details
were not reported. In 1970 Jakobovitz carried out a similar study
where he compared the efficacy of a combined methyl testosterone and
thyroid extract preparation with matched placebo in one hundred
impotent subjects. Jakobovitz claimed that a "favourable response" was
noted in 787- of the men receiving the active preparation compared with
45% of those receiving placebo. This would appear to be a convincing
demonstration of the efficacy of the androgen preparation over placebo.
However, again the details of the study were not reported, and in light
of the preparation used, it is entirely possible that the beneficial
effects were due to the thyroid extract alone. In a similar study,
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Cooper jet _al_. ( 1973) compared a combined preparation containing
methyl testosterone, strychnine and caffeine against placebo in the
treatment of erectile impotence. The authors reported slight transient
beneficial effects of the active preparation compared with placebo.
However, the authors themselves concluded that the improvement was
probably due to the central nervous system stimulation caused by the
non-steroid constituents of the preparation.
From a methodological point of view, perhaps the most satisfactory
study that has been published to date is that of Benkert et al. (1979).
These authors compared the effects of oral testosterone undecanoate
(T.U.) administered at a dosage of 120 mg/day with matched placebo on
the sexuality and endocrinology of twenty-nine impotent men. Thirteen
men received T.U., sixteen received placebo. An improvement in sexual
potency was reported by five of the patients who received T.U. compared
with eight who were given placebo, therefore the authors concluded that
testosterone administration had no effect on the sexuality of the
impotent man. Interestingly, Benkert et _al_ (1979) reported that the
only signficant effect of T.U. treatment was to decrease the total
plasma testosterone level (see Chapter 4).
An additional relevant, though uncontrolled study recently
investigated the effects of administering mesterolone ( a
non-aromatisable synthetic androgen) at a dosage of 75 mg/day to 25 men
presenting with "typical" secondary impotence (Cooper, 1980).
Clinically the drug proved to be without significant benefits. (This
is perhaps not a surprising finding, given that Luisi and Franchi
(1980) reported mesterolone to be ineffective in improving the sexual
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behaviour of a group of hypogonadal men). Again, as was the case in
the Benkert et al. (1979) study, androgen administration did not act to
increase plasma testosterone levels in Cooper's group of
endocrinologically normal impotent men.
When one attempts to review the evidence for and against the
efficacy of androgen administration in the treatment of erectile
impotence one is faced with a dearth of adequately reported controlled
studies. Remarkably, one is forced to conclude that, to date, not one
study, using double blind assessment of behavioural response to
androgen treatment compared with placebo, presenting evidence that the
androgen administration resulted in a significant elevation in
circulating androgen level has been published*. There is obviously a
need for such studies to be carried out, (a) using men whose presenting
complaint is erectile difficulty with no accompanying loss of sexual
interest and (b) using men whose primary complaint is loss of, or
reduced sexual interest.
*It is perhaps appropriate to state that Cooper et _al_. (1972) did
successfully elevate circulating testosterone levels in five men
complaining of erectile dysfunction using clomiphene, a non-steroid
triethylene derivative, without any resultant beneficial effects on
potency. However, clomiphene is an oestrogen antagonist, acting to
inhibit the negative feedback to the hypothalamus by competing for and
occupying hypothalamic oestrogen receptors. In the absence of
appreciable levels of oestrogen (as is the case in the male) clomiphene
can act as a weak oestrogenic agonist. Given that the inhibitory
effects of oestrogens on male sexuality are well documented (e.g.
Bancroft _et _al_., 1974) any firm conclusions drawn from the results of
the Cooper jet _al_. (1972) study must be considered extremely suspect.
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1.5 ANDROGENS AND NOCTURNAL ERECTIONS
The occurrence of periodic nocturnal erections in man was first
described by Ohlmeyer et al (1944). These authors reported a recurrent
eighty-five minute cycle of penile tumescence during sleep, each
episode lasting for approximately twenty-five minutes. Eleven years
later, Aserinsky and Kleitman(1955) noted that these episodes of
nocturnal penile tumescence (NPT) tended to be coincidental with the
rapid eye movement (REM) stage of sleep. Since then, a vast amount of
research has been carried out investigating the NPT phenomenon,
focusing particularly upon the possible use of NPT assessment as a
diagnostic tool which could differentiate between organic and
psychogenic forms of impotence (see Schiavi and Fisher, 1982 for
review). However, the assumption that men whose erectile difficulties
are due to psychological factors display "normal" NPTs and men whose
impotence is due to organic factors display abnormal NPTSs has yet to
be proven (Bancroft and Wu, 1980). Also, the psychogenic/organic
distinction between different forms of impotence is not a clear cut one
(Wasserman et _al_, 1980), and the equivalence of NPTs with erotically
induced erections in the waking state has still to be established.
(Bancroft, 1983 has suggested that the nocturnal erection may differ
qualitatively from the conscious erotic erection is that the NPT
episode may be brought about solely by activation of the venous
shut-off mechanisms, i.e. no increase in arterial blood flow. This
hypothesis would account for the slower rate of tumescence which is
observed during the night. However, recent evidence has demonstrated
that arterial blood flow in the penis is highly correlated with penile
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circumference change during NPT episodes (Karacan et al. 1983). These
authors conclude that the venous system, if it has a role in erectile
function, must be supportive of the arterial system).
1.5.1 Androgen Levels during REM Sleep
Evans _et _al_ (1971) were the first investigators to report that
testosterone levels reached a peak "in conjunction with or adjacent to"
REM sleep phases. Miyatake et al (1980), however failed to find any
mean difference in testosterone levels when they compared samples drawn,
from REM and non-REM sleep stages, using normal men as subjects. These
negative findings were replicated by Roffwarg et al (1982), but using a
more sophisticated form of analysis, these latter authors reported that
the nocturnal peaks in testosterone concentration tended to be
associated with the transition from non-REM to REM sleep. The authors
suggest that abrupt elevations in testosterone levels may act to
"prime" PEM sleep processes. Conversely, it is possible that REM sleep
in some way stimulates nocturnal testosterone production, as a recent
study has shown that sleep deprivation acts to reduce circulating
androgen levels in healthy young men (Cortes-Gal 1 egos _et _al_., 1983).
Given that there appears to be a relationship between testosterone
and REM sleep, and that it has been estimated that 66-90% of all NPT
episodes occur during REM sleep (Schiavi and Fisher, 1982), the
possibility arises that a relationship may exist between testosterone
and NPT episodes.
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1.5.2 Androgen Levels during NPT Episodes
In 1977 Schiavi et _al_. reported the results of a study which
looked at the relationships between NPT episodes, REM sleep and
circulating testosterone levels in five normal men. The authors
reported that abrupt elevations in circulating testosterone levels
occurred during the night without a significant relationship to stage
of sleep. However, mean testosterone levels during REM with tumescence
were considerably raised compared with sleep periods free from REM and
tumescence, suggesting a link between testosterone, REM and nocturnal
erections. The authors then went on to look at the relationship
between testosterone, NPTs and sleep patterns in normal men compared
with men complaining of erectile impotence. Schiavi jet _al_. (1982)
reported that the two groups did not differ in terms of sleep
parameters, mean tumescence time or frequency of NPT episodes. Again
the authors found that the normal men had testosterone levels during
REM with tumescence which were significantly elevated as compared with
non-REM sleep stages without tumescence. The impotent men however had
testosterone levels which did not differ when REM sleep with tumescence
was compared with non-REM non-tumescence sleep. This result suggests
that subtle differences may exist between impotent and normal men with
respect to the interaction between androgens, sleep stage and nocturnal
erections.
While reviewing the evidence for a relationship between androgens
and nocturnal erections, it is fascinating to note that males during
puberty demonstrate an abrupt elevation in total nocturnal tumescence
time relative to REM (Schiavi and Fisher, 1982) which is coincidental
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with the marked increase in circulating gonadotrophin and androgen
levels which ocurs at this time (Rose, 1975).
1.5.3 hocturnal Erections in States of Endocrine Dysfunction
Very little research has been carried out looking at the sleep
patterns and NPTs of men with proven endocrine disorders. Wasserman
et aj_. (1980) presented a case study of a patient who complained of
progressive erectile impairment over a period of three years. This
individual had his NPTs recorded in the laboratory for three successive
nights and produced erections which fell within the normal limits with
respect to penile circumference change from basal levels. However,
rigidity judgements based on direct observation suggested that the
erections produced were insufficient for vaginal entry. Subsequent
clinical investigations revealed a massively elevated prolactin level
which was treated with bromocriptine 10 mg/day. NPT assessment was
repeated after five months of chemotherapy and the nocturnal erections
were found to be improved and were judged as being sufficient for
sexual intercourse. (Extrapolations from an uncontrolled single case
study should, of course, be made with caution. In particular, in this
case, the discovery of a likely physical basis for his sexual problem,
followed by chemotherapy would probably have a profound psychological
effect on the individual's sexual functioning and upon his subjective
rating of his erection).
In a large scale screening study Cunningham et _aj_. (1982) measured
testosterone and prolactin levels in one hundred and seventy two men
complaining of erectile impotence who underwent NPT assessment. Six
men were subsequently found to be hypogonadal and six
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hyperprol actinaemic. All of the hypogonadal men and five of the six
hyperprol actinaemic patients were judged as displaying abnormal NPTs
(in this particular study changes in penile circumference were not
reported, abnormality was defined according to penile rigidity - if
penile buckling occurred at less than 450g pressure the erection was
considered incapable of vaginal entry and was classified abnormal).
This study reporting that hypogonadal men have a marked impairment of
NPTs has recently been replicated by Kwan et _al_. (1983). This is an
important discovery, particularly in light of Bancroft and Wu's (1983)
report that conscious erections in response to erotic films are
relatively unaffected by androgen status in the hypogonadal man.
Cunningham et _al_, (1982) also made the intriguing observation that
of twelve men complaining of erectile difficulties who were found to
have testosterone levels which exceeded the upper limits of the normal
range, eight displayed abnormal NPTs, (i.e. penile buckling occurred at
less than 450g pressure). This finding suggests that both too low and
too high a testosterone level may have inhibitory effects on nocturnal
erections.
1.5.4 Administration of Androgens - Effects on Nocturnal Erections
1.5.4.1 The Hypogonadal Kan
Kwan et al. (1983) recently presented the results of a small study
where NPTs were recorded in six hypogonadal men "on" and "off" androgen
replacement therapy. The authors reported that nocturnal erections
were reduced in the untreated hypogonadal men, and were significantly
increased following treatment with testosterone injections. This study
is open to criticism on the grounds that portable home monitors were
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used to measure the nocturnal erections and no objective data on sleep
quality was collected. This study is in urgent need of replication.
1.5.4.2 The Eugonadal Man
The only published study in this area is that of Jovanovic and
Tan-eli (1969) who compared the NPTs of impotent men before and after
treatment with a methyl testosterone preparation. These authors
reported that men complaining of erectile impotence had less frequent
and less marked NPTs when compared with age matched controls, and that
administration of the androgen preparation acted to normalise the
NPTs.
Given the recent literature suggesting that most men presenting
with erectile difficulties exhibit relatively normal nocturnal
erections, coupled with the evidence against the efficacy of androgen
treatment of erectile impotence (see section 1.4.2), this uncontrolled
and inadequately reported study by Jovanovic and Tan-el i (1969) also
needs to be replicated.
The outstanding questions in relation to androgens and NPTs to be
tackled in this thesis are:-
(a) Do hypogonadal men display a reduced frequency, duration or
amplitude of nocturnal erections, and are these NPTs improved following
androgen replacement therapy?
(b) Are the NPTs of eugonadal men with erectile disorders (which are
not obviously secondary to physical illness, e.g. diabetes) affected by
high dosage testosterone administration?
28
1.6 Androgens and Cognitive Functioning
The study of cognitive sex differences has become one of the most
controversial areas in the history of psychology. In the most
authorative reivew of the literature to date, Maccoby and Jacklin
(1974) came to the conclusion that there are only four valid and
replicable sex differences in human behaviour; visuo-spatial, verbal,
mathematical and aggression. The suggestion that human males and
females may differ with respect to cognitive functioning has evoked
fierce opposition, however Fairweather (1976) in his scathing review
of sex difference studies is forced to concede "There is finally good
evidence of a clear adult male superiortiy for a small nucleus of
definitive spatial skills".
Spatial ability has been defined as the ability to visually
manipulate images without the aid of verbal mediation (Petersen, 1975).
Attempts have been made to explain why males demonstrate this slight
but consistent spatial superiority, mostly arguing from an
evolutionary perspective, e.g. reasoning that primitive man required
superior visuo-spatial ability for hunting, etc. (Hamburg, 1974).
Such propositions have been criticised (Nicholson, 1979) and as yet we
have no satisfactory explanation for the almost universal demonstration
of male superiority with respect to performance on spatial tasks.
The sex difference in spatial ability is one of particular
interest to psychoneuroendocrinologists as it is a measure which shows
clear differences which are generally reported as appearing at puberty
(see below), which is coincidental with the pubertal increase in sex
hormone level (Rose, 1975). Focusing on the male, spatial ability and
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androgen status appear to parallel each other throughout adulthood,
both increasing at puberty, then reaching a plateau, and there is
evidence that there is a slight decline in spatial performance in later
life (Likert and Quasha, 1970), and a similar decline in androgen
level, particularly the "free" bio-active hormone fraction (Davidson
est aj_, 1980; Vermeulen et al , 1972).
The observation that androgen level and spatial ability display
this parallel pattern throughout the male life-span makes androgen
status a possible physiological contributer to the observed variance in
visuo-spatial skill.
It has also been proposed that tests of spatial ability merely tap
general intelligence. While the solution of spatial tasks undoubtedly
involves higher cognitive functioning, these tests cannot be simply
measuring "g" as there are no reported differences between the sexes on
tests of general intelligence (although females do demonstrate a slight
but consistent verbal superiority over males, Kaccoby and Jacklin,
1974) and correlations as low as 0.07 have been reported between
performance on spatial and general intelligence tests (Paterson et al ,
1930). (Recently however, Cooperman (1980) presented data suggesting
that subjects who scored highly on spatial tests also performed better
on tests of rote learning and verbal reasoning than poor spatial test
scorers).
1.6.1 Biological and Environmental Determinants of Spatial Ability
Although the sex difference in spatial ability has been generally
accepted, the causal factors which generate this disparity between the
sexes have yet to be established.
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Environmentalists propose that humans are reinforced
differentially from birth, dependent on their sex, e.g. boys are given
building blocks and construction kits as gifts while girls are given
dolls and prams (Singleton, 1976). Therefore the environmentalist
argument states that the spatial superiority demonstrated by the male
is a result of developmental learning and experience. The major
criticism that has been raised against this hypothesis is the well
documented finding that the sex difference in spatial ability begins to
appear at puberty (Broverman et al_., 1968; Buffrey and Gray, 1972;
Bock and Kalakowski, 1973; Harris, 1978; Maccoby and Jacklin, 1974;
Rogers, 1976; Petersen, 1976; Waber, 1976; 1977(a); 1977(b); McGee,
1979). (Although recently it has been claimed that pre-pubertal sex
differences may exist in spatial performance, Sal kind (1976); Orsini
et al_., (1982)). The environmentalist hypothesis has also been
criticised for lack of hard supportive evidence, e.g. "Evidence for
differential socialisation in the development of visuo-spatial skills,
too, is scanty and inferential at best While there is a clear
difference in toy preference between the sexes, there is no evidence
for any relationship between these preferences or modes of play and
development of vi suo-spati al skills in adulthood" (Burstein et al.,
1980).
The ability to perform well at spatial tasks has been claimed to
be a heritable trait (Vandenberg, 1968), but simple genetic
explanations for the sex difference, such as sex-linkage on the X
chromosome have generally been discredited (a) by the lack of
consistent supportive evidence from parent-child correlations
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(Boles, 1980) and (b) by the very poor spatial performance of sufferers
of Turners (X0) syndrome (Money and Alexander, 1966).
One of the most intriguing hypotheses regarding the development of
cognitive sex differences is that of Waber (1976; 1977a; 1977b) who
proposes that the cognitive sex differences are due solely to the
difference in the rate of physical maturation that exists between males
and females (Tanner, 1978). Waber argues that in general males are
superior on visuo-spatial tasks because they pass through puberty later
than females, "Sex differences in mental abilities, it is argued
reflect differences in the organisation of cortical functioning that
are related to differential rates of physical maturation" (Waber,
1976). Evidence in support of the hypothesis is supplied by the author
herself (Waber, 1976) and by Ray _et (1981). Fairweather (1976)
however is critical of the hypothesis and suggests that substantial
replication is necessary before it can be accepted, and Gordon and
Galatzer (1980) point out that sufferers of Turners (X0) syndrome have
prolongation of prepubertal maturation, yet demonstrate severe spatial
deficits when compared with controls.
1.6.2 Androgens and Spatial Ability
One of the first reports which suggested an endocrine factor
contributing to cognitive deficiency was that of Dawson (1967) who
studied males feminised by a kwashiorkor-induced endocrine dysfunction.
(Kwashiorkor is a desease of the liver resulting from protein
deficiency in infancy, which prevents the inactivation of the normal
amount of oestrogen present in the male). Dawson discovered that
kwashiorkor affected males as adults demonstrated impaired spatial
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ability and were more field dependent than normal control males.
However, one must always remember the strong environmental
contributions in such cases, e.g. Masica _et _al_. (1969) demonstrated
that males with the testicular feminising syndrome of androgen
insensitivity scored in the feminine or masculine direction on
psychological tests depending on the sex they were brought up as.
Preliminary research has been carried out using endocrinologically
normal populations in an effort to investigate the role androgens play
(if any) in the regulation of cognitive functioning (Rroverman et al.,
1968; K1aiber et al., 1967; Petersen, 1976). These investigators,
using a correlational approach, came to the conclusion that in males,
low androgenisation is correlated with good spatial performance and
vice versa. This is an interesting, if slightly puzzling finding. It
is possible that an optimal level of circulating androgen is necessary
for optimal spatial performance, but androgen levels above this
threshold level may have an inhibitory effect (recently just such a
hypothesis has been proposed, focusing instead on the optimal oestrogen
level, Nyborg 1983). However, as McGee (1979) points out the measures
of androgenicity that were used in the Broverman _et _al_. (1968) and
Petersen (1976) studies were far from satisfactory. Ratings were made
from photographs, pubic hair and muscular development were scored, and
these scores represented the subjects androgenicity index which was
then correlated with performance on visuo-spatial tasks. To quote
McGee (1979) "Until more direct methods of hormonal assay are employed
on larger samples, the precise nature of the relationship between
spatial ability and hormonal balance will remain an open question".
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The findings of Broverman et al. (1968) and Petersen (1976) are made to
appear even more suspect in light of the data supplied by Krause and
Hintze (1980) who correlated fifty-two typical signs of masculine
differentiation with circulating androgen levels in one hundred and
twenty-nine healthy young men. Krause and Hintze (1980) came to the
following conclusion, "Stages of body hair are obviously independent
from actual androgen plasma levels. Also body proportions and size of
the genital organs are not correlated to hormone levels". In
accommodating this data, Broverman et al. (1980) recently stated,
"Blood levels of the gonadal hormones are poor indicators of degree of
hormonal stimulation, metabolic clearance and production rates of the
gonadal hormones seem to be more closely related to anthropometric
indices of gonadal hormone stimulation and to cognitive and affective
functioning". In investigating gonadal hormone clearance rates,
K1aiber et al. (1967) measured 17-ketosteroid excretion in adult males
and reported a significant correlation between this measure and spatial
test scores. However, Farr (1978) in a recent replication failed to
find any significant relationship between 17-ketosteroid production,
selected anthropometric measures and cognitive functioning.
Perhaps the most exciting study to have been published to date
concerning the relationship between hormones and cognitive functioning
is that of Hier and Crowley (1982) who investigated the spatial ability
of hypogonadal men. These authors compared the spatial performance of
men who had idiopathic hypogonadotrophic hypogonadism (I.H.H.) with
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controls and with men v/ho had acquired hypergonadotrophic hypogonadism
(A.H.H.) after puberty. The patients with I.H.H. displayed markedly
impaired spatial ability when compared with the A.H.H. and control
groups, and spatial performance was positively correlated with
testicular volume in the I.H.H. group. This evidence supplied by Hier
and Crowley appears to be in opposition to the Waber hypothesis(see
section 1.6.1) concerning the generation of the sex difference in
spatial ability as the I.H.H. men, is common with sufferers of Turners
(XO) syndrome have prolongation of pre-pubertal maturation, yet have
markedly impaired spatial ability.
Bancroft and Wu (1983) investigated the effects of androgen
replacement and withdrawal on erectile response to erotic fantasy and
to erotic film in hypogonadal men, and found that only the ability to
produce erections in response to erotic fantasy appeared to be
dependent on androgen status. As Bancroft (1980) states, "Mental
imagery is an active visuo-spatial process, it is possible that
androgens may facilitate this process and hence facilitate erotic
imagery in a relatively non-specific way". However, Rubin et al.
(1979) and Lange _et _al_* (1980) found that testosterone levels were
highly correlated with penile diameter changes in response to erotic
film using eugonadal subjects, and Hier and Crowley (1982) reported
that three months of androgen replacement therapy did not result in
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improved spatial performance in six hypogonadal men. (Hier and Crowley
(1982) did point out that because of the small sample size, a slight
but significant improvement in test scores with androgen treatment
cannot be ruled out, leaving the effects of androgen administration on
cognitive performance in men an area requiring further study).
In this thesis the following questions are addressed in an effort
to further investigate the relationship between androgens and cognitive
functioning in men:-
(a) Does the spatial performance of the hypogonadal men improve
following longterm androgen replacement therapy?
(b) Does raising the circulating level of androgens above the normal
range have an effect on the spatial performance of the eugonadal man?
1.7 ANDROGENS AND PERSONALITY
Apart from the interest shown in the possible relationship between
androgens and cognitive functioning, very little research has been
carried out looking at whether androgens are related to various other
aspects of personality in man.
Those personality measures which have received most attention are
the personality dimensions of Hans Eysenck and the Sensation Seeking
Scale of Marvin Zuckerman. In this section the research carried out to
date equating these behavioural measures with androgen levels will be
briefly reviewed.
1.7.1 The Eysenck Personality Dimensions
Over the last thirty years H.J. Eysenck has developed and refined
a series of self-report inventories which he claims classify
individuals in terms of three dimensions of personality, namely
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extraversion (E), neuroticism (N) and psychoticism (P). Of these throe
dimensions, the newest, and for our purposes the most interesting, is
the psychoticism or P scale. (It is perhaps appropriate to point out
that Eysenck's definition of psychotism differs somewhat from the
standard psychiatric definition of the term. A high P scorer is not
described as being insane, but rather as being solitary, insensitive,
hostile and lacking in feeling and empathy, Eysenck (1978)).
Eysenck has repeatedly proposed that this dimension is in some way
related to androgen levels in man, e.g. "It seems likely that the
biological basis of P will be found to be closely related to male sex
hormones" (Eysenck and Eysenck, 1975). "The fact that males have much
higher P scores than females suggests that the androgen/oestrogen
balance will be involved" (Eysenck and Eysenck, 1976). "High P scorers
are also very strongly determined in their behaviour by genetic
factors, and this is probably mediated by male hormones" (Eysenck and
Wilson, 1979). In his book "Sex and Personality" (Eysenck, 1978) the
author cites the work of Daitzman (1976) who attempted to correlate
endogenous steroid hormone levels with various psychometric test
measures. With regard to psychoticism, Daitzman reported positive but
insignificant correlations with androgen level. Eysenck appeared to be
undaunted by this lack of significant association between psychoticism
and androgens stating "These results, given the small numbers involved
and the pioneering nature of the experiment, tend to fit in quite well
with our conceptualisation" (Eysenck, 1978). In a more recent study,
Daitzman and Zuckerman (1980) again failed to find any relationship
between circulating testosterone levels and psychoticism in young men.
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In fairness to Eysenck, in neither of these studies (Daitzman, 1976;
Daitzman and Zuckerman, 1980) was the Eysenckian measure of
psychoticism, namely the P scale used.
Only one study known to the present author has looked at the
effect of exogenous androgen administration on measures of personality
in man. This was a study by Kaiser et aj_. (1978) who carried out a
controlled double blind behavioural comparison of androgen versus
placebo in ageing males. Half of the sixty-six subjects received
mesterolone 75 mg/day for five weeks, half received matched placebo.
The authors claimed that the active medication acted to reduce
"psychovegatative symptomatology" and resulted in a decrease in
neuroticism and an increase in extraversion scores. (P scores were not
evaluated, as the authors used an earlier version of Eysenck's
personality test, the EPI as opposed to the more recent EPQ, (Eysenck
and Eysenck, 1975)). These beneficial effects of mesterolone are
surprising, given that at double the dosage used in the Kaiser et al.
(1978) study, Luisi and Franchi (1980) found mesterolone ineffective in
the treatment of hypogonadism, whereas another androgen preparation
(testosterone undecanoate) was shown to be highly efficacious in a
group of patients where androgen-behaviour relationships are usually
demonstrated most clearly (see section 1.3).
1.7.2 The Sensation Seeking Scale
In 1964 Zuckerman et al. developed a self-report inventory which
they claimed measures a set of behaviours described as "sensation
seeking" (a sensation seeker is described as someone who actively seeks
stimulation and excitement, roughly equivalent to an Eysenckian
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impulsive extravert). A series of studies have been published which
indicate that the Sensation Seeking Scale (SSS) is a reliable, valid
and useful measure (see review by Zuckerman, 1979). The SSS is of
particular interest in light of recent evidence which suggests that a
positive correlation exists in the eugonadal man between SSS scores and
gonadal hormone level (Daitzman et _al_., 1978 Daitzman and Zuckerman,
1980). In an attempt to explain this finding Zuckerman has formulated
a hypothesis which proposes that elevated gonadal steroid levels may
act to reduce mono-amine oxidase activity which leads to an increase in
central nervous system mono-amine levels which would in turn facilitate
neural transmissions and perhaps stimulate sensation seeking behaviour
(Zuckerman, 1979; 1983; Zuckerman et a]_. , 1980). This is an
interesting, if slightly speculative hypothesis. To date all the
evidence in favour of this hypothesis has been derived from
correlational studies, equating endogenous steroid levels with
behaviour in the eugonadal man. A better method of testing the
hypothesis that gonadal hormone levels are causally related to
sensation seeking behaviour would (in the opinion of the present
author) be to look for behavioural changes brought about as a result of
exogenous androgen administration. If the Zuckerman hypothesis is
valid, this endocrine manipulation should lead to an increase in
sensation seeking behaviour, which in turn should be reflected in SSS
scores. Similarly the hypothesis should predict that hypogonadal men,
on account of their markedly reduced circulating gonadal steroid
levels, should produce reduced SSS scores which increase following
androgen replacement therapy.
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1.8 ANDROGENS AND AGGRESSION
1-8-1 Androgens and Aggression in Animals
Evidence derived from research carried out in animals in general
suggests that a relationship exists between androgens and aggression in
the male, e.g. in the adult male mouse castration decreases and
testosterone replacement increases the frequency of bouts of inter-male
aggression. Also fighting among intact males usually begins to appear
about the time of puberty, as androgen levels in the blood are rising,
however pre-pubertal inter-male fighting can be induced by injections
of testosterone (Bronson and Desjardins, 1971). It is important to
stress, however, that species differences exist in hormone mediated
effects on aggressive behaviours. As we ascend the phylogenetic scale,
social experience appears to play a major role in determining
aggressive responses to castration and androgen replacement. Dixon and
Herbert (1977) observed a group of Talopoin monkeys and reported that
castrate males were sometimes more highly ranked than intact males and
that testosteorne administration acted to increase the aggressive
behaviour of these castrates, but only directed against more
subordinate males. The authors conclude that previous social
experience influences androgen induced aggressiveness. Certainly, the
strong direct relationship between androgens and aggression observed in
rodents does not appear in the study of non-human primates (Benton,
1981).
It is also important to emphasise that "aggression" is a broad
descriptive term encompassing various types of specific behavioural
response which can be classified as aggressive, e.g. predatory,
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inter-male, fear induced, irritable, maternal, sex related and
instrumental (Moyer, 1976). It is also probable that different gonadal
hormones have differing effects on these sub-factors of aggressive
behaviour, e.g. androgens and oestrogens have markedly similar effect
on reintroducing displays of sex related aggression in castrate red
deer stags, but only androgens act to stimulate bouts of inter-male
social aggression which determine dominance hierarchies (Fletcher and
Short, 1974; Fletcher, 1978).
1.8.2 Androgens and Aggression in Man
Detailed evidence regarding the behavioural consequences of
castration in the adult human male is lacking, but it is generally
thought that the major effect of the operation is to reduce the level
of libido of the castrate man, with no appreciable effect on non-sexual
aggressive behaviours (Rose, 1978). The evidence that in the human
male castration always leads to a decrease in sexual drive has not,
however, been completely demonstrated (Fleim and Flursch, 1979).
Relatively little attention has been given to the influence of
castration on human aggression of a non-sexual nature, although in a
study of the behavioural effects of castration in two hundred and
forty-four men, Bremer (1959) concluded that castration is an
inappropriate treatment for human aggressive behaviour.
In the human it is of interest to note that most acts of violent
aggression are committed by young men, and that such actions become
progressively rarer with advancing age (Eysenck and Eysenck, 1976) and
that androgen levels are highest in young men and decline with age
(Davidson _et aj_., 1980; Pirke _et _al_, 1981; Vermeul en _et _al_., 1972),
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but as with sexual behaviour there is no evidence of a causal
relationship between the two variables.
Uncontrolled clinical reports have suggested that withdrawn
psychiatric patients could be made more outgoing, and aggressive
patients made even more violent by androgen treatment (Strauss et al.,
1952; Sands and Chamberlain, 1952). However, serious attempts at
investigating possible androgen/aggression relationships only began
approximately twelve years ago. In one of the first of these studies,
Persky et _al_., (1971) reported a significant correlation between
aggression (as measured using the Buss-Durkee Hostility Inventory,
Buss and Durkee, 1957) and testosterone production rate in young men.
Meyer-Bahlburg _et _al_. (1974) attempted to replicate this study using a
very similar experiment design but failed to find the association
claimed by Persky _et _al_ (1971). Both these studies can be criticised
because of the experimental procedure employed. In an effort to
determine testosterone production rate, radioactive testosterone was
infused into the systemic circulation of each man as they completed
behavioural questionnaires and had serial blood samples taken. In
effect, measures of behaviour were being made in an attempt to relate
them to endogenous testosterone levels, while exogenous testosterone
was being infused.
Doering et al., (1974) and Monti _et _aK , ( 1977) also failed to
find any relationship between Buss-Durkee rated aggressive behaviour
and mean testosterone level in normal young men. In light of this
evidence suggesting a lack of association between testosterone and
aggression in normal men, investigators began to look for possible
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relationships in behaviourally extreme populations.
Using male prisoners as subjects, Kreuz and Rose (1972) reported
that mean testosterone levels correlated neither with the incidence of
observed fighting behaviour, nor with various questionnaire measures of
aggression. However, the authors did make the fascinating observation
that the earlier the age of first conviction for violent crime, the
higher the mean plasma testosterone level at this later age. In a
similar study using a prison population, Ehrenkranz et al., (1974) (who
had several years personal knowledge of the prison population and were
thus able to divide the prisoners into specific behavioural categories)
reported that a group of very aggressive prisoners had mean
testosterone levels which were significantly elevated in comparison
with a group of "typical" prisoners. Interestingly a group of socially
dominant though non-aggressive prisoners also had higher testosterone
levels than control prisoners. It is important to note that the
Buss-Durkee Inventory and other psychological tests did not
discriminate between these three categories of prisoners. In contrast,
Matthews (1979) found no difference in mean testosterone levels when he
compared violent prisoners with non-violent prisoners, matched for age,
height, weight and length of time spent in prison. In a study of men
who were aggressive specifically in a sexual situation, Rada et al
(1976) reported that violent rapists had higher testosterone levels
than non-violent rapists or normal controls. This result fits in well
with the theorising of Brain (1981) who suggests that androgens may be
related specifically to sexual aggression, and he cites the work of
Hawke (1950) who proposed that castration may be an effective means of
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curbing violence in sex offenders. Reports have also been made
claiming that Pharmacological antiandrogens are effective in reducing
aggression in sex offenders (Laschet, 1973; Laschet and Laschet,
1975).
More recent studies have provided additional evidence suggesting a
possible relationship between testosterone and aggression in man.
Using sport as a situation where societal constraints on aggressive
behaviour are temporarily lifted, Scaramella and Brown (1978) reported
that male hockey players whom the team coach rated as being the most
aggressive when provoked had the highest testosterone levels. This was
an interesting finding, but as only one blood sample was taken per
subject, and only fourteen subjects were studied, the results must be
interpreted with caution. However, they have been to a certain extent
substantiated by Olweus et _al_. (1980) who carried out a study of
adolescent Norwegian males. The authors correlated mean plasma
testosterone with various behaviours which were assessed mainly by
inventories. They found a significant correlation between testosterone
and self-reported physical and verbal aggression, "mainly reflecting
responsiveness to provocation and threat" (01 weus _et _al_., 1980). These
findings were replicated by Mattson _et _al_. (1980) in a population of
institutionalised male deliquents.
1.8.3 Methodological Problems in Androgen-Aggression Research
When reviewing the studies to date in this area, three major
methodological problems involved in this type of research become
apparent:-
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1.8.3.1 Measurement of Human Aggression
Most of the studies cited above have relied on the Buss-Durkee
Hostility Inventory to assess aggressive behaviour. As Rose (1975)
points out, scores on this self-report questionnaire do not appear to
relate to observed aggressive behaviour, "If there are significant
correlations between aggression and testosterone in humans, we need
much better methods of assessing various aspects of behaviour than are
currently available" (Rose, 1975).
1.8.3.2 Blood Sampling Methodology
As outlined in section 1.4.1 it is essential that several blood
samples be taken from each subject because of the high degree of
intra-individual variation in circulating testosterone levels that
exists in the adult human male. This allows the investigator to arrive
at a representative mean hormonal value for each individual to
correlate behavioural measures against. Unfortunately, single blood
samples have been used to determine androgen status in most of the
studies carried out to date.
1.8.3.3 Cause-Effect Relationships in Androgen-Aggression Research
Many investigators in this field of research have carried out
correlational studies, assuming that if a relationship between
testosterone and aggression does exist, then it is the hormone which in-
some way "causes" the aggressive behaviour. It is vitally important to
bear in mind that the expression of aggressive behaviour may have a
marked effect on the endocrinology of the human male, e.g. Elias (1981)
has demonstrated that male wrestlers exhibit significant elevations in
circulating testosterone levels during wrestling bouts (interestingly
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winners displayed greater testosterone increases from basal levels than
losers) and Mendelson et al_. (1982) have recently shown that LH (i.e.
the major stimulant for testosterone production) levels were found to
be elevated in postmortem blood samples obtained from men who sustained
sudden and violent deaths. Thus (to take a hypothetical example), if a
sub-group of highly aggressive prisoners were shown to have very high
circulating testosterone levels, it is possible that the elevated
androgen is a result of the aggressive behaviour rather than the cause
(Archer & Lloyd, 1982).
In summarising the evidence for and against androgens playing a
role in the expression of aggressive behaviour in the adult human male,
the present author would tend to agree with Rose (1978) who states "It
is obvious that the question remains unanswered but some suggestion of
a relationship appears consistent with the results obtained to date".
It is surprising that virtually all the investigators in this area have
relied on the correlational approach for data collection. Experimental
manipulation of androgen levels using behaviour as the dependent
variable would appear to be the best method of gaining evidence to test
the hypothesis that a relationship exists between androgens and
aggressive behaviour in man.
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CHAPTER 2
GENERAL MATERIALS AND METHODS
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2.1 BEHAVIOURAL ASSESSMENT
In order to arrive at a detailed and accurate assessment of any
changes in behaviour which are brought about as a result of androgen
administration, three methods of behavioural measurement have been
employed in the studies described in this thesis:-
(a) self report diary data
(b) interview ratings
(c) psychophysiological measurement
2.1.1 Daily Diary Ratings
Sexual Behaviour
Self report data is often criticised as being "unscientific" and
not amenable to objective verification (Allen and Potkay, 1973).
However, as Barlow (1977) points out, self report of sexual function
and dysfunction may be more important than behavioural and
physiological measures, because in adult patients self report of the
dysfunction is often the only necessary criterion for entry into
treatment. Similarly self-assessment of progress is often the major
criterion for terminating the intervention.
Each of the subjects who were studied were asked to complete a
daily diary form (see Appendix IV) assessing their sexual behaviour.
This diary was based on that used by Skakkebaek et al. (1981) in their
study of the effects of androgen replacement on the sexuality of the
hypogonadal man. The diary was modified in that subjects were asked to
record whether sexual activity was self, partner or jointly initiated.
Subjects were also asked to provide daily (as opposed to weekly)
ratings of frequency of sexual thoughts and sexual arousal associated
with these thoughts, on two separate visual analogue scales (see
below). It was important to collect sexual behaviour data on a daily
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basis, as it has recently been demonstrated that retrospective
(monthly) estimates of behaviour, e.g. frequency of awakening with an
erection, correlate poorly with daily records (Reading et aj_., 1982;
Reading, 1983).
Mood State
As a great deal of research has (and is) been carried out testing
the general hypothesis that endocrine changes influence mood state in
women (e.g. Sanders _et _al_. 1983), it was considered appropriate to also
investigate the effects of androgen administration on mood state in the
man.
In order to quantify mood change, a series of ten visual analogue
mood scales were incorporated into the daily diary assessment form.
These v/ere based upon the mood scales devised by Sanders (1980) and
have been cross-validated with Lorr-McNair MACL scores (McNair and
Lorr, 1964) by Sanders (1980). Visual analogue scales have the
advantage of being simple, concise, quick to complete and are not
influenced by response sets (Bond and Lader, 1974). The analogue
nature of the scale avoids imposing artificial digital categorisation
of moods and feelings (Mackay, 1980). Data from visual analogue scales
are suitable for both parametric and non-parametric techniques of
statistical analysis (Maxwell, 1978). Data from analogue scales cannot
be compared inter-individually (Pirke and Kockott, 1982); however,
they do appear to be suitable for quantifying intra-individual changes
(Aitken, 1969; Zealley and Aitken, 1969; Folstein and Luria, 1973;
Bond and Lader, 1974; Maxwell, 1978; Peck and Dean, 1983).
Standardisation of Visual Analogue Scores
In order to combine data from groups of subjects to graphically
portray and compare results, a method of standard!sing the visual
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analogue scores v/as developed. As individuals vary as to where they
centre themselves on the 100 mm scale, and also vary as to the range of
the scale they use to represent swings of mood, raw means and standard
deviations are inappropriate. To control for this between subject
variation, scores were standardised by expressing the difference
between each subject's treatment phase score and his overall entire
study phase mean score as a percentage of the range of the scale used
by that individual. This method of standardisation of visual analogue
data was suggested by Maxwell (1978). To illustrate this method of
standardisation, a simple hypothetical example is outlined below.
Two subjects are treated with Drug A for three days and placebo
for three days. Subjects rate themselves on a daily visual analogue
scale labelled "Energetic". The raw scores are given below.
Subject No.l
Subject No.2
Daily Visual Analogue Ratings
PIacebo Drug A
30 40 50 60 70 80
13 15 18 22 25 26
As can be seen, both subjects appeared to rate their energy level
as higher during active treatment. However, one cannot say that
Subject No.l reported a greater effect than Subject No.2 as he may have
centred himself differently on the 100 mm scale and used a wider range
of the scale to reflect changes in mood.
Using the standardisation method outlined above, one calculates
the overall mean score for each individual over the six day study
period, and the range of the scale used by that individual (maximum
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minus minimum score). For Subject No.l, mean = 55, range = 50; for
Subject No.2, mean = 19.8, range = 13. Standardised scores are
obtained by calculating the difference between each subject's raw score
and his overall mean score and expressing this difference as a
proportion (percentage) of the range of the scale used by that
individual. The standardised scores are given below.
Daily Visual Analogue Ratings
PIacebo Drug A
Subject No.l
Raw Scores 30 40 50 60 70 80
Standardised Scores -50 -30 -10 +10 +30 +50
Subject No.2
Raw Scores 13 15 18 22 25 26
Standardised Scores -52 -37 -14 +17 +40 +48
Mean Standardised Mean Standardised
Score -32% Score +32%
Therefore in our hypothetical example using the proportional
method of standardisation of visual analogue scores we summarise the
data from the two individuals by concluding that Drug A brought about a
mean 32% increase in self-rated energy.
However, it is important to stress again that visual analogue data
is not appropriate for between subject comparison. This
standardisation procedure was devised so as to enable the author to
combine data from individuals in order to graphically present results
for groups of subjects.
vfrrg -OS
2.1.2 Interview Assessment
A structured interview rating of sexual functioning (see Appendix
V) was carried out by the author at the end of each of the androgen and
placebo treatment periods in the studies on the eugonadal men
complaining of reduced sex interest (Chapter 5) and erectile
dysfunction (Chapter 6). This interview assessment was in addition to
the daily diary self-ratings. The interview (see Appendix V) was based
on that used by Bancroft et al. (1982). Blind ratings were made of
sexual functioning during the preceding treatment period. Ratings were
made of intercourse and masturbation frequency, level of sexual
interest, positive and negative feelings during sexual contact,
non-genital arousal during sexual contact, orgasm frequency, quality of
erection, degree of ejaculatory control and receptivity (i.e. the
subject's response to partner initiated sexual contact).
2.1.3 Psychophysiological Assessment
In addition to the self ratings and interview ratings of sexual
behaviour, a laboratory method, directly measuring nocturnal erections,
was included in the experimental design of the studies carried out on
the hypogonadal man and the eugonadal man complaining of erectile
dysfunction. In both studies, nocturnal erections were measured "on"
and "off" androgen treatment. The details of the measurement of
nocturnal erections are described in Chapter 7.
2.2 ENDOCRINOLOGICAL ASSESSMENT
In each of the studies described in this thesis, 10 ml blood
samples were collected into 1ithium-heparin tubes. Plasma was
separated by centrifugation at 700g for ten minutes at 4°C. Plasma was




Testosterone was measured using the method of Corker and Davidson
(1978). 50 ul aliquots of plasma and 50 ul of phosphate buffered
saline (PBS) were extracted with 1 ml hexane-ether 4:1 (v/v). After
freezing of the aqueous phase, the organic layer was tipped off into
assay tubes. The organic layer was taken to dryness under nitrogen at
40°C and reconstituted in 100 ul PBS. The extraction procedure
resulted in recovery of 85-92% (n=30) of 1,000 cpm of l^cA
^H-testosterone (Amersham International). Therefore for all
calculations an adjustment multiplication constant of 10/9 was
introduced.
The extracted samples were then assayed in duplicate using an
antiserum (E01, supplied by Dr. S. Tillson) which was raised in the
goat against testosterone-3-carboxymethyloxime BSA. The antiserum
showed significant cross-reaction only with 5dL-dihydrotestosterone
(23.9%) and was used at an initial dilution of 1:10,000. lc<2
-•^-testosterone was used as a tracer. Standards of testosterone were
obtained from Steroloids Inc. and assayed in a reference curve of
20-640 pg/ml. All 3|-| assays were counted on a Packard Tri-cab liquid
scintillation spectrometer. The inter and intra coefficients of
variation for the testosterone assay were 9% and 6% respectively.
2.2.2 Pihydrotestosterone
5<^Dihydrotestosterone (DHT) was measured using a modification of
the method of Thorneycroft _et _al_. (1973). After addition of 1,000 cpm
^H-DHT (New England Nuclear) to act as a recovery check, 200 ul of
plasma was extracted with 2 ml hexane-ether 4:1 (v/v). After freezing
of the aqueous phase, the organic layer was taken to dryness under
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nitrogen at 40°C in a fresh tube and 500 ml iso-octane added.
Chromatographic separation of DHT from testosterone and other steroids
was carried out on celite columns which were made up from 5 ml Kimble
disposable pipettes (Owens, Illinois, U.S.A.). Column flow was
restricted with a glass bead.The columns were filled with 5 cm of a
well mixed quantity of 1 gui celite and 0.5 ml ethylene glycol. The
column was washed with 10 mis iso-octane prior to use. Elution of DHT
from the column was achieved using 3.5 ml 5% benzene/iso-octane. The
resulting eluate was dried down under nitrogen at 40°C and
reconstituted in 200 ul of PBS, 50 ul of which was used as a recovery
check for each sample (mean value 69%) and 100 ul used for
radioimmunoassay. Assay standards were obtained from Steroloids Inc.
The DHT antiserum (171) was raised in the rabbit to 5
dihydrotestosterone-3 carboxymethyloxime-BSA by Mr. D.W. Davidson (MRC
Reproductive Biology Unit, Edinburgh) and was used at a dilution of
1:6,000. The only significant cross-reaction was with testosterone
(57%). The radioimmunoassay procedure was as described for
testosterone by Corker and Davidson (1978) with a standard curve from
5-320 pg/ml. The inter and intra coefficients of variation for the DHT
assay were 14% and 9% respectively.
2.2.3 Sex Hormone Binding Globulin
Sex Hormone Binding Globulin (SHBG) was measured using a
modification of the method of Anderson _et _al_. ( 1976). This assay
utilises DHT as a high affinity ligand, and the competition between DHT
and ^h-DHT reflects the relative SHBG concentration of the plasma
sample.
250 ul plasma samples were diluted 1:8 with 1.75 ml phosphate
buffer. Standard solutions Y and Z were made up, Y containing 100 ul
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2.5 ug/ml PUT and 100 ul 25 uCi/ml 3h_phT made up to 50 ml with
phosphate buffer. Standard solution Z was made up as above, but with
50 ul 2.5 ug/ml DHT instead of 100 ul. Six tubes were set up for each
plasma sample, two total counts (TC) tubes, two Y labelled tubes and
two Z labelled tubes. To the TC tubes 40 ul of 2.5 ug/ml DHT solution
was added and dried down under nitrogen at 40°C. The TC and Y labelled
tubes then had 300 ul of solution Y added, and the Z labelled tubes had
300 ul of solution Z added. All six tubes then had 200 ul of the
diluted plasma sample added. The contents were then briefly rotamixed
and allowed to incubate at room temperature for 30 mins prior to
overnight storage at 4°C. The following day, tubes were transferred
from the fridge to an ice-water bath, and to one tube at a time, while
rotamixing to avoid high local salt concentrations, 0.5 ml saturated
ammonium sulphate was added to precipitate the protein. Tubes were
then left in the ice-water bath for a further 30 mins and then
centrifuged at 3,000g and 4°C to sediment the precipitate. The
supernatant was then decanted into scintillation mini-vials (Sterilin
Ltd.), 2 ml scintillation fluid added, vials were then stoppered and
briefly rotamixed and placed inside glass scintillation vials and
counted in the 3}-|_sc-jnti 11 ation spectrometer, after several hours
equi1ibration.
SHRG concentrations were calculated by subtracting the mean Y
value from the mean TC value, multiplying the difference by 100 and
dividing the result by the mean TC value. This figure was then
multiplied by the molar concentration constant which was 0.221 for the
Y solution and 0.118 for the Z solution. The average of the final Y
and Z values represented the SHBG binding site concentration of the
plasma sample, X 10-8^. j0 convert this value to nmol/1 the result
55
was multiplied by 10. The inter and intra coefficients of variation of
the SHBG assay were 9% and 8% respectively.
2.2.4 Gonadotroph!" ns
LH and FSH were measured in duplicate using the specific double
antibody radioimmunoassay described by Hunter and Bennie (1979).
Antisera to human LH and FSH were raised in the rabbit and kindly
supplied by Professor W.R. Butt, Birmingham. 125j_iabel 1ed LH was
prepared from h-LH IRC-2 (Dr. A. Stockell, Hartree, Cambridge) and
12 5 j _ -j abell ed FSH from highly purified h-FSH (Professor Butt)
according to the method of Hunter and Bennie (1975). Cross-reactivity
with other hormones is described by McNeilly and Hagen (1974). After
incubation, tubes were centrifuged for 30 mins at 4°C and l,500g, the
supernatant poured off and the precipitate containing antibody-bound
hormone counted in an LKB-Wallac gamma counter.
The inter and intra coefficients of variation for the LH assay
were 13% and 9% and for the FSH assay 11% and 8% respectively.
2.2.5 Prolactin
Plasma prolactin was measured by a double antibody
radioimmunoassay described by McNeilly and Hagen (1974). Highly
purified human prolactin was kindly supplied by Dr. H. Friesen
(Manitoba). Prolactin was iodinated to a specific activity of 40-80
uCi/ug by a modification of the chloramine-T method and purified by
column chromatography on Sephadex G-100 (40 x 2.2 cm). The antibody to
prolactin was raised in the rabbit by Dr. A.S. McNeilly (Edinburgh).
50 ul samples were diluted with 450 ul 0.05 M barbitone, pH 8.6
containing 2.5% BSA (BDH) and 50 ul antiserum (1:12,000 dilution).
Tubes were then incubated for 24 hrs at 4°C. After addition of
25J_pro 1 actin (50 ul ; 200-500 pg) incubation was continued for
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24-48 hrs at 4°C, when antibody-hound and free hormone were separated
by the second antibody (as described in detail by McNeilly and Hagen,
1974) with a further incubation for 16-24 hrs at 4°C. Tubes were then
centrifuged at l,500g for 30 mins, supernatant tipped off and the
precipitate containing bound hormone counted in an LKB-Wallac gamma
counter.
The inter and intra coefficients of variation for the prolactin
assay were 12% and 9% respectively.
2.3 INTERDEPENDENCE OF HORMONE-BEHAVIOUR VARIABLES
In the studies reported in this thesis we are manipulating the
endocrine status of men and monitoring any resultant behavioural
changes, i.e. behaviour is being used as the dependent variable. Using
properly controlled experimental methodology, this would appear to be a
valid and appropriate method of tackling many of the unresolved
problems in this area. However, it is important to note that several
researchers have reported that the expression of sexual behaviour may
affect the neuro-endocrine system in man, e.g. an anonymous
investigator claimed that his beard growth (a proposed bio-assay of
testosterone production) increased during periods when he was
anticipating returning to his sexual partner after prolonged separation
(Anon., 1970). However, Hunter jrt _al_. (1983) have recently reported a
lack of association between beard growth and serum testosterone levels.
Turning to the effects of sexual arousal on the androgen status of the
human male, Lincoln (1974) measured plasma testosterone and LH levels
in men during and after exposure to erotic films, and he reported no
effect. Pirke et _al_ (1974) in a very similar study demonstrated a
delayed effect; several hours after watching the erotic films the
subjects displayed a slight elevation in circulating testosterone
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1evels.
Focusing on the effect of sexual activity on endocrine measures in
the human male, Fox et _al_. (1972) reported that plasma testosterone
levels were elevated in one man prior to, and following coital orgasm.
The same authors also reported that masturbation had no significant
effect on plasma testosterone levels. However, Purvis _et _al_« (1976)
claimed that masturbation led to an increase in testosterone levels
whereas Stearns _et _al_. (1973) found no hormonal changes following
orgasm during coitus or masturbation.
Given these opposing findings, no conclusions can be made as yet
regarding the effect of sexual arousal and activity on hormonal
measures in men, but as Hatch (1981) states, a complex bidirectional
relationship may exist between gonadal hormones and sexual behaviour in
man, sexual behaviour being partly determined by hormone levels and
certain sexual behaviours possibly playing a role in determining plasma
concentrations of some gonadal hormones.
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CHAPTER 3
THE BEHAVIOURAL EFFECTS OF VARYING THE REPLACEMENT DOSE OF
TESTOSTERONE IN THE HYPOGONADAL MAN - A CONTROLLED EXPERIMENT
59
3.1 INTRODUCTION
Preliminary evidence has been presented which suggests that a
dose-response relationship exists between androgen replacement and
sexual behaviour in the hypogonadal man (Davidson et _al_. 1979;
Salmimies _et _al_. 1982). However, these studies are open to criticism
(see Section 1.3.2). Double-blind experiments using adequate control
over androgen replacement leading to physiological levels of
circulating testosterone have yet to be carried out, e.g. Davidson
_et a]_. (1979) point out that the intra-muscul ar depot injections that
have been used in the studies to date lead to supra-physiological
testosterone levels in the few days following administration. It could
be argued that any resultant behavioural changes are thus due to a
pharmacological rather than a true physiological effect.
The study reported in this chapter was designed in an attempt to
investigate further the relationship between androgen replacement and
effects on specified aspects of sexual functioning and mood in the
hypogonadal man, and is in effect a direct extension of the work
carried out by Salmimies _et _al_. (1982).
3.2 Materials and Methods
3.2.1 Subjects
Male hypogonadal subjects were recruited from the endocrine clinic
at the Western General Hospital in Edinburgh. Between October 1981 and
December 1982 the author searched the endocrine out-patient clinic
files on a weekly basis, and all hypogonadal clinic attenders were
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offered a place in the study. Prospective subjects were informed by
the clinician that we were carrying out research on a new oral form of
testosterone replacement therapy, and that we were keen to monitor the
behavioural effects of varying the dose. Patients who were interested
were referred to the author who explained the study in detail.
Subjects were informed that they would be investigated thoroughly and
that this would involve fortnightly blood sampling and the completion
of daily diary forms assessing sexual functioning and mood state
throughout the five month study period. The subjects were assured of
confidentiality and that the results would be extremely valuable from a
research point of view, and would also enable us to make firm
recommendations regarding the most suitable long-term replacement dose
of testosterone for them as individuals.
Ten hypogonadal men agreed to participate in the trial and were
recruited. Unfortunabely, two subjects dropped out at an early stage,
one because he experienced difficulty swallowing the capsules and the
other because he refused to continue completing the diary assessment
forms. Complete behavioural data was therefore collected for eight
hypogonadal men. Patient characteristics are shown in Table 3.1.
3.2.2 Androgen Preparation
The natural form of the major testicular androgen, testosterone,
cannot be administered orally as it is rapidly metabolised by the liver
(K1 oer _et _al_. 1980; Nieschlag and Frieschem, 1982). As a result, in
general clinical practice, testosterone must either be injected
intramuscularly or implanted sub-cutaneously (or less frequently,
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TABLE 3.1
PATIENT CHARACTERISTICS OF THE HYPOGONADAL SUBJECTS
No. Age Diagnosis Previous Treatment
1 29 Bilateral testicular tumour.
Castration age 28.
T.U.
2. 31 Kallman's syndrome. Testosterone implants
HCG, Sustanon
3.+ 32 Pituitary tumour.
Excision age 22.
F1uoxymesterone
4.++ 24 Pituitary tumour.
Excision age 17.
Sustanon
5. 26 Klinefelter1s syndrome None
6. 35 Bilateral testicular
torsion at age 15 + 16.
F1uoxymesterone




8. 55 Pituitary tumour.
Excision age 53.
Sustanon
+ Retention of sexual response while in the hypogonadal state,
masturbating to orgasm and ejaculation at a frequency greater than
once per week.
++ Massively obese.
+++ Complained of feeling unwell for the few days following i.m.
testosterone injections (when circulating levels would be at
their highest). Similarly affected during blind high dosage
T.U. treatment.
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administered via rectal suppository) in order to reach the target
organs before hepatic degradation, or the molecule must be modified by
introducing a methyl group at the carbon 17 position to become orally
effective (Neumann et al. 1978). As frequent injections and minor
surgery are obviously inconvenient for the patient and practitioner,
orally active androgens would appear to be the preferable method of
treatment (Davidson _et _al_. 1979). Orally active androgens such as
methyl testosterone have been used clinically, but evidence is mounting
that carbon 17 alkylated derivatives of testosterone have hepatoxic
side-effects (Hirschhauser and Hopkinson, 1974; Coert _et _al_. 1975;
Farrell et_ _al_. 1975; Leska jrt _al_. 1976; Neumann _et _al_. 1978). In
reviewing the field, Neumann et _al_. (1978) state that "all orally
active androgens are 17 alkylated derivatives of testosterone. There
is therefore a real fear that by administration of these derivatives
over longer periods of time, liver damage may occur". Neumann et al.
(1978) were not totally accurate making this statement, for recently a
non-17 alkylated orally active androgen, Testosterone Undecanoate
(T.U.) has been manufactured (Hirschhauser and Hopkinson, 1974;
Nieschlag et_ _al_. 1975). T.U. is fat soluble and is absorbed via the
lymphatic system and the peripheral circulation is reached before
inactivation of the steroid by the liver (Kl oer jirt jfl_, 1980).
Experiments carried out on hypogonadal and eugonadal men have
shown that T.U. administration results in an increase in plasma
androgen concentration after several hours (Hirschhauser and Hopkinson,
1974; Hi rschhauser et _al_. 1975; Nieschl ag et _al_. 1975). Over the
last few years T.U. has been used extensively as replacement therapy
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for male hypogonadism, with a high degree of reported efficacy. The
doses of T.U. that have been used to treat male hypogonadism are shown
in Table 3.2.
In none of the studies cited were any hepatoxic effects reported.
Franchi _et a]_. (1978) studied liver function and size and consistency
of the prostate, and eight months of treatment with T.U. resulted in no
change. More recently Gooren _et _al_. (1982) reported that treatment for
up to fifty-six months had no adverse effects on the liver function of
the patients who were studied.
The evidence accumulated to date indicates that oral T.U. is a
safe and acceptable form of androgen therapy. Frequent oral
administration of the androgen facilitates better control over the
input of testosterone to the systemic circulation of the hypogonadal
man, in contrast to the depot loading and uncontrolled release of
testosterone which follows intramuscular injection.
3.2.3 Design
The study lasted for five months, i.e. five assessment periods
each lasting one month. The first assessment period acted as a
baseline, and in the remaining four periods T.U. was administered.
All subjects stopped taking their existing androgen preparations
at least four weeks before the start of the study (i.e. each subject
v/as withdrawn from testosterone replacement for at least eight weeks
prior to the beginning of T.U. administration within the study).
During the first assessment period basal endocrine and behavioural
measures were obtained. A minimum of three blood samples were taken
from each subject during the baseline month to confirm the hypogonadal
64
TABLE 3.2







Hirschhauser & Hopkinson 1974 1 60-90
Mies & KrempI 1977 10 160
Sarris et al. 1977 3 120
Franchi et al. 1978 34 40-120
Franchimont et al. 1978 10 120-240
Skarabalo et al. 1978 4 160
Geere et al. 1980 9 40-80
Luisi & Franchi 1980 12 120
Weil et al. 1980 12 40-80
Maisey et al. 1981 69 80-160
Skakkebaek et al. 1981 12 160
Gooren et al. 1982 65 80-160
Salmimies et al. 1982 15 80-200
Wu et al. 1982 4 160
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diagnosis. Following the baseline assessment period subjects were
administered T.U. for four months. Four of the eight subjects received
monthly increments in T.U. replacement, i.e. 40 -> 160 mg/day, four
TABLE 3.3 Daily T.U. Dosage per Month
Month 1 Month 2 Month 3 Month 4 Month 5
N = 4 0 40mg 80mg 120mg 160mg
N = 4 0 160mg 120mg 80mg 40mg
received successive monthly decrements, from 160 40 mg/day, as shown
in Table 3.3. Throughout the four months of T.U. administration bloods
were taken twice a day at 0900 and 1300 hours at fortnightly intervals,
that is prior to, and four hours after ingestion of the morning dose of
T.U. (as previously described by Skakkebaek et _al_. 1981). For the four
months of T.U. administration each subject took two capsules at 0900
hrs and two at 1700 hrs, as shown in Table 3.4. Using this methodology
subjects were blind as to their replacement dosage, as all subjects
took four identical capsules per day for the four months of T.U.
administrati on.
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TABLE 3.4 Daily T.U. Dosage Scheme
T.U. Dose 0900 hrs 1700 hrs
40 mg/day 1 40mg capsule
1 placebo capsule
2 placebo capsules




120 mg/day 2 40mg capsules 1 40mg capsule
1 placebo capsule
160 mg/day y 2 40mg capsules 2 40mg capsules
The design was double-blind and the dosage regimes were allocated
to subjects arbitrarily. This methodological design is an improvement
on that used by Salmimies et _al_. (1982) who stated "A double-blind
design was not used for several reasons. A double-blind study would
have required an alteration in the sequence of treatment periods.
However, it is difficult to study a low dose after a period with a high
testosterone dose because overlap can occur". The experimental design
developed for the present study, i.e. gradual increments or decrements
in replacement dose would appear to overcome these difficulties. The
range of T.U. dosage regimes was selected as being representative of
the doses that have been reported in the literature for the treatment
of male hypogonadism (see Table 3.2).
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3.2.3.1 Endocrine Assessment
Following venepuncture blood samples were centrifuged and plasma
stored at -20°C. All samples were measured for testosterone in a
single assay using the method described by Corker and Davidson (1978).
3.2.3.2 Behavioural Assessment
All subjects completed a coded daily diary form for the duration
of the study (Appendix IV). On this form subjects reported presence or
absence of erections on waking, occurrence, description and qualitative
rating of sexual activity, whether the activity was self, partner or
jointly initiated, and whether or not ejaculation resulted. Subjects
also rated themselves for frequency of sexual thoughts and sexual
excitement accompanying these thoughts on two separate 100mm visual
analogue scales. Mood state was also recorded daily. (Subjects
completed the daily diary form for four weeks before entering the study
proper. This allowed subjects to become accumstomed to completing the
diary form on a daily basis. During this period the author checked the
forms and advised individuals who were unsure as to what was required.
This "practice" data was not included in the final analysis).
3.2.4 Analysis
In order to allow direct comparison with the very similar study of
Salmimies et_ aj_. (1982), exactly the same form of statistical analysis
was employed, i.e. comparing each subject's monthly treatment mean
behavioural rating against his mean basal levels, using Wilcoxon's test
for paired data. All visual analogue data was standardised using the
method described in Chapter 2.1.1, i.e. each man's monthly mean visual
analogue scores were expressed as deviations from his overall mean
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score for the five month stud)' period. These deviations were then
standardised using the proportional method and were expressed as a
percentage of the range of the scale used by that individual over the
five months.
The effect of T.U. ingestion on circulating testosterone levels
was assessed using the paired t-test (a.m. versus p.m. values).
Complete endocrine data was available for only seven out of the eight
subjects, as subject no.l was unable to attend for all of the blood
sampling due to work commitments.
3.3 RESULTS
The results of the effects of varying the replacement dosage of
T.U. on circulating testosterone levels, sexual behaviour and mood
state are displayed in Figs. 3.1 - 3.10.
Oral ingestion of T.U. resulted in marked elevations in plasma
testosterone levels (although at the highest dose, 160 mg/day, this
increase did not reach statistical significance).
The behavioural data is summarised in Figs. 3.2 - 3.10. The mean
score represents the standardised mean visual analogue score for the
whole group over the entire study period. The behavioural effects of
varying the replacement dose of T.U. are expressed as percentage
deviations from this overall group mean.
Dose response relationships between T.U. replacement and sexual
behaviour were demonstrated most clearly for frequency of sexual
thoughts, arousal accompanying these thoughts, and frequency of
reported erections on waking. The hypogonadal men also rated
themselves as feeling less tense and anxious, changeable, and irritable
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FIGURE 3■1
The effect of varying the replacement dose of T.U. on mean









0 40mg 80mg 120mg I60mg
T.U. dosage per day
The effect of varying the replacement dose of T.U. on mean frequency
of sexual thoughts and mean sex acts per month in eight
hypogonadal men.
*p<0.05, **p<0.025, ***p<0.01 in comparison with no treatment










0 40mg 80mg 120mg l60mg
T.U. dosage per day
FIGURE 3.3
The effect of varying the replacement dose of T.U. on mean frequency of
morning erections and self-rated arousal accompanying sexual thoughts in
eight hypogonadal men.
















0 40mg 80mg 120mg 160mg
T.U. dosage per day
FIGURE 3.4
The effect of varying the replacement dose of T.U. on mean frequency of
self-initiated sex acts per month and mean ejaculation frequency per
month in eight hypogonadal men.
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0 40mg 80mg 120mg 160mg
T.U. dosage per day
FIGURE 3.5
The effect of varying the replacement dose of T.U. on mean self-rated
sexual satisfaction per month in eight hypogonadal men. All











0 40mg 80mg I20mg I60mg
T.U. dosage per day
FIGURE 3.6
The effect of varying the replacement dose of T.U. on self-rated mood
states "Sociable and Friendly" and "Energetic" in eight hypogonadal















0 40mg 80mg 120mg I60mg
T.U. dosage per day
The effect of varying the replacement dose of T.U. on self-rated
mood states "Tense and Anxious" and "Irritable" in eight hypogonadal
men.
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T.U. dosage per day
FIGURE 3.8
The effect of varying the replacement dose of T.U. on self-rated
mood states "Cheerful and Happy" and "Fatigued and Tired" in eight
hypogonadal men. All comparisons with no treatment non-significant



















0 40mg 80mg I20mg 160mg
T.U. dosage per day
riGURE 3.9
rhe effect of varying the replacement dose of T.U. on self-rated mood
states "Changeable or Up and Down" and "Aggressive" in eight
nypogonadal men.



























0 40mg 80mg 120mg 160mg
T.U. dosage per day
FIGURE 3.10
The effect of varying the replacement dose of T.U. on self-rated mood
states "Depressed and Unhappy" and "Relaxed" in eight hypogonadal





Administration of T.U. acted to increase circulating testosterone
levels. However a linear incremental increase in systemic testosterone
level with increasing dosage of T.U. was not observed (Fig. 3.1). This
may be due to the limitations of our single post-dose blood sampling
regime, and could be accounted for by the recent findings that
hypogonadal men display a marked degree of intra- and inter-individual
variation in the rate at which testosterone blood levels peak following
T.U. administration (Cantrill _et _al_. 1983; Schurmeyer _et _al_. 1983).
Using a more frequent blood sampling regime, a clearer relationship
between testosterone input and circulating testosterone levels may have
been observed.
During all dose regimens the post-dose testosterone level was
higher than the pre-dose level. Interestingly, at the highest dose of
T.U. (160 mg/day) this difference did not reach statisticial
significance. This is probably due, in part, to the elevation in the
pre-dose (0900 hr) circulating testosterone level, as a result of the
high dosage androgen administration.
3.4.2 Sexual Behaviour
The effects of varying the replacement dosage of T.U. on sexual
behaviours are exhibited in Figs. 3.2 - 3.5, and in general are very
similar to the findings of Salmimies _et _al_. (1982).
Frequency of sexual thoughts when compared with basal values were
significantly elevated during the 120 and 160 mg T.U./day dosage
regimes. Similar results were observed for the self-rating scale
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measuring arousal accompanying sexual thoughts. Ejaculation frequency
was significantly raised compared with basal values only during the 160
mg/day period, perhaps indicating that this facet of sexual functioning
requires prolonged and high dosage androgen replacement in order to
produce marked effects (Skakkebaek _et _al_. 1981). All subjects reported
that ejaculation was associated with orgasm on all occasions during the
study period. Several men reported an increase in ejaculate volume
throughout the study.
The mean frequency of sexual acts, while higher on T.U. than on no
treatment, did not appear to vary in a dose-dependent manner. This may
be because androgens act primarily on sexual interest (Bancroft, 1980),
and this is not reflected in the gross measure of the sexual activity
of the dyad. The findings of the present study suggest that sexual
interest (as reflected by self-rated sexual thoughts) varies in a
dose-dependent manner with androgen replacement, thus supporting the
Bancroft (1980) hypothesis. One would then perhaps expect this
androgen effect on sexual appetite to be reflected in the frequency of
self-initiated sexual acts; however, this effect was not observed.
It is also of interest to note that while Bancroft (1980)
suggested that erectile function per se is not affected by androgen
status, the present study confirms Davidson _et _al_s' (1979) finding,
i.e. morning erections in the hypogonadal man vary in a dose-dependent
manner with androgen replacement (Fig. 3.3). This finding has to be
viewed in light of the recent report by Bancroft and Wu (1983) who
claimed that erections in response to erotic film were not affected by
androgen replacement or withdrawal, whereas erections in response to
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erotic fantasy were markedly affected. It may be that erections on
waking (i.e. residual nocturnal erections) are qualitatively different
from conscious erections in response to erotic film, e.g. erections on
waking may be similar to the fantasy erections of the Bancroft and Wu
(1983) study in that the stimulus for the erection is generated
internally as opposed to the external film stimulus. (The effect of
androgen replacement on nocturnal erections is discussed in detail in
Chapter 7). However, it is also important to note that Kwan et al.
(1983) have recently failed to replicate Bancroft and Wu's (1983)
finding by reporting that erections in response to erotic film and
fantasy were both unaffected by testosterone withdrawal and
replacement.
Davidson _et _al_. (1982) hypothesised that androgens mediate their
behavioural effect by increasing the subjective pleasurable awareness
of sexual response. This was tested in the present study by comparing
self-rated sexual satisfaction across treatment periods (Figure 3.5)
and no significant differences were observed. However, it is difficult
to make firm conclusions regarding the Davidson _et aj_ (1982) hypothesis
from this small experiment, the major problem being that sexual
activity is such a rare occurrence in the untreated hypogonadal man.
However, one subject in the present study (no.3) did display a
masturbation and ejaculation frequency of greater than once per week
while markedly hypogonadal (mean testosterone level, 6.6 nmol/1).
Salmirnies est _al_. (1982) similarly reported that four of their fifteen
subjects also reported a marked degree of sexual activity while in the
hypogonadal state.
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In conclusion, dose-response relationships between androgen
replacement and sexual behaviour were demonstrated most clearly for
self-rated frequency of sexual thoughts, associated arousal and
erections on waking.
3.4.3 Mood
In general, the effects of T.U. administration on self-rated mood
are very simlar to those observed by Skakkebaek et. _al_. (1981) who,
using the Lorr-McNair MACL, reported that anxiety and tension, anger
and fatigue were decreased and vigour increased following T.U.
administration as compared with placebo. In the present study the
hypogonadal subjects rated themselves as feeling less tense and
anxious, changeable and irritable while taking the higher doses of T.U.
as compared with no treatment. It is also extremely interesting to
note that the hypogonadal men rated themselves as feeling 1 ess
aggressive while taking the higher doses of T.U. (The relationship
between androgens and aggression in man is discussed in detail in
Chapter 9).
The design of the present study does not enable us to directly
test the hypothesis proposed by Kinsey et a]_. (1953), i.e. that
androgens act primarily on general metabolism and mood and only
secondarily on sexual behaviour. However, as the general effect of
T.U. treatment on mood state was modest (e.g. no effect on six out of
the ten mood scales) and not closely related to androgen replacement
dose, it is possible that the mood changes rather than causing the
improvement in sexual behaviour were in fact a result of the general
improvement in sexual functioning. Anxiety and general negative mood
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states may have been partially due to the sexual difficulties
associated v/ith hypogonadism and would thus tend to improve following
the beneficial effects of androgen replacement on sexual functioning.
The Kinsey et jil_ (1953) hypothesis appears even less convincing when
one considers that Davidson et _al_. (1979) and Salmimies et jfL (1982)
both reported no effect of testosterone administration on mood, yet
found clear beneficial effects of androgen replacement on sexual
functioning in the hypogonadal man.
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CHAPTER 4
ANDROGEN ADMINISTRATION TO EUGONADAL MEN - THE DIFFICULTIES IN
RAISING CIRCULATING ANDROGEN LEVELS
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4.1 INTRODUCTION
Androgen replacement is generally considered to be unhelpful in
the treatment of sexual dysfunction in men with normal circulating
levels of testosterone (Cooper _et _al_. , 1973; Renkert et al., 1979).
Hypogonadal men, on the other hand, show definite improvements in
sexual interest and function with androgen replacement (Davidson
et aj_., 1979; Skakkebaek et al ♦, 1981). The usual explanation given
is that a certain amount of androgens are required for sexual response
and any increase above this level will have no additional effect (Pirke
& Kockott, 1982). A further explanation deserves consideration; the
normal homeostatic mechanisms (LH suppression with consequent reduction
in endogenous testosterone production and sex hormone binding globulin
(SHBG) reduction leading to increased metabolic clearance) make it
difficult to raise circulating testosterone levels in eugonadal men.
In the studies of eugonadal men receiving androgens for sexual
dysfunction circulating testosterone levels have either not been
measured (Jakobovitz, 1970) or have shown no increase with treatment
(Benkert et al., 1979). If it were possible to sustain a substantial
increase, behavioural effects might be produced even with increases
within the normal range.
Two types of testosterone administration are now in general use;
testosterone undecanoate administered orally and intramuscular
injections of testosterone esters (e.g. Sustanon or testosterone
oenanthate).
Testosterone undecanoate (T.U.) is largely absorbed by the
lymphatics, and so far hepatoxic effects have not been observed even
after long-term administration (Franchi jet _al_., 1978; Gooren et al.,
1982). It has been shown to be a very satisfactory form of androgen
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replacement in hypogonadism (Franchi et_ _al_., 1978; Franchimont et al.,
1978; Skakkebaek et al., 1981; Maisey et _al_, 1981). In normal men,
single dose administration leads to a significant increase in
circulating testosterone levels, reaching a maximum approximately 4-5
hours after oral ingestion (Nieschlag et al., 1975). However with more
prolonged administration, especially of high doses, the plasma
testosterone concentration may be suppressed (Benkert et. _al_., 1979;
Nieschl ag et a_l_., 1978). In studies of hypogonadal men, testosterone
undecanoate produces an increase in circulating DHT which is relatively
greater and more sustained than the rise in testosterone (Franchimont
_et _al_* > 1978; Skakkebaek _et _al_. > 1981; Wu _et _al_., 1982).
The pharmacodynamics of injected testosterone esters in eugonadal
men have mainly been studied in the case of testosterone oenanthate,
cypionate and propionate (Nieschlag j?t _al_., 1976; Steinberger, 1980;
Schulte-Beerbuhl & Nieschlag, 1980 and Sokol et _al_., 1982). In most
cases plasma testosterone levels were maximal for one to two days and
remained elevated for seven to ten days following each injection.
Plasma DHT was found to be raised after testosterone oenanthate for
about 5 days (Schulte-Beerbuhl & Nieschlag, 1980).
In this study we have compared three different dosages of
testosterone undecanoate as wel1 as Sustanon 250 injection (a mixture
of 4 esters, propionate 30 mg, phenyl propionate 60 mg, isocaproate
60 mg and decanoate 100 mg) in normal men with particular reference to
the total and free testosterone, DHT, SHBG and LH levels in the plasma.
The purpose of this study is to establish the best regime for producing
maintained elevation of plasma testosterone in eugonadal men, in order
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to investigate the behavioural effects of this endocrine manipulation
in eugonadal men complaining of sexual dysfunction.
4.2 MATERIALS AND METHODS
4.2.1 Subjects
Eight normal men (age 20-44 years, mean 34.1 years) were recruited
from hospital and Unit staff. Each was shown to have normal liver
function tests and plasma acid phosphatase levels before inclusion in
the study.
4.2.2 Oesign
The study period lasted for 10 weeks, during which time blood
samples were taken at 0900 hrs and 1300 hrs on tv/o days per week. By
taking samples before the morning dose, at 0900 hrs and four hours
later, we aimed to measure the "peak" and "trough" in daily T levels
and arrive at a representative mean T level for the day.
The 8 men had blood samples taken for one week to determine
baseline values and were then randomly allocated into two groups A and
B, four men in each. Group A had two 3 week periods of T.U.
administration separated by a 3 week interval (to act as a washout
phase). The two dose regimes were 80 mg per day and 160 mg per day and
the order of presentation of these two regimes was balanced. The T.U.
capsules (40 mg each) were taken at 0900 hrs and at 1700 hrs. The
design for group B was exactly the same except the comparison was
between a single injection of Sustanon 250 and T.U. at a dosage of 240
mg per day (taken in 80 mg doses at 0900 hrs, 1300 hrs and 1700 hrs).




Total testosterone was assayed using the method described by
Corker A Davidson (1978). A ratio of free to total testosterone was
measured according to the method of Rergink et al. (1981);
concentration of free testosterone was then estimated by applying this
ratio to the total testosterone concentration. SHBG was measured
according to Anderson et al. (1976) and LH according to Hunter & Bennie
(1979). DHT was assayed only in group B, after chromatography on




Mean differences in hormone levels were assessed using analysis of
variance for repeated measures and the Scheffe method to compare
differences between treatments. Due to the highly skewed distribution
of plasma concentrations following Sustanon administration, log
transformation of the data was used for group B.
4.3 RESULTS
Mean levels for total testosterone, estimated free testosterone,
SHBG and LH for the baseline week and each 3 week period are shown for
Group A in Table 4.1 and for group P in Table 4.2 (together with
pi asma DHT 1 eve! s).
In group A there were no significant differences between either
dose regime and baseline or interval levels in any of the hormones
measured, though total and estimated free testosterone were higher and
SHBG and LH levels lower during the high dose administration.
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In group R, differences were more marked. The higher mean levels
of testosterone during Sustanon administration were mainly due to very
high levels within the first few days (see Fig. 4.1). With log
transformation the differences between periods did not reach
statistical significance. Both T.U. 240 mg per day and Sustanon
produced significant lowering of SHRG compared with baseline levels*.
In addition, SHRG remained significantly depressed during the interval
washout period, presumably due to carry over suppression following the
first androgen administration.
Although LH levels were lower during Sustanon and T.U.
administration, the differences were not significant when compared with
basal values. DHT levels were significantly greater during T.U. 240 mg
per day administration compared with both baseline (p=<0.01) and
Sustanon administration (p=<^0.01).
In group B changes in the SHBG levels and ratio of free to total
testosterone were looked at week by week (see Figs 4.2 and 4.3).
Following Sustanon injection, the percentage of free testosterone was
maximal in the first week and thereafter progressively fell.
Reciprocally the SHRG levels were lowest during the first week followed
by a progressive rise. Comparison of levels the day after the Sustanon
inejction with baseline showed an approximately 400% increase in total
testosterone concentration (Fig. 4.1). During administration of
*The degree of reduction in SHBG levels following T.U. administration
observed in this study may have been slightly over-estimated as a
































































































Effect of a single Sustanon 250 injection on total testosterone






















Basal Week Week Week
1 2 3
Basal Week Week Week
1 2 3
FIGURE 4.2
Percentage unbound (free) testosterone during administration of
Sustanon 250 and T.U. 240 mg/day.
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SUSTANON 250 T.U. 240mg/day
Basal Week Week Week
1 2 3
Basal Week Week Week
1 2 3
FIGURE 4.3
SHBG levels during administration of Sustanon 250 and T.U. 240 mg/day.
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240 mg of T.U. the pattern was quite different. SHBG was progressively
falling and the ratio of tree to total testosterone rising during the 3
weeks.
A further difference in the kinetics of the two types of
administration is to be expected in the variations during each day.
Intermittent oral administration will produce periodic rises reaching a
peak several hours after each oral dose. We therefore compared the
0900 hrs (pre-dose) and 1300 hrs (4 hrs post-dose) plasma levels
during T.U. administration. Normally there is a fall in testosterone
during this part of the diurnal cycle (Mansfield et al., 1974). The
effect of treatment was assessed by comparing the change scores (1300
hrs minus 0900 hrs) during the no-treatment (interval) period with
those during hormone administration. In group A, the mean change
scores (+_ .S.D.) for the 3 conditions were -3.5 (5.2), 1.6 (7.6) and
10.1 (10.76) nmol/1 for no treatment, 80 mg T.U. and 160 mg T.U.
respectively. Using the paired t-test, the change score comparison
was significant for 160 mg T.U. (p=^0.01) but not for 80 mg T.U. In
group B the change scores were 4.9 (7.3), 4.5 (16.7) and 3.1 (16.7)
nmol/1 for no-treatment, T.U. 240 mg and Sustanon 250 mg respectively.
The differences were not statistically significant in this group.
4.4 DISCUSSION
With the dosage regimes used in this study, no substantial and
sustained increases in circulating testosterone (total or free) were
achieved and it is clearly not easy to overcome the homeostatic
mechanisms in eugonadal men to produce such an increase. With Sustanon
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substantial increases were confined to the first week and when the
whole 3 weeks period was taken, and hormone concentrations log
transformed to correct the skewed distribution, no significant
difference from baseline was found. Injection of Sustanon 250 mg every
7 to 14 days would probably be more effective. A frequency of 10 to 14
days has been suggested for testosterone oenanthate or cypionate
(Nieschlag et al., 1976; Schulte-Reerbuhl & Nieschlag, 1980; Sokol
et _al_., 1982). As yet no reports have been published of the kinetics
of using such frequent parenteral administration.
For the testosterone undecanoate, the increases in total
testosterone were generally very modest. However, progressive increase
in the ratio of free to total testosterone shown during administration
of T.U. 240 mg daily does raise the possibility that with more
prolonged administration a more substantial rise in free testosterone
will eventually result.
An alternative explanation for the general lack of effect of T.U.
found in this study deserves serious consideration. As stated in the
introduction, the post-dose blood sample was taken four hours after
ingestion of the T.U. dose. This protocol was chosen in light of the
evidence known to the author at the time which suggested that following
oral ingestion of T.U., plasma testosterone levels in the eugonadal men
reached a maximum after approximately four hours (Nieschlag et al.,
1975). However, since the present study was completed, evidence has
been presented which suggests that there is in fact a great deal of
inter- and intra-individual variation in the rate at which men absorb
T.U., with plasma androgens reaching a peak anything from one to eight
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hours following ingestion (Cantrill et _al_., 1983; Schurmeyer et al.,
1983). Therefore it is possible that because of the limited single
post-dose blood sampling regime used in the present study, the
absorption peaks in plasma testosterone levels may not have been picked
up. (This variability in the rate of absorption of T.IJ. was confirmed
by the author in a small additional study, summarised in Appendix
III).
In the meantime, we must conclude that oral administration of
testosterone undecanoate may offer particular advantages in the
treatment of male hypogonadism, whereas frequent injection of
testosterone esters such as Sustanon would appear to be the best method




A CONTROLLED EVALUATION OF TESTOSTERONE TREATMENT IN MEN
WITH REDUCED SEXUAL INTEREST
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5.1 INTRODUCTION
Clinical impressions concerning the results of androgen
replacement therapy in the treatment of hypogonadism led pioneers in
the field such as Money (1961) to conclude that "The level of sex drive
or libido is hormonally influenced and androgen is probably the libido
hormone in both men and women". However it is only in the last four
years that methodologically acceptable controlled experiments with
hypogonadal men have confirmed the hypothesis that testosterone is
directly related to sexual interest and activity in men (Davidson et
al. 1979; Luisi and Franchi, 1980; Skakkebaek et al. 1981).
In the eugonadal man, however, correlational studies have
suggested that a simple relationship does not exist between circulating
total testosterone levels and degree of interest in sex (Monti et al.
1977; Brown et al. 1978) or between circulating testosterone levels
and frequency of sexual activity (Raboch and Starka, 1972; 1973;
Doering et _al_. 1974), although positive (Reinberg and Lagoguey, 1978;
Tsitouras _et _al_. 1982) and negative relationships (Kraemer et _al_. 1976)
have been suggested.
Most previous studies have concluded that "impotence" is not
alleviated by exogenous androgen administration (see Schiavi and White,
1976 for review). However, previous investigators have generally
failed to distinguish between loss of sexual appetite and erectile
disorders. Evidence is mounting that erectile mechanisms per se may be
relatively unaffected by androgen status (Eancroft and Wu, 1983) and
the relationship between androgens and sexual interest in the male has
only recently received serious attention.
Wu _et _al_. (1982) using an experimental rather than a correl ational
approach, reported the behavioural effects of testosterone administered
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to adult Klinefelter men who had exogenous testosterone levels which
were in the low to normal range. These authors reported that the
principal effect of testosterone administration, as compared with
matched placebo treatment, was to increase the frequency of self-rated
sexual thoughts and sexual excitement associated with those thoughts.
Wu ert j3j_. (1982) suggest that further studies are required to determine
whether testosterone administration has a similar effect on the sexual
behaviour of the endocrinologically normal man. It is important to
note that Skakkebaek et al. (1981), in their study of testosterone
replacement in hypogonadal men, reported that changes in sex interest
were closely related in time to androgen replacement and withdrawal.
Similarly Heim and Hursch (1979) in their review of the literature on
the effects of castration in the male concluded that while many
castrates retained the erectile capacity necessary for intercourse, the
majority reported a marked decrease or disappearance of spontaneous
interest in sex.
In light of this recent literature suggesting that in the male,
sex interest rather than erectile function may be related to androgen
status, a controlled investigation into the effects of substantially
raising circulating androgen levels in eugonadal men complaining of
loss of, or reduced sexual interest appears to be warranted. The
rationale behind the present study can be summarised as follows:-
(a) Sexual interest may be that sub-factor of overall male sexual
behaviour which is most directly influenced by alterations to
circulating androgen levels.
(b) Individuals may differ as to their threshold androgen requirements
necessary for a "normal" degree of sexual interest.
(-c) Men who complain of reduced interest in sex may benefit from having
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their circulating androgen levels raised.
5.2 MATERIALS AND METHODS
5.2.1 Subjects
The sample was recruited from eugonadal male reporters to the
local sexual problems clinic (Royal Infirmary of Edinburgh). The
recruitment criteria were that the subjects be aged between 18-65 years
and whose primary presenting complaint, as determined by the referring
therapist and subsequently confirmed by the author, was loss or lack of
interest in sex which was not secondary to erectile failure, or any
obvious physical or mental illness. Patients were informed of the
purpose of the study and were offered the opportunity to participate
while on the waiting list for psycho-sexual counselling. Between May
1981 and December 1982, ten subjects aged between 33-64 years (mean
44.6 _+ 10.3 yrs) were recruited. All subjects had a current sexual
partner; in fact all were married. Before inclusion in the study each
subject was shown to have normal liver function and no indications of
prostatic disease, using standard laboratory tests.
5.2.2 Design
For a period of four weeks (which acted as a baseline) subjects
had weekly blood samples taken to determine resting endocrinological
status. Thereafter subjects were administered Sustanon 250 injections
(Organon International Ltd.) intramuscularly every fortnight for six
weeks and matched placebo injections fortnightly for six weeks. The
design was balanced in that five subjects received the testosterone
preparation for the first six weeks, five received the placebo
injections first. Sustanon was chosen as the androgen preparation as
previous research (described in Chapter 4) had shown that marked
elevations in circulating testosterone levels are consistently brought
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about by this mode of administration compared with oral androgen
preparations.
All injections were administered in a double blind manner.
5.2.2.1 Hormone Measurement
Weekly blood samples (10 mis by venepuncture) were taken at the
same time of day (at a time convenient to the subject) throughout the
sixteen week study period. Androgen and placebo injections were
administered at the same time as the blood sample was taken. Plasma
samples were assayed for testosterone using the method of Corker and
Davidson (1978) and for SHBG using the method of Anderson et al.
(1976).
5.2.2.2 Behavioural Assessment
Each subject completed a coded daily diary form (see Appendix IV)
for the duration of the study, indicating presence or absence of
morning erections, incidence and description of sexual activity,
whether ejaculation resulted and whether the sexual activity was self,
partner or jointly initiated. Frequency of sexual thoughts and arousal
associated with these thoughts were scored on 100 mm visual analogue
scales. Mood state was also evaluated daily by means of ten
independent visual analogue scales. The four week baseline phase
allowed subjects to become accustomed to completing the diary form on a
daily basis prior to entering the study proper. During this period the
experimenter checked the forms and advised individuals who were unsure
as to what was required.
The experimenter also carried out a structured interview (see
Appendix V) at the end of each of the testosterone and placebo
treatment periods, rating each subject on various aspects of his sexual
functioning, e.g. intercourse frequency, degree of sexual interest,
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positive and negative feelings during sexual contact, degree of
non-genital arousal during sexual contact, quality of erection, degree
of ejaculatory control and receptivity.
5.2.3 Analysis
Mean differences in self-rated (diary) sexual behaviour
(testosterone versus placebo treatment) were analysed using the paired
t-test. The data from the visua!-analogue scales were reduced to
weekly means and compared across treatment periods using repeated
measures analysis of variance. Interview ratings of sexual functioning
were compared across treatments using the Sign Test. The effect of
Sustanon injections on circulating testosterone and SHBG levels was
assessed using repeated measures analysis of variance.
5.3 RESULTS
The results of the effects of high dosage testosterone injections
compared with placebo are summarised in Tables 5.1 to 5.3 and in Figs.
5.1 and 5.2. In Fig. 5.1 the visual analogue scores were standardised
using the proportional method (see Chapter 2.1.1). The difference
between each subject's weekly mean score and his overall entire study
phase mean score was expressed as a percentage of the range of the
scale used by that individual. Change scores represent each subject's
behavioural rating while receiving testosterone minus his rating while
receiving placebo. These values were then meaned for the group as a
whole. The observed testosterone effect on frequency of sexual
thoughts was not a transient one following the first active injection,
as analysis of variance revealed no significant differences in
self-rated sexual interest across time (F=0.23, N.S.) and there was no
evidence of an interaction effect, treatment against time (F=0.02,
N.S.).
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TABLE 5.1 DIARY DATA
THE EFFECT OF HIGH DOSE TESTOSTERONE VERSUS PLACEBO TREATMENT
IN MEN COMPLAINING OF REDUCED SEXUAL INTEREST (n=10)'
Change Score
(Testosterone minus Paired
Behavioural measure PIacebo; Mean ±S.D. t-test
Frequency of Morning Erections (%) 8.4 (16.7) N.S.
Frequency of Sexual Activity
per treatment period 1.2 (3.7) N.S.
Frequency of Self-Initiated
Sexual Activity per
treatment period 1.1 (2.4) N.S.
Visual Analogue Scales (0-100) ANOVAR
Sexual Thoughts 5.0 (5.3) p < 0.02
Sexual Excitement Associated
with Sexual Thoughts 4.4 (7.8) N.S.
Mood
Cheerful and Happy 0.6 (5.4) N.S.
Fatigued and Tired 1.6 (7.2) N.S.
Sociable and Friendly 1.0 (4.9) N.S.
Energetic 2.8 (13.5) N.S.
Tense and Anxious 2 (5.6) N.S.
Irritable -2.4 (5.4) N.S.
Changeable 0.9 (5.2) N.S.
Aggressive -0.8 (5.1) N.S.
Depressed and Unhappy 0.5 (3.6) N.S.
Relaxed 1.6 (6.5) N.S.
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TABLE 5.2 INTERVIEW DATA
THE EFFECT OF HIGH DOSE TESTOSTERONE VERSUS PLACEBO TREATMENT











Sexual Activity Frequency 4 2 N.S.
Sexual Interest 4 0 p < 0.1
Negative Feelings (frequency) 0 0 N.S.
Negative Feelings (strength) 0 0 N.S.
Positive Feelings 0 0 N.S.
Sexual Arousal (frequency) 0 0 N.S.
Sexual Arousal (strength) 2 1 N.S.
Orgasm (frequency) 0 0 N.S.
Erection (quality) 1 2 N.S.
Ejaculation (retarded) 0 0 N.S.
Ejaculation (premature) 0 1 N.S.
Receptivity 2 2 N.S.
+CompIete interviev/ data available for 8 out of the 10 subjects
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ANOVAP. ** Sustanon> Baseline, p <10.01
Sustanon> Placebo, p<0.01
* Sustanon .cBasel ine, p<0.05
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FIGURE 5.1
The effect of Sustanon (testosterone) versus placebo treatment on
self-rated frequency of sexual thoughts in ten men complaining of





































The effect of Sustanon (testosterone) andplacebo treatment on the ratio
of testosterone in 10 men complaining of reduced sexual interest.
SHBG
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There was no correlation between each man's mean basal
testosterone level and his percentage increase in sexual interest (r =
-0.18, N.S.) or between each man's age and percentage increase in
sexual interest (r = 0.33, N.S.).
5.4 DISCUSSION
The results of the present study indicate that testosterone
administration acted to significantly increase circulating total
testosterone levels and to decrease circulating SHBG levels,
effectively acting to increase the proportion of unbound bio-active
androgen in the plasma (Fig. 5.2). This elevation in "free"
testosterone level appeared to act to increase the sexual interest of a
group of men whose primary complaint was loss of libido (Fig. 5.1).
This effect was apparent both when self-ratings and blind assessors
interview ratings were analysed.
High dosage testosterone treatment had no effect on mood state.
This negative finding is important in light of Kinsey _et _al_.s (1953)
suggestion that androgens act primarily on general metabolism and mood,
and only secondarily on sexual functioning. The present findings are
thus in direct opposition to the Kinsey hypothesis.
At present one can only speculate as to the mechanisms underlying
the effect of androgen administration on sexual interest. It is
possible that certain individuals require a higher theshold level of
androgen than others in order to stimulate "normal" sexual appetite. A
decrease in the circulating "free" androgen level may act to reduce the
level of sex interest in such individuals. Such a decrease in androgen
levels could be brought about by environmental factors, e.g. stress
(Kreuz _et _al_. 1972). The stress produced by marital or sexual problems
in a couple could act to make the situation worse. As Carney et al.
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(1978) state, "prolonged inhibition of sexual response could affect
endogenous androgen production, which in turn could serve to exacerbate
and prolong the dysfunction". It is perhaps appropriate to state that
hormonal factors probably play a minimal role in the development of
sexual problems in the majority of eugonadal couples. However, subtle
differences in endocrine status may be enough to tip the balance
towards dysfunction, e.g. declining sexual interest in the male in a
partnership where the man is expected to take the sexual initiative may
result in feelings of unattractiveness and rejection in the female,
perhaps leading to resentment and hostility. This could then develop
into a self-perpetuating "vicious circle" (see Fig. 5.3).
This proposed circle could be broken in a number of ways, e.g.
psychotherapeutic counselling for the marital problems, encouraging
the female to take the sexual initiative, and perhaps via exogenous
androgen administration.
One highly relevant study carried out recently was that of the
World Health Organisation task force on psychosocial research in family
planning (W.H.O. 1982). The authors investigated the acceptabi1ity of
hormonal methods of male contraception and their major finding with
respect to effects on behaviour was that anti-androgens such as
cyproterone acetate acted to decrease the sexual interest and increase
the incidence of sexual problems of a group of normal men. However,
methyl testosterone administration acted to increase the frequency of
sexual thoughts, as assessed by interview ratings, in a group of normal
healthy male volunteers. The W.H.O. (1982) authors attached little
significance to these stimulatory effects of testosterone
administration, and put the results down to small sample size.









Hypothesised "vicious circle" implicating androgens and reduced
sexual interest in the development and/or maintenance of sexual
and marital dysfunction.
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supplied by Wu et al. (1982) in their study of testosterone undecanoate
administration to Klinefelter men, and the findings of the present
study, evidence is mounting suggesting that androgens may have a
stimulatory effect on the sexual interest of the eugonadal man.
Longer term replicative studies are required to determine whether
this effect of testosterone acting to increase the sexual interest of
men complaining of loss of sexual appetite is maintained over longer
periods of hormone administration. It is also important to point out
that in only three of the ten subjects in the present study did the
testosterone induced increase in sex interest act to bring about a
significant beneficial effect on the overt sexual behaviour of the
couple, i.e. an increase in intercourse frequency. It is possible that
the couples' behaviour had become entrained in that sexual activity had
become a relatively infrequent occurrence, and given communication
difficulties, resentment, hostility, etc. any increase in the sexual
appetite of the male brought about by endocrine manipulation, may have
been insufficient to overcome the interpersonal conflicts that may have
developed. If the findings of the present study are replicated, it is
reasonable to suggest that in couples where the major problem appears
to be loss of sexual interest in the male, the best mode of therapeutic
intervention may be to combine androgen administration with
psycho-sexual counselling where the emphasis would be placed upon
improving the communication between the couple and where appropriate,
encouraging the female to take the sexual initiative.
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CHAPTER 6
A CONTROLLED EVALUATION OF TESTOSTERONE TREATMENT
IN MEN WITH ERECTILE DYSFUNCTION
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6.1 INTRODUCTION
Many investigators studying the relationship between hormones and
sexual behaviour in man have tended to use the rather unspecific and
general term "impotence" to describe groups of men with various
disorders of sexual functioning, e.g. men presenting with loss of
sexual interest, premature ejaculation and erectile dysfunction have
often been grouped together and studied as a homogeneous patient sample
(Schiavi and White, 1976). In this thesis an attempt has been made to
introduce operational behavioural definitions of the various male
sexual dysfunctions and in the present chapter a study is reported
where eugonadal men complaining specifically of erectile dysfunction
participated in a controlled trial of the effects of high dosage
testosterone treatment.
6.2 MATERIALS AND METHODS
6.2.1 Subjects
The sample was recruited from eugonadal male reporters to the
local sexual problems clinic at the Royal Infirmary of Edinburgh. The
recruitment criteria were that the subjects be aged 18-65 years and
that their primary complaint, as determined by the referring therapist
and subsequently by the experimenter, was difficulty in achieving or
maintaining a full erection during sexual contact, which was not
secondary to loss of sexual interest or any obvious physical or mental
illness. Patients were informed of the purpose of the study (i.e. to
investigate high dosage testosterone effects on erectile function) and
were given the opportunity to participate while on the waiting list for
psycho-sexual counselling.
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Between May 1981 and December 1982 twelve subjects were recruited.
Two subjects dropped out at an early stage, one because he complained
of excessive pain following the intra-muscular injections, and the
other because of lack of behavioural improvement (it transpired that
this particular patient dropped out after receiving three placebo
injections). Complete behavioural data was therefore obtained for ten
subjects aged between 19-64 years (mean 45.4 +_ 13.0 yrs.). Nine of the
ten subjects had current sexual partners (eight were married). Before
inclusion in the study each subject was shown to have normal liver
function and no indications of prostatic disease, using standard
laboratory tests.
6.2.2 Design
The experimental design was exactly the same as that described in
Chapter 5, i.e. after a four week baseline period, subjects were
administered Sustanon 250 testosterone injections every fortnight for
six weeks and matched placebo injections fortnightly for six weeks.
The design was balanced in that half the subjects received the active
preparation for the first six weeks, half the subjects received the
placebo preparation first.
6.2.2.1 Hormone Measurement
As described in Chapter 5, weekly blood samples were taken
throughout the sixteen week study period. Plasma samples were assayed
for testosterone using the method of Corker and Davidson (1978) and for
SHBG using the method of Anderson et _al_. (1976).
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6.2.2.2 Behavioural Assessment
The behavioural assessment was as described in Section 5.2.2.
6.2.3 Analysis
The analysis of the results was as described in Section 5.2.3.
6.3 RESULTS
The results of the effects of high dosage testosterone injections
compared wi.th placebo are summarised in Tables 6.1-6.3. Change scores
represent each subject's behavioural rating while receiving
testosterone minus his rating while receiving placebo. These values
were then meaned for the group as a whole.
6.4 DISCUSSION
The results again demonstrate that the testosterone injections
acted to significantly increase circulating total testosterone levels
and to decrease circulating SHBG levels, effectively acting to increase
the proportion of unbound bio-active androgen in the plasma. This
elevation in the "free" testosterone level was entirely without
behavioural effect on any of the measures of sexual functioning or mood
state.
This is the first controlled study to be carried out investigating
the efficacy of androgen administration in the treatment of erectile
dysfunction where evidence has been presented demonstrating that the
androgen administration resulted in a significant elevation in
circulating testosterone levels (p<0.01). Previous investigators have
either not measured blood androgen levels following treatment (e.g.
Jakobovitz, 1970) or where endocrine measures have been carried out,
androgen administration failed to overcome the eugonadal homeostatic
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TABLE 6.1 DIARY DATA
THE EFFECT OF HIGH DOSE TESTOSTERONE VERSUS PLACEBO TREATMENT
IN MEN COMPLAINING OF ERECTILE DYSFUNCTION (n=10)
Change Score
"("Testosterone minus Paired
Behavioural measure PI acebo; Mean± S.D. t-test
Frequency of Morning Erections (%) 2.4 (8.5) N.S.
Frequency of Sexual Activity
per treatment period 0.44 (0.5) N.S.
Frequency of Self-Initiated
Sexual Activity per
treatment period 0.5 (2.6) N.S.
Visual Analogue Scales (0-100) AN0VAR
Sexual Thoughts 2 (6.5) N.S.
Sexual Excitement Associated
with Sexual Thoughts 2 (4.1) N.S.
Mood
Cheerful and Happy 3.2 (6.8) N.S.
Fatigued and Tired 5.1 (8.7) N.S.
Sociable and Friendly 2.6 (6.4) N.S.
Energetic 3.4 (6.6) N.S.
Tense and Anxious 3 (9.9) N.S.
Irritable 4.6 (9.1) N.S.
Changeable 2.3 (11) N.S.
Aggressive 4.1 (10.8) N.S.
Depressed and Unhappy -3.3 (12.2) N.S.
Relaxed 1 (10.5) N.S.
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TABLE 6.2 INTERVIEW DATA
THE EFFECT OF HIGH DOSE TESTOSTERONE VERSUS PLACEBO TREATMENT











Sexual Activity Frequency 5 3 N.S.
Sexual Interest 2 2 N.S.
Negative Feelings (frequency) 0 2 N.S.
Negative Feelings (strength) 1 0 N.S.
Positive Feelings 0 0 N.S.
Sexual Arousal (frequency) 0 2 N.S.
Sexual Arousal (strength) 0 1 N.S.
Orgasm (frequncy) 3 2 N.S.
Erection (quality) 3 1 N.S.
Ejaculation (retarded) 0 0 N.S.
Ejaculation (premature) 0 2 N.S.
Receptivity 0 0 N.S.
+Complete interview data available for 9 out of the 10 subjects.
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< Basel ine, p <0.05
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mechanisms and treatment did not result in an elevation of circulating
androgen levels (e.g. Benkert et al. 1979).
General clinical opinion over the past fifteen years has
subscribed to the view that androgen treatment is unhelpful in the
treatment of erectile dysfunction unless the individual suffers from a
genuine deficiency, e.g. "Androgens... are useless as a treatment of
impotence unless it accompanies hypogonadism" (British Medical
Association, 1981). The present chapter reports the first study which
has actually tested and confirmed this hypothesis.
However, given the stimulatory effect of testosterone injections
on sexual interest in the treatment of eugonadal men complaining of
loss of libido (described in Chapter 5), it is perhaps surprising that
in the present study, androgen administration had no effect on sexual
interest in men complaining of erectile dysfunction (particularly as
the men with erectile problems had slightly lower mean endogenous
testosterone levels than the men with reduced sexual interest, 16.8
(5.4) and 23.1 (7.0) nmol/1 respectively). There are two possible
explanations for these different behavioural effects of testosterone
administration in the two patient groups
(a) The men with erectile dysfunction had a relatively "normal" degree
of sexual interest. (At initial interview, these men reported thinking
about sex with appetite and desire, on average several times per week
as opposed to the low libido men who on average reported thinking about
sex more than once per month but less than once per week). Therefore
the men with erectile dysfunction had less scope for androgen
stimulated improvement in sex interest compared with the low libido
group.
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(b) Men may have a threshold level of circulating testosterone for
optimal sexual appetite and any experimentally induced elevation in
circulating testosterone levels above this threshold would have no
behavioural effect (Raboch and Starka, 1972; Pirke and Kockott, 1982).
However, this threshold level may not be an absolute one across
subjects (i.e. x nmol/1); individuals may vary as to their optimal
level of circulating testosterone. It is possible that the men
complaining of loss of sexual interest (described in Chapter 5) were,
on average, below their optimal level whereas the men complaining of
erectile dysfunction (described in the present chapter) were, on
average, above their optimal threshold level of circulating
testosterone, and were thus unaffected by exogenous androgen
administration. This hypothesis would account for the observation that
some hypogonadal men retain a relatively normal degree of sexual
interest and activity, despite having very low circulating levels of
testosterone (e.g. as described by Salmimies _et _al_. 1982). Presumably
in these hypogonadal men the optimal threshold level of circulating
androgens is markedly lowered in comparison with other men, i.e. they
have a heightened sensitivity to the behavioural effects of
testosterone.
The present author would propose that if androgens act primarily
on sexual appetite, as suggested by Bancroft (1980), then androgen
treatment may be helpful in certain cases where the individual
complains of loss of sexual interest with relatively undisturbed
erectile function. However, androgen administration probably has no




THE EFFECT OF ANDROGEN ADMINISTRATION ON NOCTURNAL ERECTIONS
IN HYPOGONADAL AND EUGONADAL MEN
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7.1 INTRODUCTION
As reviewed in Chapter 1.5, several claims have been made in the
literature suggesting that a relationship exists between androgen
status and nocturnal erectile function in men. In particular Kwan
jet jil_. (1983) demonstrated that in the hypogonadal man, episodes of
nocturnal penile tumescence (NPT) are reduced following androgen
withdrawal, and Jovanovic and Tan-eli (1969) reported that eugonadal
men complaining of erectile impotence displayed NPTs which were
markedly impaired when compared with age-matched controls, and that
treatment with a methyl-testosterone preparation acted to improve and
"normalise" their nocturnal erections.
As the results of both of these studies are unsubstantiated, and
as both investigations are open to criticism (i.e. Jovanovic and
Tan-eli (1969) failed to provide clinical details of their patient
group and Kwan _et _al_. (1983) used portable home monitors for
self-assessment of nocturnal erectile function), an attempt is made i
this chapter to replicate their findings.
7.2 MATERIALS AND METHODS
7.2.1 Subjects
7.2.1.1 Hypogonadal Subjects
All of the hypogonadal subjects described in Chapter 3 were
invited to participate in sleep recordings where nocturnal erectile
function would be directly measured "on" and "off" androgen
replacement. This involved:-
(a) Two consecutive nights of assessment to be carried out a minimum
eight weeks after cessation of their previous androgen replacement
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(b) Two consecutive nights of assessment to be carried out a minimum of
five months after re-starting replacement with testosterone undecanoate
(i.e. four months of varying the replacement dose of T.l). (as described
in Chapter 3) plus a minimum of one month on the dosage of T.U. which
had produced the best behavioural results in that individual - on
average 120-160 mg T.U./day).
Only three out of the eight hypogonadal men described in Table 3.1
(nos. 1,4 and 8) agreed to participate. An additional 40 year old
hypogonadotrophic hypogonadal man was therefore recruited and underwent
NPT assessment while markedly hypogonadal (mean testosterone level =
3.2 nmol/1; he had received no androgen replacement for the previous
seven years). He was then re-assessed for NPTs after two months of
highly efficacious treatment with T.ll. 160 mg/day.
Thus a total of four hypogonadal men were assessed for nocturnal
erectile function for two consecutive nights \/hi 1 e in a markedly
hypogonadal state and were then re-assessed for two consecutive nights
after receiving testosterone replacement.
In order to investigate the effect of longterm androgen withdrawal
on nocturnal erectile function, a 35 year old hypogonadotrophic
hypogonadal man who had elected to stop taking his androgen replacement
underwent NPT assessment on two occasions. The subject was monitored
in the sleep laboratory for two consecutive nights after eight weeks
withdrawal from androgens. This was repeated after one year's
withdrawal.
7.2.1.2 Eugonadal Subjects
All the eugonadal subjects complaining of erectile dysfunction
(described in Chapter 6) were similarly asked whether they would be
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prepared to participate in research into the effects of androgens on
nocturnal erectile function. Subjects were informed that this would
entail spending a total of four nights in the sleep laboratory, two
successive nights during the week following their third injection and
two successive nights during the week following their sixth injection
(i.e. NPT assessments were carried out in the week following the last
testosterone injection and in the week following the last placebo
injection - see Chapter 6). Nocturnal erections were thus measured
after six weeks of high dosage testosterone treatment and again after
six weeks of matched placebo treatment.
Seven eugonadal men agreed to participate (mean age 48.4 +_ 16.4
years), with a duration of erectile dysfunction which ranged from 3-10
years (mean 4.8 years). Four subjects received the testosterone
injections as their first treatment followed by placebo injections,
three subjects were given the placebo injections first.
7.2.2 Design
Subjects were taken into the sound dampened and temperature
controlled sleep laboratory in the Royal Edinburgh Hospital at 2200
hours on the first NPT assessment night, and the experimental procedure
was explained. A mercury-in-rubber strain gauge with platinum
electrodes (Bancroft, 1974) was fitted, by the subject, around the base
of his penis, the lead from the strain gauge being firmly attached to
the patient's abdomen with elastoplast. The strain gauge was
calibrated using two perspex disc standards of differing diameters (25
and 26 mm). Calibration was carried out before and after each night of
NPT recording so that any changes in penile diameter could be readily
and accurately measured. The electrode leads were fed into a Grass
model 7D polygraph recorder situated in a room adjacent to the sleep
laboratory. Subjects were settled in bed at approximately 2230 hrs.,
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with lights off at 2300 hrs. Subjects were awakened at 0700 hrs on the
following morning.
Each subject was assessed for two consecutive nights "on" and two
consecutive nights "off" androgens. The first night of each assessment
session was used as an adaptation night to accustom the subject to the
sleep laboratory and the recording procedure. (First night measures
are not reported in this chapter). All NPT assessments and subsequent
analysis were carried out by the author. In total forty-eight nights
of NPT recordings were performed.
7.2.3 Analysis
Any definition of erection based upon penile diameter change from
basal (i.e. flaccid) is somewhat arbitrary given the large degree of
variation that exists between subjects (Schiavi and Fisher, 1982). For
this reason, two definitions of erection, taken from the research
literature, were used in the analysis. Marshall et aJL (1981) defined
an NPT episode as a 3 mm increase in penile circumference from basal
(i.e. flaccid). Hosking et _al_. (1979) and Kwan _et _al_. (1983) however
used a more selective criterion of erection, i.e. greater than or equal
to 15 mm circumference increase from basal.
In the present study, by analysing the data twice, using these two
very different decision rules as to what constitutes an NPT episode,
any hormone mediated effects on nocturnal erectile function should
become apparent.
Frequency, duration, latency to first erection, latency to maximum
erection, maximum erection attained and total tumescence time were
compared, testosterone treatment versus no treatment (in the
hypogonadal men) and testosterone versus placebo treatment (in the
eugonadal men).
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The paired t-test (one-tailed) v/as used to compare differences
across treatments.
7.3 RESULTS
The results of the effects of androgen administration on NPTs in
the hypogonadal men are shown in Table 7.1 and in the eugonadal men in
Table 7.2. The change scores represent each subject's NPT value while
receiving testosterone minus his NPT while receiving no treatment
(hypogonadal) or placebo (eugonadal). These differences were then
meaned for the group as a whole.
The NPTs of a hypogonadal man recorded after eight weeks and again
after one year of withdrawal from androgens are shown in Figure 7.1
7.3.1 Order Effect?
The results demonstrate that the NPTs of eugonadal men complaining
of erectile dysfunction were unaffected by androgen administration
whereas the nocturnal erections of hypogonadal men were markedly
affected by androgen administration. However, it is possible that the
different results obtained in the two patient groups are the result of
an order rather than a genuine hormone mediated effect. The design of
the hypogonadal study was not controlled for order in that all the
hypogonadal subjects underwent initial NPT assessment while markedly
hypogonadal and this was followed by re-assessment of nocturnal
erectile function after several months of androgen replacement therapy.
An attempt was made to control for an order effect in the eugonadal
group in that four subjects received the testosterone injections as
their first course of treatment, three received placebo first. To
investigate the possibility of an order effect in the eugonadal group,
the NPT parameters were compared first assessment session versus second
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TABLE 7.1
THE EFFECT OF T.U. TREATMENT ON NOCTURNAL ERECTILE FUNCTION










Change (m.m.) 32.8 (26.3) 2.49 p < 0.05
Latency to Max.
Erection (mins.) 74.0 (216.1) 0.51 N.S.
Erection > 15 mm
NPT Frequency 1.0 (2.8) 0.71 N.S.
Total NPT
Duration (mins.) 38.9 (31.6) 2.46 p < 0.05
Latency to First
Erection (mins.T -218.1 (161.7) 2.69 p <0.05
Erection ^ 3 mm
NPT Frequency 1.25 (3.5) 0.71 N.S.
Total NPT
Duration (mins.) . 73.7 (36.2) 4.07 p < 0.025
Latency to First
Erection (mins.) -70.7 (123.8) 1.10 N.S.
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TABLE 7.2
THE EFFECT OF TESTOSTERONE TREATMENT ON NOCTURNAL










Change (m.m.) -2.45 (13.1) 0.48 N.S.
Latency to Max.
Erection (mins.) -7.34 (121.7) 1.07 N.S.
Erection ^ 15 mm
NPT Frequency 0.28 (1.2) 0.882 N.S.
Total NPT
Duration (mins.) 5.4 (33.8) 0.143 N.S.
Latency to First
Erection (mins.) -38.9 (80.6) 0.239 N.S.
Erection ^ 3 mm
NPT Frequency 0.0 (2.4) 0.00 N.S.
Total NPT
Duration (mins.) 1.03 (102.3) 0.33 N.S.
Latency to First


































FIGURE7.1 Nocturnalerectilefun ioiahypogonadalm ,eightw ksney afterwithdrawalfromandrog nreplace ent.
assessment for each subject. All comparisons were non-significant
using the paired t-test.
This result suggests that the significant improvement in nocturnal
erectile functioning observed in the hypogonadal patients was a genuine




Androgen treatment had a marked effect on the NPTs of the
hypogonadal subjects (Table 7.1). T.U. replacement acted to increase
the magnitude of the maximum nocturnal erections attained and also
acted to increase the total time spent in penile tumescence. This
effect was apparent using both the 3 mm and 15 mm definitions of
erection. These results are almost identical to those reported by Kwan
et _al_. (1983).
Interestingly, nocturnal erection frequency (i.e. number of
erections per night) was not significantly increased in the hypogonadal
group following androgen replacement. This was possibly due to the
fact that one of the subjects (No.8) displayed a marked degree of
nocturnal erectile function while "off" androgens for eight weeks.
This atypical retention of nocturnal erectile response is similar to
the pattern of NPTs exhibited by the hypogonadal subject whose
nocturnal erections were recorded after eight weeks and again after one
year of androgen withdrawal (Figure 7.1). This man also retained a
marked degree of nocturnal erectile function eight weeks after androgen
withdrawal but one year after cessation of treatment, no nocturnal
erections were observed.
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The results of this study suggest that there may be a variable
rate of decline of androgen dependent nocturnal erectile function,
most hypogonadal men demonstrating a marked diminution in erectile
response eight weeks after androgen withdrawal, with other hypogonadal
men retaining a degree of nocturnal erectile activity for longer
periods of time.
7.4.2 Eugonadal Subjects
As illustrated in Table 7.2, androgen treatment had no effect on
any of the measures of nocturnal erectile function in the eugonadal
group. Using both Hosking et _al_.'s (1979)^ 15 mm and Marshall et al' s
(1981) ^ 3 nm circumference change from basal definitions of erection,
frequency, duration, latency to first erection, latency to maximum
erection, maximum erection attained and total tumescence time were all
unaffected by high dosage testosterone administration compared with
matched placebo. These results are contrary to those published by
Jovanovic and Tan-el i (1969). However, three important differences
exist between the two studies which may account for these discrepant
fi ndings: -
(a) The endocrine status and the clinical details of the patients in
the study of Jovanovic and Tan-eli (1969) were not reported - it is
possible that their patients' erectile disorders could have been
secondary to hypogonadism, which could account for the beneficial
effects of testosterone treatment.
(b) Their study was not blind and no placebo was used, therefore a
degree of bias may have been introduced.
(c) The methyl-testosterone preparation that these authors used also
contained a number of psycho-active agents, e.g. caffeine and
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strychnine, although the authors reported that "testosterone is
essential because of its androgenic, roborant, anabolic and stimulatory
effect" (Jovanovic and Tan-el i, 1969). Cooper _et _al_. ( 1973) using a
similar preparation found slight and transient improvements in the
treatment of erectile impotence but concluded that these beneficial
effects were due to the central nervous system stimulation caused by
the non-steroid constituents of the preparation.
In conclusion, in the hypogonadal man withdrawal from androgen
treatment was shown to act to reduce NPT activity, although diminution
of erectile response occurred at a variable rate. Androgen replacement
to hypogonadal men acted to stimulate nocturnal erectile function, in
particular total duration of tumescence and maximum erection attained
were significantly increased following testosterone replacement
therapy. In the eugonadal man complaining of erectile dysfunction,
androgen administration had no effect on nocturnal erectile function.
These results are consistent with the hypothesis that a certain
threshold level of circulating androgen is required for normal male
sexual functioning (Chapter 6). Presumably the untreated hypogonadal
subjects were below their optimal testosterone level and androgen
treatment acted to stimulate their nocturnal erections. The eugondal
men however were presumably above their theshold testosterone level and
exogenous androgen administration had no effect.
The present results, and those supplied by Kwan et al♦ (1983) tend
to suggest that nocturnal erections are reduced by androgen withdrawal
and stimulated following androgen replacement. This observation has to
be discussed in light of Bancroft's (1980) hypothesis that erectile
function is independent of androgen status in man. Nocturnal erections
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are presumably responses to some central event and it may be that it is
this central process rather than the erectile mechanisms per se which
is dependent on an adequate level of circulating androgens.
7.4.3 Methodological Point Concerning Arbitrary Definitions of
Erection
One point which emerged during the analysis of the NPT records in
the present study was the dubious validity of the Marshall et al.
(1981) definition of an erectile episode. These authors proposed that
an erection occurred when there was an increase in penile circumference
greater than or equal to 3 mm from basal, that is less than a 1 mm
increase in penile diameter. Given the presence of movement artefacts,
changes in baseline levels throughout the night, etc., the present
author found it quite difficult to judge when such small variations in
penile size constituted a true NPT episode. Using the stricter
criterion (greater than or equal to 15 mm circumference change from
basal) suggested by Hoski ng et _al_ (1979) and Kwan et al. (1983), no
such difficulties were encountered.
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CHAPTER 8
ANDROGEN ADMINISTRATION TO HYPOGONADAL AND EUGONADAL MEN -
EFFECTS ON MEASURES OF PERSONALITY AND SPATIAL ABILITY
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8.1 INTRODUCTION
As reviewed in Chapter 1.7, several investigators have proposed
that androgen levels are correlated with certain measures of non-sexual
behaviour in the adult human male. Focusing particularly on spatial
ability and the personality measures of Eysenck and Zuckerman, an
attempt was made to investigate whether these measures are sensitive to
changes in the endocrinological status of the hypogonadal and the
eugonadal man.
8.2 MATERIALS AND METHODS
8.2.1 Hypogonadal Subjects
All of the hypogonadal men (N=8) who participated in the
investigations described in Chapter 3 agreed to complete a psychometric
test battery (see below) on two separate occasions. Each man was
withdrawn from his previous androgen replacement for a minimum of eight
weeks and was then administered the psychometric test battery. For
four successive months each subject was treated with 40, 80, 120 and
160 mg oral testosterone undecanoate (T.U.) per day. Each subject was
then placed on long-term replacement with the dose of T.U. which had
produced the best behavioural results for that individual (on average
120-160 mg/day). After a minimum of one month on this final dose (i.e.
after a total of at least five months treatment with T.U.) the
hypogonadal subjects were re-tested.
8.2.2 Eugonadal Subjects
Sixteen of the eugonadal subjects who participated in the
investigations described in Chapters 5 and 6 also agreed to complete
the psychometric test battery on two separate occasions. Nine of the
men were recruited from the erectile dysfunction group and seven men
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came from the reduced sexual interest group. The eugonadal subjects
received Sustanon 250 injections every two weeks for six weeks and
matched placebo injections every two weeks for six weeks. The study
was balanced in that eight men received the testosterone injections as
their first course of treatment, eight received placebo first.
Subjects completed the psychometric test battery twice, (a) after six
weeks of high dose testosterone treatment and (b) after six weeks
treatment with matched placebo.
8.2.3 The Psychometric Test Battery
8.2.3.1 Assessment of Spatial Ability
Factor analytic studies have demonstrated that the term "spatial
ability" is a misnomer and that spatial ability as such is subdividided
into two factors, spatial visualisation and spatial orientation (McGee,
1979). Visualisation ability refers to the ability to mentally
manipulate and rotate subjects in space, whereas orientation describes
the ability to accurately identify objects and their position in
relation to the environment. The Revised Minnesota Paper Form Board
Test (MPFBT), Form AA (Likert and Quasha, 1970) was used to measure
spatial visualisation, and a modified version of the Embedded Figures
Test or EFT (Morrison, 1976) was used to assess spatial orientation
ability. This version of the EFT consists of twelve items selected
from Witkin's test for individual administration (Witkin _et _al_. 1971).
These were practice figure P-X, nos. 5,6,8,10,11,13,15,18,19,22 and 23.
The figures were reproduced in the test answer book, each with five
alternative simple figures of which only one was embedded in the
corresponding complex figure. Subjects were instructed to pick out the
simple shape contained in the complex design and to record their answer
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in the answer column. A time limit of ten minutes was assigned to the
task. A copy of the test appears as Appendix VI. This shortened
version of the EFT was used in preference to the standard EFT for
individual administration (Witkin _et a]_. 1971) because of the need for
a brief (ten as opposed to thirty-six minutes required for assessment)
and easily administered measure of spatial orientation, in view of the
demands being made on the subjects (i.e. the other tests in the
psychometric battery). One major difference between the version of the
EFT used in this study and Within's standard EFT is that in Morrison's
modified test, the subject is allowed to inspect the simple shape and
complex design simultaneously. In the opinion of the present writer,
this approach facilitates direct assessment of the ability to disembed
figures, whereas Witkin's original method (where subjects are prevented
from viewing the simple shape and complex design simultaneously)
introduces a short-term memory factor.
8.2.3.2 Assessment of Personality
The most recent form of Eysenck's personality measures, the
Eysenck Personality Questionnaire or EPQ (Eysenck and Eysenck, 1975)
was used to assess the effect of androgen administration on
extraversion (E), neuroticism (N), psychoticism (P) and Lie (L)
scores. Similarly, the Sensation Seeking Scale (SSS) Form IV, as
described by Zuckerman (1979) was employed to evaluate the effects of
androgen administration on the five SSS subscales, namely General
Sensation Seeking (Gen), Thrill and Adventure Seeking (TAS), Experience
Seeking (ES), Disinhibition (Pis) and Boredom Susceptibility (RS).
As we are effectively altering the male sex hormone balance of the
hypogonadal and eugonadal men, it was also decided to include a measure
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of self-rated psychological masculinity and femininity in the
psychometric test battery, namely the Pern Sex Role Inventory or BSRI
(Bern, 1974). This scale is based upon Bern's philosophical standpoint
that behavioural masculinity and femininity are not extremes of a
single dimension but are in fact orthogonal. Evidence has been
presented suggesting that the BSRI is a reliable and valid form of
assessment (Wakefield _et _aj_. 1976; Carlsson SMagnusson, 1980). The
BSRI classifies individuals on three scales, masculinity (M),
femininity (F) and androgyny (And), and has the advantage of being
brief and easily administered.
To reiterate, a group of hypogonadal and a group of eugonadal
subjects completed a psychometric test battery on two occasions, "on"
and "off" androgen treatment. The test battery comprised the Eysenck
Personality Questionnaire, the Bern Sex Role Inventory, the Sensation
Seeking Scale, the Revised Minnesota Paper Form Board Test and the
Embedded Figures Test.
8.2.4 Analysis
Psychometric test scores were analysed for intra-individual change
as a result of androgen treatment using the paired t-test.
8.3 RESULTS
The results for the hypogonadal subjects are summarised in Table
8.1 and the results for the eugonadal subjects are summarised in Table
8.2. Change scores were calculated by subtracting the test scores
obtained for each individual during the baseline (hypogonadal) or
placebo (eugonadal) period from his test score while receiving




PSYCHOMETRIC TEST BATTERY SCORES FOR EIGHT HYPOGONADAL MEN, AFTER
8 WEEKS WITHDRAWAL FROM ANDROGEN REPLACEMENT AND AFTER A MINIMUM OF
5 MONTHS OF TREATMENT WITH TESTOSTERONE UNDECANOATE
Psychometric Measure*
Change Score (Testosterone Paired
minus Baseline) MeaniS.D. t-test
Bern Sex Role Inventory
Mas. 0.063 (0.28) N.S.
Fern. 0.198 (0.34) N.S.
And. 0.312 (0.99) N.S.
Sensation Seeking Scale
Gen. 0 (1.3) N.S.
T. A. -0.63 (1.5) N.S.
E.S. -0.5 (0.9) N.S.
Dis. 0 (1.85) N.S.
B.S. -0.75 (1.66) N.S.
E.P.Q.
P. -0.38 (0.74) N.S.
L. -0.125 (2.53) N.S.
E. -0.25 (1.83) N.S.
N. 0.75 (2.1) N.S.
Spatial Tests
EFT 0 (1.7) N.S.
MPFBT 0.57 (8.9) N.S.
*See text for details
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TABLE 8.2
PSYCHOMETRIC TEST BATTERY SCORES FOR SIXTEEN EUGONADAL MEN, AFTER
6 WEEKS OF HIGH DOSAGE TESTOSTERONE INJECTIONS AND AFTER 6 WEEKS OF
MATCHED PLACEBO INJECTIONS
Psychometric Measure*
Change Score (Testosterone Paired
minus PlaceboJ Mean ±S.D. t-test
Bern Sex Role Inventory
Mas. 0.17 (0.37) N.S.
Fern. 0.19 (0.40) N.S.
And. 0.14 (0.94) N.S.
Sensation Seeking Scale
Gen. 0.46 (1.9) N.S.
T.A. -0.07 (1.8) N.S.
E.S. 0.73 (1.9) N.S.
Dis. -0.2 (1.3) N.S.
B.S. 0.53 (1.8) N.S.
EPQ
P. 0 (1.03) N.S.
L. 0.06 (3.9) N.S.
E. -0.06 (1.3) N.S.
N. 1.0 (1.78) p<0.01
Spatial Tests
EFT 0.3 (1.7) N.S.
MPFBT -1.18 (6.7) N.S.
*See text for details
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8.4 DISCUSSION
8.4.1 Tests of Spatial Ability
The results, as displayed in Tables 8.1 and 8.2 demonstrate that
androgen administration had no effect on the spatial performance of
hypogonadal or eugonadal men. The eugonadal results tend to oppose the
hypothesis that a relationship exists between androgenicity and spatial
ability in the normal adult male, as has been previously suggested
(Broverman _et _al_. 1968; Kl aiber et aj_. 1967; Petersen, 1976), as
experimentally induced elevations in plasma androgen levels had no
effect on spatial test scores.
The observation that the spatial ability of the hypogonadal man
was not improved following testosterone treatment confirms the findings
of Hier and Crowley (1982) who reported that three months of androgen
replacement did not result in improved spatial performance in a group
of hypogonadal men. Taken together, the data supplied by Hier &
Crowley (1982) and the results of the present study provide serious
opposition to the hypothesis put forward by Bancroft (1980) who, in
attempting to account for the observation that the ability of
hypogonadal men to produce erections in response to erotic fantasy
waxed and waned with androgen replacement and withdrawal (Bancroft &
Wu, 1983), proposed that androgens may act to facilitate the
visuo-spatial cognitive process in a non-specific manner. The Bancroft
(1980) hypothesis is made to look even more suspect in light of the
recent failure to replicate the Bancroft & Wu (1983) study. Kwan
et_ _al_. (1983) reported that the ability to produce erections in
response to erotic fantasy was relatively unaffected by androgen
replacement and withdrawal. (It is important to point out that
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although Kwan et al. (1983) concluded that the erectile responses of
the hypogonadal group as a whole to erotic film and fantasy were not
significantly affected by androgen administration, three out of the six
hypogonadal men produced erections in response to fantasy which were
below or at the bottom of the range for normal men, and androgen
treatment resulted in an increased erectile response to erotic
fantasy in two out of these three subjects). Kwan et al. (1983)
suggest that the conflicting results obtained in their study as
compared with the Bancroft X Wu (1983) study may be accounted for by
cultural differences between California and Scotland, or by chance
sampling of different patient types. In the opinion of the present
author the latter explanation would appear to be more feasible given
the small number of subjects used in each study, six and eight
respectively. An alternative explanation for the conflicting results
obtained in these two studies is that weaker erotic stimuli may be
affected most easily by androgen withdrawal, and films may be more
powerful than fantasy in this respect (Bancroft, 1980). It is possible
that the hypogonadal men in the Kwan _et _al_. (1983) study may simply
have been better at producing more stimulating erotic fantasies than
the men in the Bancroft & Wu (1983) study.
As only one out of the eight hypogonadal patients in the present
study suffered from idiopathic hypogonadotrophic hypogonadism (IHH),
the hypothesis put forward by Hier and Crowley (1982) that IHH men have
markedly impaired spatial ability when compared with men with acquired
hypergonadotrophic hypogonadism could not be tested. Taking the
hypogonadal groups as a whole, comparing their spatial performance with
the eugonadal group while on no treatment, no significant differences
between the groups were observed for either test of spatial ability.
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In conclusion the results of the present study fail to support the
hypothesis proposed by Bancroft (1980), i.e. that androgen replacement
acts to facilitate visuo-spatial ability in the hypogonadal man.
However, the eugonadal results do not enable us to reject the general
hypothesis that androgens are involved in the regulation of spatial
ability in the human male. In the present study, short-term androgen
administration had no effect on spatial test scores but it is possible
that androgens have important organisational effects on the central
nervous system at critical periods in development and thus influence
later visuo-spatial performance.
8.4.2 Personality Measures
8.4.2.1 The Sensation Seeking Scale
In two separate studies, Daitzman _et _al_. (1978) and Daitzman &
Zuckerman (1980), the authors claimed that significant correlations
existed between circulating androgen levels and sensation seeking
behaviour, particularly between testosterone levels and the
Disinhibition (Dis) subscale of Zuckerman's inventory. To the author's
knowledge, the present study was the first experiment to be carried out
where androgen levels were manipulated in hypogonadal and eugonadal men
and changes in Sensation Seeking Scale scores monitored. Tables 8.1
and 8.2 demonstrate that androgen administration had no effect on any
of the SSS scores in either of the subject groups. From the results of
this experiment no support can be drawn for the hypothesis proposed by
Daitzman _et _al_. (1978), Daitzman & Zuckerman (1980) and Zuckerman et
_a^(1980), i.e. that a relationship exists between gonadal hormone
levels and SSS scores. In both hypogonadal and eugonadal groups of
men, androgen levels were experimentally elevated with no consequent
effect on SSS scores. However, one must bear in mind the questionable
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sensitivity of these psychometric measures to short-term alterations in
the endocrine status of the groups being studied.
8.4.2.2 The Eysenck "Personality Questionnaire
H.J. Eysenck has repeatedly proposed that the biological basis of
his new P scale is closely related to the level of the male sex
hormones (see Chapter 1.7.1 for review). The findings of the present
study fail to support this hypothesis. Testosterone administration to
hypogonadal men had no effect on the P, L, E or N scores of Eysenck's
EPQ, and similarly a course of high dosage testosterone injections had
no effect on the P, L or E scores of a group of eugonadal men.
However, the N scores of the eugonadal men were significantly elevated
following androgen treatment as compared with placebo treatment. This
is a surprising finding because:-
(a) Eysenck has implicated androgen levels only with his P scale
(b) Androgen administration had no effect on N scores in the
hypogonadal group
(c) Kaiser _et _al_. (1978) reported that five weeks of treatment with
mesterolone 75 mg/day acted to decrease neuroticism and increase
extraversion scores in a group of elderly men
(d) Androgen administration had no effect on "neurotic" mood ratings in
the eugonadal group, as assessed by the visual analogue scales in the
studies described in Chapters 5 and 6. In these studies subjects rated
themselves on a daily basis on scales labelled Tense and Anxious,
Irritable, Changeable and Up and Down, etc. and high dosage
testosterone injections had no effect compared with placebo on any of
these measures of mood. The present writer would tentatively suggest
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that these daily assessments (N=42 per treatment period) would have
been more sensitive and more likely to "pick up" any genuine androgen
induced effect on neurotic behaviour. (However, it could be argued
that daily ratings of mood may not be the best method of measuring an
androgen induced shift in tonic mood state, and that daily scales are
more suitable for picking up day-to-day fluctuations).
Inspection of the actual item content of the N scale of the EPQ
does not shed any light on these contradictory findings as most of the
questions deal with general worry and nervousness. It is possible that
the significant elevation in N scores following androgen administration
is due to chance alone. However, the author is aware that the level of
significance (p<0.01) makes this a somewhat unsatisfactory
explanation.
The correlation between Eysenck's personality dimension and
androgen level was originally investigated by Daitzman (1976). It is
fascinating to note that although Eysenck proposes a relationship
between androgens and psychoticism, Daitzman (1976) in fact reported
stronger positive correlations between circulating androgen levels and
neuroticism than with psychoticism. Obviously further research is
necessary before firm conclusions can be made concerning the
relationship (if any) between Eysenck's personality measures and
gonadal hormone status, but the evidence to date would tend to support
a stronger case for a relationship existing between androgens and N
than for androgens and P.
8.4.2.3 The Bern Sex Role Inventory
Androgen treatment had no effect on self-rated masculinity,
femininity or androgyny in the groups of hypogonadal and eugonadal men.
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Daitzman and Zuckerman (1980) claimed that circulating testosterone
levels were negatively correlated with self-rated MMPI femininity in a
group of forty young male American students. One would then perhaps
have predicted that hypogonadal men would rate themselves as relatively
feminine on account of their very low circulating testosterone levels,
and for androgen treatment to masculinise or de-feminise their scores.
This effect was not observed.
In conclusion, androgen administration to a group of hypogonadal
and a group of eugonadal men had a general lack of effect on
psychometric test battery scores, and the results oppose hypotheses
generated from correlational studies which suggest that relationships
exist between androgens and these test variabiles. However, it must be
stated that these psychometric measures aim to measure relatively
stable aspects of personality, and although short-term androgen
treatment did not result in significant effects on test scores, the
results do not entitle us to reject the hypothesis that, in the long
term, alterations in circulating androgen levels may have an effect on
certain aspects of non-sexual behaviour which, in turn, may be
reflected in these psychometric test scores.
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CHAPTER 9




As reviewed in Chapter 1.8, a small number of studies have
investigated the relationship between circulating androgen levels and
aggressive behaviour in the eugonadal man, and have produced
inconsistent results. A series of recent review articles on the
subject (Benton, 1981; Brain, 1981; Herrman A Beach, 1976; Hinton,
1981; Kling, 1975; Rose, 1975; 1978; 1980; Rubin, 1982) agree in
their criticisms of the studies carried out to date. In particular,
unsatisfactory methods of measuring human aggression have often been
employed (e.g. self-report questionnaires of doubtful validity) and
single blood samples have often been used to determine an individual's
androgen status. In spite of these methodological flaws, and the
contradictory results supplied by these studies, the concensus of
opinion suggests that the evidence is most convincing in respect of the
relationship between androgens and aggression in behaviourally extreme
populations, e.g. the violent rapist (Rada _et _al_. 1976) and the violent
long-term prisoner (Ehrenkranz _et aj_. 1974).
Adequately controlled studies investigating the relationship
between aggression and hypogonadism have been lacking. All the data in
this area have been derived from follow-up interviews carried out with
castrated sex offenders. In general the results suggest a major and
dramatic effect of castration in acting to reduce the sexual interest
and sexual activity of the offender. However, a significant proportion
of castrates report no adverse influences in their sex drives, e.g. 10%
(Cornu, 1973) and 18% (Langeluddeke, 1963). Of those interviewees who
do report a diminution in sexual appetite, this could be interpreted as
the expected response of an ex-prisoner who does not want to return to
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jail. However, it is certainly true that very few castrated sex
offenders return to prison.
At a first glance, recidivism rates of, for example, 2.2% (Sturup,
1968) appear very impressive; however, extreme caution is necessary
when interpreting such figures:-
(a) As Heim and Hursch (1979) and Heim (1981) point out, there is very
probably a large placebo effect following such radical genital surgery
(b) Following imprisonment alone, as few as 6% of rapists have been
reported as being re-convicted for rape (Soothi11, 1980)
In one of the most famous studies of the behavioural effects of
castration in the human male, Bremer (1959) followed-up two hundred and
forty-four men in Norway who had been castrated following repeated
sexual offences. He reported that castration did have a general
beneficial effect on aberrant sexual behaviour, but that the operation
had no effect on aggression per se. Bremer concluded that castration
is an inappropriate method of treatment for non-sexual aggressive
behaviour in the human male.
Given the relative dearth of good evidence of an association
between androgens and aggression in the human male, it is perhaps
surprising how generally held the belief is that the two variables are
causally related in man, e.g. "The evidence strongly suggests that
aggression, hostility and fighting behaviour are all related to
androgen level - the more androgen, the more aggressive the person!"
(Eysenck and Wilson, 1979).
In the present chapter a controlled case study is reported of the
behavioural effects of oral androgen replacement in a hypogonadal
institutionalised man who had a previous history of aggressive
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outbursts while receiving intramuscular testosterone injections.
9.2 MATERIALS AND METHODS
9.2.1 The Patient
D.R. was a 21 year old mentally retarded inmate of a hostel for
the mentally handicapped run by Lothian Region Social Work Department.
At the age of 7 years, he lost his left leg and both testes in a road
traffic accident. At the age of 15 years he was treated for one year
with the synthetic androgen fluoxymesterone. At the end of this course
of treatment D.B. was clinically judged as having a rather acromegalic
appearance, and in an effort to stimulate epiphyseal closure he was
converted to high dosage testosterone treatment in the form of monthly
Sustanon 250 injections, which allegedly precipitated frequent and
relatively violent aggressive outbursts, and consequently the treatment
was stopped.
D.B. was referred to Dr. John Bancroft and the author by the staff
at the endocrine clinic of the Western General Hospital in Edinburgh.
We were faced with the problem that the patient obviously required
androgens to stimulate epiphyseal closure but that the administration
of exogenous androgens appeared to provoke severe behavioural problems.
It was our opinion that if androgen treatment was in fact causing
these aggressive outbursts, then Sustanon 250 injections may not be the
most suitable form of replacement therapy, as we had previously
observed that these intramuscular injections produce very high
pharmacological levels of circulating testosterone, i.e. 400% of normal
adult male levels for the few days following injection (see Fig. 4.1).
We hypothesised that with a more gradual and stable method of
testosterone administration, the androgenic effects necessary for bone
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maturation may be provided without precipitating the bouts of
aggressive behaviour that had previously been observed following the
high dose testosterone injections.
A single-case study protocol was devised where the behavioural
effects of gradually increasing the dose of testosterone undecanoate
(T.U.) were assessed relying on blind daily ratings of P.B.'s behaviour
by hostel staff members.
9.2.2 Behavioural Assessment
Satisfactory methods of measuring human aggression are lacking
(see review by Edmunds and Kendrick, 1980). Inspection of published
staff rating methods of patients behaviours (e.g. Hall, 1977; Shatin
and Freed, 1955) revealed that none were suitable in this particular
case as they did not deal specifically with aggressive behaviour.
Self-report inventories which claim to measure aggression (e.g.
Blackburn, 1974; Buss and Durkee, 1957) could not be used because of
the patient's degree of mental retardation. The author therefore
constructed a daily scale where hostel staff memebers, at their daily
meetings, could assess D.B.'s behaviour over the previous 24 hours. A
draft version of a simple seven point rating scale describing five
aspects of behavioural functioning: Aggressive, Energetic, Sociable and
Friendly, Irritable, and Cheerful and Happy was presented to the hostel
staff and discussed. In general the daily rating scale met with their
approval, but the majority felt that while D.B. had been receiving the
high dose testosterone injections, he had been particularly prone to
violent mood swings, and asked if some measure of this mood lability
could be incorporated into the rating. In light of this suggestion an
additional scale, Changeable or Up and Down was included. A copy of
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the daily assessment form appears as Fig. 9.1.
D.B. was interviewed by the author prior to the study. He
presented as a pleasant mentally slow young man. He denied having any
degree of sexual interest or activity, but stated that he did have a
girlfriend at the adult training centre he attended. When pressed, he
stated that he did kiss and caress his girlfriend, but the impression
that emerged was of a child-like, almost platonic relationship. D.B.
denied ever having masturbated, or ever noticing any change in the size
of his penis. Physical examination revealed a very small markedly
deformed penis embedded in scar tissue, with the scrotum and testes
absent.
D.B.'s parents and the hostel staff expressed concern over the
possibility that androgen administration would stimulate sexual
feelings which he would find difficult to cope with. They were
informed that sexual counselling would be provided if required.
9.2.3 Design
For a baseline period of four weeks, hostel staff members
completed the daily rating form assessing D.B.'s behaviour while
receiving no androgens. The patient and the staff were then informed
that D.B. would be given testosterone capsules, and that he v/ould be
administered a different dose every month for three months, but to
ensure that the staff were not aware when he was on high or low doses
of testosterone, every day for three months D.B. would be given four
identical capsules, one, two or three of which would contain 40mg of
active T.U., the remainder being made up with matched placebo. Two
capsules were taken at 0800 hours, two at 1700 hours. Following the
baseline month the dose was increased every month from 40 to
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120 mg T.U./day, as described in Table 9.1 In addition to the daily
staff ratings, D.B. was visited every month by the author who conducted
an informal inverview to monitor any androgen mediated effects on
sexuality.
In order to investigate the effects of T.U. administration on
plasma testosterone levels, D.B. was brought into hospital for one day
at the end of the study to participate in an absorption study. Blood
samples were taken every 30 minutes, prior to, and six hours following
oral ingestion of 80 mg T.U. Testosterone was assayed according to the
method of Corker and Davidson (1978).
9.2.4 Analysis
The effect of varying the replacement dose of T.U. on D.B.1s
behaviour, as assessed by hostel staff members, was analysed using
repeated measures analysis of variance (ANOVAR).
9.3 RESULTS
9.3.1 Behavioural Results
Table 9.2 reveals that increasing the replacement dose of T.U. had
no effect on any of the daily ratings of behaviour as assessed by
hostel staff members. In addition, at the monthly informal interviews
conducted by the author, D.B. denied any increase in sexual feelings.
(In fact, he repeatedly stated that the T.U. capsules were "just like
sweets", i.e. he felt that they were completely without behavioural
effect).
9.3.2 Endocrine Results
As can be seen (Fig. 9.2) oral ingestion of 80 mg T.U. led to
circulating testosterone levels which were maintained within the normal




Month 0800 hr. dose 1700 hr. dose
1 (Baseline) - -
2 (40 mg/day) 1 40 mg capsule
1 placebo capsule
2 x placebo capsules
3 (80 rug/day) II 1 40 mg capsule
1 placebo capsule
4 (120 mg/day) 2 x 40 mg capsules II
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TABLE 9.2
STAFF RATINGS OF AGGRESSIVE BEHAVIOURS OF A HYPOGONADAL MAN WHILE
RECEIVING NO ANDROGEN TREATMENT AND ON THREE MONTHS OF INCREASING
REPLACEMENT DOSAGE OF TESTOSTERONE UNDECANOATE
Mean (+ S.D.) Staff Rating
Per Monthly Treatment Period
Behaviour Basal T.U.40 T.U.80 T.U.160 ANOVAR
Energetic 4.1(1.9) 3.6(1.1) 3.5(1.1) 4.5(1.0) F=2.53, N.S.
Irritable 2.3(1.2) 2.1(1.4) 2.4(1.6) 2.2(1.7) F=0.03, N.S.
Aggressive 1.8(1.9) 1.4(1.1) 1.9(1.3) 2.2(1.8) F=0.72, N.S.
Cheerful 5.2(1.5) 4.9(1.2) 4.1(1.4) 4.6(1.7) F=1.53, N.S.
Sociable 5.0(1.6) 4.8(1.3) 4.0(1.4) 4.5(1.9) F=1.67, N.S.
Changeabl e 1.7(1.0) 2.4(1.8) 1.7(1.2) 1.7(1.2) F=0.91, N.S.
157
FIGURE 9.1
Daily Assessors Rating Form for D.B. Date
Please indicate on the scales below, (by circling the appropriate










































The effect of oral ingestion of 80 mg T.U. on circulating
testosterone levels in a hypogonadal man.
159
9.4 niscussiON
In this particular hypogonadal man we have managed to provide a
satisfactory degree of testosterone replacement without provoking the
aggressive outbursts \/hich had been reported while D.B. was receiving
treatment with Sustanon 250 injections. There are four possible
reasons for this differential behavioural response to the different
androgen preparations
(1) The aggressive outbursts which occurred while D.B. was receiving
the Sustanon injections may have been coincidental rather than causally
related. The bouts of aggression could possibly have been more due to
inter-personal conflicts with particular patients or staff at that
time, and may have had nothing to do with the treatment.
(2) The staff may have been biased in their behavioural reports as they
were aware that D.B. was being given high dosage "male hormone"
injections (although no such reports were made previously while D.B.
was being treated with the oral fluoxymesterone).
(3) The aggressive outbursts were a direct result of the very high
testosterone levels which result following Sustanon injections. These
massive swings in circulating testosterone levels may have acted on the
brain to make D.B. more predisposed to aggressive outbursts. While
receiving T.U., plasma levels of testosterone were kept within the
normal adult male range, i.e. this mode of androgen replacement
resulted in an androgen profile more similar to that of the normal
man.
(4) The aggressive outbursts brought about as a result of the Sustanon
injections could have been indirectly due to the elevated testosterone
levels which were then aromatized to oestradiol which in turn
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stimulated "aggression centres" in the central nervous system. (Many
of the organisational effects of androgens on the brain are thought to
be brought about via neural aromatization to oestradiol, Gorski and
Jacobson, 1982). T.U. replacement did not have this effect as T.U.
administration leads to a greater proportional elevation of systemic
non-aromatizable DHT compared with testosterone (Skakkebaek et al.
1981). (Most of the somatic effects of androgens have been shown to
depend on DHT, Mainwaring, 1977).
It is possible that if androgens have a stimulatory effect on
aggressive behaviour in the human male, the mechanism of action is via
aromatization of testosterone to oestradiol. This hypothesis would
account for the observation that during the one year of treatment with
the non-aromatizable synthetic androgen, fluoxymesterone, hostel staff
did not report aggressive outbursts (see Section 9.2.1).
This explanation of the differential behavioural effects of T.U.
and Sustanon is obviously rather speculative. Preliminary data on the
relative effects of testosterone, oestradiol and DHT on aggressive
behaviour in animals have been presented, e.g. in the mouse (Finney and
Erpino, 1976) and in the deer (Fletcher, 1978) but as yet details of
the relative contributions of testosterone, oestradiol and DHT in the
regulation of human aggressive behaviour are lacking.
The results of the present case study demonstrate that gradually
increasing the dose of T.U. did not act to precipitate bouts of
aggressive behaviour in a hypogonadal man who had previously been
reported as acting very aggressively while receiving high dose
testosterone injections. Possible reasons for these different
behavioural results with the different androgen preparations have been
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suggested. Gradually increasing the dose of T.U. may offer particular
advantages over injectable preparations such as Sustanon where the
somatic effects of the androgen are of primary importance and where
alternative androgen preparations have produced unwanted behavioural
side-effects such as hyperaggression.
Finally, it is important to remember how poor the evidence is of
an androgen involvement in human aggression, and how few properly
controlled studies have been carried out. In the studies described in
this thesis, no evidence was produced to suggest that androgen
administration acted to stimulate aggressive behaviour in man. In fact
in the hypogonadal study (Chapter 3), the hypogonadal men rated
themselves as feeling 1 ess aggressive while receiving the highest
replacement doses of testosterone undecanoate. In the eugonadal
studies of the behavioural effects of androgen administration in men
complaining of loss of libido (Chapter 5) and erectile dysfunction
(Chapter 6), daily self-ratings of irritability and aggression were not
significantly different when placebo treatment was compared with high
dosage testosterone treatment.
Eysenck's psychoticism or P scale (Eysenck and Eysenck, 1975) has
been proposed as an indirect measure of human aggressiveness (Edmunds
and Kendrick, 1980). Again, in the hypogonadal and eugonadal studies
androgen administration had no effect on P scores (Chapter 8).
Thus the results reported in this thesis fail to provide any
evidence to support clinical impressions that androgen administration
provokes aggressive outbursts in man (Sands and Chamberlain, 1957;
Strauss et a]_. 1957). However, controlled double blind studies are
urgently required which carefully monitor aggressive behaviour
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following androgen administration in the hypogonadal man. Until such
studies are carried out, the question of a relationship between






In this final chapter the relationship between androgens and
behaviour in man is reviewed in light of the experimental findings
presented in this thesis. This discussion is presented in four
sections: Androgens and Erectile Function, Androgens and Sexual
Interest, Androgens and Mood and Personality, and Methodological Issues
arising from the Research Presented.
10.2 ANDROGENS AND ERECTILE FUNCTION
Bancroft (1980) proposed that the primary behavioural action of
androgen in man is to stimulate sexual appetite, and that erectile
function per se is relatively independent of androgen status. Evidence
to support this hypothesis was presented by Bancroft A Wu (1983) and
Kwan _et _al_. (1983) who reported that erectile response to erotic film
was unaffected by androgen replacement and withdrawal in the
hypogonadal man. (However, Bancroft & Wu (1983) made the fascinating
observation that erections in response to erotic fantasy were markedly
reduced following androgen withdrawal).
Davidson _et _al_* (1979) claimed that the reported frequency of
erections on waking in the hypogonadal man was clearly stimulated by
androgen replacement therapy. Similar data was supplied by Salmimies
_et _al_* (1982). In the hypogonadal study described in Chapter 3, the
reported frequency of morning erections was demonstrated to vary in a
clear dose-dependent manner with androgen replacement. Similarly in
Chapter 7 direct measurement of nocturnal erectile response revealed
that hypogonadal men display diminished nocturnal erectile function
which improves following androgen replacement therapy. Kwan et al.
(1983) also reported this stimulatory action of androgen replacement on
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nocturnal erectile function in the hypogonadal man.
We are therefore faced with this contrary data, i.e. that the
reported incidence of morning erections (residual nocturnal erections),
directly measured nocturnal erections, and erections in response to
erotic fantasy all appear to be clearly androgen dependent, whereas
erections in response to erotic film are relatively unaffected by
androgen replacement and withdrawal. It is possible that erections in
response to erotic fantasy and nocturnal erectile responses differ
qualitatively from erections in response to erotic film in that the
former are generated in response to an "internal" stimulus as opposed
to the external film stimulus, i.e. the central cognitive stimulus for
erection in man may be androgen dependent, whereas the hypogonadal man
retains the ability to produce erections in response to a powerful and
sexually stimulating external stimulus. This hypothesis would account
for the observation that some castrate men retain the ability to
produce erections during sexual contact (Heim, 1981). It is important
to note that this hypothesised central action of androgens was shown
not to be (as Bancroft, 1980 suggested) the result of a general
stimulatory effect of androgens on visuo-spatial ability (See Chapter
8).
In their recent attempts to replicate the Bancroft & Wu (1983)
study, Kwan et _al_. (1983) reported that the ability of hypogonadal men
to produce erections in response to erotic fantasy v/as relatively
unaffected by androgen replacement. However, careful reading of the
Kwan _et _al_. (1983) paper reveals that three out of their six
hypogonadal subjects produced very poor erections in respose to erotic
fantasy, and two out of these three men demonstrated an improved
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response to fantasy following testosterone treatment. Therefore the
Kwan et al♦ (1983) results are not totally contrary to those supplied
by Bancroft & Wu (1983).
The results of two recent studies using eugonadal men as subjects
provide data which is difficult to reconcile with the Bancroft & Wu
(1983) hypothesis, i.e. that circulating androgen levels are not
related to erectile response to erotic films. Lange _et _al_. (1980) and
Rubin et al♦ (1979) both reported that circulating testosterone levels
were in fact highly correlated with latency to full erection in
response to erotic film. However, in general, studies investigating
the efficacy of androgen administration in the treatment of erectile
dysfunction have produced negative results. As was suggested in
Chapter 1.4.2, it is possible that these negative results were due to
the fact that the androgen administration did not result in an increase
in circulating androgen levels due to the eugonadal homeostatic
mechanisms which operate. In Chapter 4, we managed to overcome these
homeostatic mechanisms using frequent intramuscular depot injections of
testosterone. However, this method of androgen administration was
shown to be ineffective in the treatment of erectile dysfunction in the
eugonadal man (Chapter 6).
At this point in time the issue of the relationship between
androgens and erotically induced erections remains unresolved; however,
there is good evidence to support the hypothesis that nocturnal
erectile function in man is androgen dependent.
10.3 ANDROGENS AND SEXUAL INTEREST
Several investigators have proposed that androgens act to
stimulate sexual interest or libido in man (e.g. Money, 1961;
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Bancroft, 1980; Davidson _et _al_. 1982) although until very recently few
studies had attempted to directly test this hypothesis. In 1980 Luisi
& Franchi presented data in support of the hypothesis. These authors
reported that androgen administered to hypogonadal men acted to
significantly increase their level of self-rated libido. Similar
results were presented by Skakkebaek eT _al_. (1981). In their study the
frequency of sexual thoughts and sexual excitement associated with
these thoughts of a group of hypogonadal men were clearly stimulated by
androgen administration as opposed to placebo treatment. In the
hypogonadal study described in Chapter 3, frequency of sexual thoughts
and sexual excitement associated with these thoughts were shown to vary
in a clear dose dependent manner with androgen replacement. This
result confirms the findings of Salmimies _et _al_. (1982) who reported
that "sexual drive" increased with androgen replacement dose.
Similarly Kwan et al. (1983) reported that "sexual feelings" displayed
a progressive increase following blind injections of placebo and
increasing doses of testosterone.
Thus the evidence derived from studies carried out on the
hypogonadal man strongly support the hypothesis that androgens have a
major stimulatory effect on sexual interest, and that this effect is a
dose dependent one.
When we turn to look at the relationship between androgens and
sexual interest in the eugonadal man, the picture is less clear.
Previous investigators have generally failed to find any relationship
between circulating testosterone levels and sexual interest or activity
in the normal man (e.g. Brown et al. 1978) and androgen treatment is
generally considered to be unhelpful in the treatment of sexual
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dysfunction in the eugonadal male. However in Chapter 5 a study is
reported where testosterone injections were shown to be superior to
placebo in the treatment of eugonadal men complaining specifically of
low sexual interest. This effect was apparent both when self-rating
and interview ratings of sexual interest were analysed. This is an
important finding, and if replicated could prove to have far reaching
consequences in the field of sex therapy. However, in only three out
of the ten men studied did this increase in sexual appetite constitute
a sufficient therapeutic response, i.e. in terms of increased sexual
activity. It was proposed that in most of the subjects other factors,
e.g. communication difficulties, resentment, hostility, etc. prevented
this increase in sexual appetite being reflected in an increased
frequency of the sexual activity of the couple. A model was proposed
linking marital dysfunction, stress, reduced androgens, decreased
sexual interest and a decreased frequency of sexual activity in a
self-perpetuating "vicious circle" (see Fig. 5.3). The author
suggested that this vicious circle could be broken in a number of ways,
e.g. androgen treatment for the man with low sexual interest coupled
with psycho-sexual counselling for the couple where the emphasis would
be placed upon improving the communication between the couple and, if
necessary, encouraging the female to take the sexual initiative.
Although the results of the hypogonadal study (Chapter 3) and the
results of the study on the eugonadal men complaining of loss of sexual
interest (Chapter 5) support the hypothesis that androgens have a
stimulatory effect on sexual interest, in the study described in
Chapter 6 a group of eugonadal men complaining of erectile dysfunction
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with no loss of interest in sex were treated with depot testosterone
injections, and androgen administration was shown to be entirely
without behavioural effect. In accounting for this differential effect
of androgen administration in the different patient groups, the author
proposed that (a) the erectile dysfunction group had a relatively
"normal" degree of interest in sex and therefore had less scope for
improvement, and (b) that although the evidence suggests that androgens
stimulate sexual interest in the majority of hypogonadal men, there may
be an optimal circulating theshold testosterone level in man, any
alteration above this theshold having no behavioural effect. It is
proposed that this optimal level of circulating testosterone may not be
an absolute one in terms of nmol/1 (as has been previously suggested,
Pirke & Kockott, 1982) but is highly variable across individuals. This
hypothesis would account for the observation that some hypogonadal men
display a relatively normal degree of sexual interest and activity
despite having very low circulating testosterone levels (e.g. Salmimies
et _al_. 1982) and would also account for the stimulatory effect of the
testosterone injections in the low libido eugonadal men (Chapter 5) v/ho
had a mean basal testosterone level which was greater than 20 nmol/1.
Further studies are necessary to determine exactly which facets of
sexual functioning in the adult human male are androgen dependent;
however the results of the studies described in this thesis suggest
that sexual interest and nocturnal erectile function are dependent on
an adequate level of circulating androgen.
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10.4 ANDROGENS AND MOOD AND PERSONALITY
10.4.1 Androgens and Mood
Studies carried out to date investigating the relationship between
androgen replacement and mood in the hypogonadal man have produced
inconsistent results. Luisi & Franchi (1980) claimed that "mental
state" was markedly improved following androgen replacement. Similarly
Skakkebaek jet _al_. (1981) reported that fatigue and tension/anxiety were
reduced and vigour increased during active treatment compared with
placebo. Davidson _et _a]_. (1979) and Salmimies _et _al_. (1982) however
reported a lack of effect of testosterone replacement on mood. In the
hypogonadal study described in Chapter 3, the effects of androgen
replacement on mood were generally modest, but the hypogonadal men did
rate themselves as feeling less tense and anxious, changeable, and
irritable while taking the higher doses of testosterone undecanoate.
However, neither the eugonadal men complaining of reduced sexual
interest (Chapter 5) nor the eugonadal men complaining of erectile
dysfunction (Chapter 6) reported any effect of high dosage testosterone
administration on mood state.
It is possible that the improvements in mood state that have been
reported in the literature following androgen treatment for
hypogonadism are a result of the general improvement in sexual
functioning, i.e. anxiety and general negative mood states in the
untreated hypogonadal man may be partially due to the very severe
sexual difficulties associated with hypogonadism and would thus tend to
improve following the beneficial effects of testosterone therapy on
sexual functioning.
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This hypothesis is in direct opposition to that proposed by Kinsey
et _al_. (1953), i.e. that androgens act primarily on general metabolism
and mood and only secondarily on sexual functioning. Further studies
closely analysing the temporal changes in sexual functioning and mood
following androgen replacement in the hypogonadal man are required to
determine which aspects of behavioural functioning are affected first.
10.4.2 Androgens and Personality Measures
Several investigators have proposed that scores on certain
personality measures are related to circulating androgen levels in the
eugonadal man. To date, all the evidence in support of this hypothesis
has been derived from correlational studies equating mean circulating
testosterone level with psychometric test scores (See Chapter 1.6-1.7).
In the studies described in this thesis experimental elevation of
circulating androgen levels resulted in a general lack of effect on
psychometric test scores in both the hypogonadal and eugonadal groups
of men (Chapter 8). No support was therefore drawn for hypotheses
which had suggested that sensation seeking behaviour, spatial ability
and scores on Eysenck's P scale were related to androgen levels.
However, these negative results must be qualified in that the
psychometric tests claim to measure relatively stable dimensions of
personality. It could therefore be argued that these test scores would
be unlikely to show significant changes following relatively short-term
androgen treatment. In reply, it is important to note that Kaiser
_et _al_. (1978) reported significant effects on a variety of personality
tests following five weeks treatment with mesterolone using a group of
elderly men as subjects. (The Kai ser _et _al_. (1978) result is
surprising given that Luisi & Franchi (1980) found mesterolone to be
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ineffective and testosterone undecanoate highly efficacious in the
treatment of male hypogonadism, suggesting that mesterolone is a
behaviourally weak androgenic preparation).
10.5 METHODOLOGICAL ISSUES ARISING FROM THE RESEARCH PRESENTED
10.5.1 Free Steroid Estimation
An important methodological point which emerged from the studies
carried out in the eugonadal man was the difficulty involved in
estimating the actual concentration of free androgen in the plasma,
i.e. the fraction of bio-active hormone that is available at the
receptor (Berg ink _et _al_. 1981). One relatively recent approach which
would appear to offer a distinct advantage over labour intensive assay
methods which estimate the free steroid concentration in the plasma is
the method of salivary steroid assessment (Walker, 1983). These new
asays measure the amount of steroid which passes from the systemic
circulation into the saliva. Salivary steroid concentrations have been
shown to correlate very highly with plasma estimates of free steroid,
obtained using a variety of laborious methods (Riad-Fahmy _et aj_. 1982).
In future studies, steroid assay of salivary samples may offer a
simpler, more direct and more accurate assessment of bio-active
androgen status in the human male and female. Salivary sampling also
removes the stress experienced by some individuals prior to and during
venepuncture. (It is important to note that venepuncture itself may
have an effect on the neuro-endocrine system in man, e.g. Lincoln,
1974).
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10.5.2 SHBG Estimation Following Testosterone Undecanoate
Administration
A study is described in Appendix II which demonstrates that
following administration of testosterone undecanoate (T.U.), plasma DHT
levels become elevated and this elevation in PHT acts to interfere with
the accuracy of the SHBG assay by binding to the SHBG molecule, leaving
fewer binding sites on the protein to be filled by the tritiated DHT
used in the SHBG assay. It is therefore recommended that in future
studies samples from men receiving T.U. have steroids removed from
plasma samples prior to SHBG estimation when the DHT-binding assay is
to be used.
10.5.3 Variability in Absorption of Testosterone Undecanoate
Recent evidence (Cantrill et_ _al_. 1983; Schurmeyer _et aj_. 1983)
has demonstrated that individuals vary in the rate at which they absorb
testosterone undecanoate. (This variability in T.U. absorption rates
was confirmed in a small study described in Appendix III). In the
studies described in Chapters 3 and 4 it is probable that our fixed
single post-dose blood sampling regime was inadequate for assessing
these variable effects of T.U. ingestion on circulating androgen
levels. In future studies using T.U., absorption curves involving
frequent post-dose blood sampling will have to be carried out for each
individual in order to pick up these variable peaks in plasma
testosterone levels that occur following T.U. administration. It is
important to note that these absorption rates may vary both inter- and
intra-individually.
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10.5.4 Methods of Raising Circulating Testosterone Levels in
Eugonadal Men
In Chapters 4,5, and 6 it was demonstrated that intramuscular
Sustanon injections proved to be a satisfactory method for increasing
circulating testosterone levels in the eugonadal man. However, this
experimentally induced elevation in systemic testosterone level was not
sustained; for the few few days following injection plasma testosterone
levels were massively elevated (i.e. 400% of the normal adult male
levels), thereafter testosterone levels fell back to basal levels over
a two week period. (Oral administration of T.U. did not appear to
overcome the eugonadal homeostatic control mechanisms, and plasma
testosterone levels were not significantly affected (Chapter 4).
However, as stated above, the single post-dose blood sampling regime
employed was probably inadequate for assessing the effect of T.U.
ingestion on plasma testosterone levels, given the variability that
exists in T.U. absorption rates).
It is possible that sustained elevations in circulating
testosterone levels without these wild supraphysiological swings could
be brought about using silastic testosterone implants. However the
effect of testosterone implants on the endocrinology of the eugonadal
man awaits experimental investigation.
10.5.5 Behavioural Measurement
10.5.5.1 Assessment of Sexual Behaviour
All of the studies reported in this thesis can be criticised in
that the effect of androgen administration on the sexual behaviour of
men has been investigated with no formal assessment incorporating the
sexual partner. In many instances, this was unavoidable as the female
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partners refused to attend for psycho-sexual counselling and the man
was forced to seek help alone. However, in future studies, every
effort should be made to include both partners in the experimental
design.
It is also important to stress the need for daily assessments of
sexual behaviour, i.e. diaries. While some investigators have claimed
that retrospective (recall) data is a valid form of behavioural
assessment (e.g. Spanier, 1977), recent evidence comparing daily
records with monthly estimates of sexual behaviour have shown that, for
example, monthly estimates of frequency of morning erections correlate
poorly with daily records (Reading et al. 1982; Reading, 1983).
10.5.5.2 Assessment of Aggressive Behaviour
There has been relatively little research carried out on the
relationship between androgens and human aggression. In the studies
that have been published, too much reliance has been placed upon
self-report questionnaires such as the Buss-Durkee Hostility Inventory
(Buss and Durkee, 1957), even though scores on these inventories have
been shown not to correlate with observed aggressive behaviour (Rose,
1975). In the opinion of the present author, future studies should
attempt to utilise observer ratings of aggressive behaviour. Using
highly aggressive subjects (e.g. violent incarcerated criminals) the
observer rating method described by Ehrenkranz et _al_. (1974) would
appear to be an approach worthy of replication. In less behaviourally
extreme samples, social taboos on the expression of aggressive
behaviour make it difficult to directly observe human aggression.
However studies such as that by Scaramella & Brown (1978) which utilise
sport as an area of human activity where societal constraints on the
176
expression of aggressive behaviour are temporarily lifted (and in some
instances aggressive behaviour is actively encouraged) would again
appear to be an approach worthy of further investigation.
10.5.6 Surgically Induced Hypogonadism - The Question of
Pre-Operative Counselling
In discussions with the hypogonadal subjects described in Chapter
3, several men demonstrated a lack of knowledge concerning the
consequences of their condition. To take an example, one castrate man
asked if he would be able to make his wife pregnant. He was under the
impression that his fertility would be reduced but had not discussed
the topic with a clinician. The same hypogonadal patient told the
author that after being given his pre-medication prior to his bilateral
orchidectomy, the surgeon asked him if he would be interested in having
prostheses inserted. The patient did not know what a prosthesis was.
It is possible that these were isolated incidents, but it would
surely be a good routine policy to have detailed pre-operative
counselling sessions with such patients, where the likely physiological
and psychological effects of the operation could be explained. Also,
the question of prosthetic replacement and the various alternative
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APPENDIX I
THE EFFECTS OF BROMOCRIPTINE ON THE SEXUAL BEHAVIOUR OF A
HYPERPROLACTINAEMIC MAN: A CONTROLLED CASE STUDY*
*This study was carried out in collaboration with Dr. J. Bancroft,
A. McNeilly and Professor R. Shaw.
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The association between hyperprolactinaemia and sexual dysfunction
in men is now well established (Carter _et _al_. 1978; Perryman &
Thorner, 1981). Improvement in sexual function has been widely
reported to follow treatment with bromocriptine and the consequent
reduction in prolactin levels (Franks _et _al_. 1978; Nagulesparen et
_aj_. 1978) - As yet there are no controlled studies of these associations
or treatment effects. It therefore remains uncertain which aspects of
male sexuality are primarily affected by the hyperprolactinaemia. Is
it sexual appetite or does the raised prolactin have a direct effect on
erectile function?
The case study reported here throws some light on this issue.
CASE HISTORY
The patient (M.J.) is a 44 year old engineer who presented in 1977
with his wife at a sexual problems clinic, complaining of loss of
sexual interest and erectile impotence. At that stage, he and his wife
were treated in a study evaluating testosterone treatment in comparison
with placebo, each being combined with counselling for the couple.
M.J. received placebo together with counselling and by the end of
treatment there had been considerable improvement. His erectile
problems had disappeared, and whereas there had been a slight increase
in his spontaneous sexual interest, the important change was in his
wife's attitude. Previously, she had been reluctant to initiate sexual
activity. As a result of the counselling she was quite prepared to do
so and they were both able to enjoy the lovemaking that resulted.
Six months after treatment, this improvement had been maintained
and after many years of infertility she had become pregnant with twins.
211
Serial blood samples from M.J. had been taken before treatment and
again six months after treatment ended. As the response to treatment
was so satisfactory, no priority was given to completing all the
hormone assays. Three years later it was found that both prior to
treatment and at follow-up he had hyperprolactinaemia (4670 and 4756
mU/L respectively). His mean testosterone levels on these two
occasions were normal at 20.7 and 16.5 nMol/L. As a result of these
hormone measurements, he was contacted again, when he reported that his
sexual relationship had remained satisfactory, though his spontaneous
sexual interest was still somewhat low. His plasma prolactin level was
found to be still high at 5721 mU/L with his testosterone at 15 nMol/L.
Further investigations were then carried out. Skull X-ray and CAT scan
demonstrated slight asymmetry of the fossa floor, but no increase in
volume. Tissue density within the fossa was normal with no change by
contrast injection and no abnormal tissue formation in the suprasellar
region. Combined pituitary function tests showed normal GH, TSH, LH,
FSH and Cortisol responses. Prolactin levels increased from a basal of
4790 mU/L to 6420 mU/L at 30 min following 200 ug TRH. There was
therefore no evidence of a pituitary tumour. Seminal analysis showed a
total sperm count of 468 x 10^. He was advised to have treatment to
lower his prolactin levels and agreed to participate in a double blind
controlled evaluation of bromocriptine and placebo (Study 1).
Following this he was prescribed bromocriptine and followed up a year
later. Due to a misunderstanding he had stopped taking bromocriptine
some months previously. Both his sexual interest and prolactin levels
had returned to their previous level, though otherwise sexual function
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was still satisfactory. He again agreed to undergo a double blind
comparison of bromocriptine and placebo (Study II).
METHOD
Study 1
For a period of seven months, M.J. completed a daily diary
indicating the incidence of sexual activity, whether initiated by self,
partner or mutually, presence or absence of morning erections and the
degree of sexual interest (See Appendix IV). Weekly blood samples for
endocrine assessment were taken throughout this period and were
subjected to established assays of testosterone (Corker & Davidson,
1978), SHBG (Anderson _et _al_. 1976), prolactin (McNeilly & Hagen, 1974),
LH and FSH (Hunter & Bennie, 1979). The presence of different
molecular forms of prolactin was investigated by chromatographic
separation of plasma samples before and after bromocriptine treatment.
Samples were passed down a Sephadex G-100 (1 x 60 cm) column, using the
method described by Hagen & McNeilly (1975). All samples were measured
in a single assay.
The first six weeks were used as baseline, with no treatment
given. For the next six weeks, M.J. was administered testosterone
(Sustanon 250 injections at three weekly intervals). He was then
started on bromocriptine, with gradually increasing dosage to assess
his prolactin response and the appropriate dosage to use. His
prolactin levels rapidly dropped to sub-normal levels on the dosage of
10 mg bromocriptine per day (55 mU/L) and he experienced mild
gastro-intestinal side-effects. A dosage of 7.5 mg, free from side
effects, was therefore selected for the double blind placebo
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comparison. This maintained plasma prolactin at a mean of 259 +_ 84
mU/L. Thereafter he received treatment according to a double-blind
schedule; 5 weeks on bromocriptine, 5 weeks on placebo and 5 weeks
bromocriptine.
Study II
The same measures of sexual activity and interest were used and
blood samples were taken at two weekly intervals. After a two week
baseline period of no treatment, he received tv/o weeks of placebo and
six weeks of bromocriptine (7.5 mg daily), in a double blind fashion.
In both studies, sexual interest scores during placebo and
bromocriptine administration were compared using t-tests after
logarithmic transformation.
RESULTS
The mean levels of sexual interest and sexual activity, together
with the proportion of sexual acts initiated by the subject and the
proportion of days in which M.J. experienced waking erections, during
the baseline period, Sustanon administration and the double blind
administration of bromocriptine and placebo for Studies I and II are
shown in Table 1.1.
Self-rated sexual interest was significantly higher whilst on
bromocriptine than on placebo in both studies. There was no difference
in this measure between the baseline and Sustanon periods in the first
study. Frequency of sexual activity did not change significantly
throughout either study, although there was a tendency for the
proportion of acts initiated by M.J. to be higher during both Sustanon
and bromocriptine treatment (especially in Study II). No erectile
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PLASMA HORMONE LEVELS IN A HYPERPROLACTINAEMIC
MAN DURING VARIOUS STAGES OF TREATMENT: STUDY I
Treatment Prolactin Testosterone SHBG LH FSH
mU/L nMol/L nMol/I U/L U/L
Baseline Mean 4999 17.8 25.5 5.7 2.6
(s.d.) (429) (2.6) 25.4
Sustanon Mean 5134 22.2 23.6 2.9 1.7
(s.d.) (650) (9.7) (3.7) (1.8) (0.7)
PIacebo Mean 2095 20.8 29.2 4.4 2.9
(s.d.) (1159) (5.2) (4.9) (0.5) (0.3)
Bromocriptine Mean 259 21.2 27.7 4.5 3.0
(s.d.) (84) (2.8) (5.3) (0.6) (0.5)
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The effect of bromocriptine and placebo treatment on sexual interest
(frequency of sexual thoughts) and plasma prolactin levels in a
hyperprolactinaemic man.
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difficulties were reported at any stage and there were no differences
in the incidence of morning erections. The change in sexual interest
in Study II is shown in Fig. 1.1.
ENDOCRINE CHANGES
Mean levels of prolactin, testosterone, SHBG, LH and FSH during
each of the treatment periods in Study I are shown in Table 1.2.
Prolactin levels during Study II are shown in Fig. 1.1. Prolactin did
not change during Sustanon administration, but dropped to normal levels
during bromocriptine therapy. On placebo, levels rose but did not
reach those prior to treatment. The percentage of "big" prolactin
prior to and during the bromocriptine phase was 15.7% and 66.3%
respectively (Study I).
DISCUSSION
This case study is informative for a number of reasons. It shows
that erectile impotence associated with hyperprolactinaemia can be
treated by psychological means, an observation made fortuitously
because of the delay in measuring the prolactin. This suggests that
the erectile failure was a psychological reaction to the loss of sexual
interest in a couple where the man was expected to take the initiative.
The main effect of counselling was to alter this expectation so that
the male partner did not feel under pressure to initiate and became
able to respond normally when his wife did so. Once the improvement
occurred, normal sexual function persisted over several years in spite
of continuing very high prolactin levels and low levels of spontaneous
sexual interest.
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The residual effect of the hyperprolactinaemia was a somewhat
reduced level of sexual interest as indicated by the statistically
significant effect of bromocriptine treatment in increasing sexual
interest as compared with placebo. Whilst there was no increase in the
incidence of sexual activity, treatment did result in an increase in
the number of acts initiated by the subject. In both studies, there
was a large transient increase in sexual interest when first starting
on bromocriptine. Why this level of response was not maintained is not
clear, but it is not unusual in treating hypogonadal men with
testosterone replacement to obtain an initial marked increase in sexual
interest before a more moderate stable state is maintained.
This controlled case study validates the uncontrolled
observations reported by Schwartz _et _al_ (1982). One hundred and thirty
six men had received psychotherapy for sexual dysfunction at the
Masters & Johnson Instititue. Blood samples had been taken prior to
therapy but prolactin was not measured until some years later when 8
men (6%) were found to have substantial hyperprolactinaemia due to
pituitary adenomas. Contact with these men after treatment was limited
to the telephone, but all had reported improvement in sexual function
(especially erection) following psychotherapy and a further improvement
in sexual interest after the hyperprolactinaemia had been treated with
bromocriptine.
The main difference was that all the eight hyperprolactinaemic
men reported by Schwartz et _al_ (1982) had low levels of testosterone.
In our case this was not so, though his levels were in the lower part
of the normal range. He showed no significant increase in testosterone
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during bromocriptine therapy however and this, together with the lack
of response to Sustanon, made it unlikely that his loss of sexual
interest was the direct result of testosterone deficiency. Many
hyperprolactinaemic men do have testosterone levels in the hypogonadal
range (Ferryman & Thorner, 1981; Legros _et _al_. 1980) and in such cases
androgen deficiency could be adding to the behavioural effects of
hyperprolactinaemia.
Hypogonadism of Hyperprolactinaemia - Mechanism of Effect
Several mechanisms have been proposed to account for this
association between elevated prolactin and reduced testosterone levels.
Fonzo _et aj_. (1977) suggest a direct effect of prolactin on the testis;
other hypotheses include: a prolactin mediated disorder of the negative
feedback to the hypothalamic-pituitary axis (Carter _et _al_. 1978;
Franks, 1981; McNeilly, Sharpe & Fraser, 1983); a reduced turnover of
testosterone to dihydrotestosterone presumably mediated via 5 ck
-reductase inhibition (Magrini _et _al_. 1976; Legros _et _al_. 1980); and
recently Vermeulen et aj_. (1982) proposed a reduction in the SHBG level
in the hyperprolactinaemic man leading to increased metabolic clearance
of testosterone and hence a reduced free testosterone level in the
blood. In the face of these differing hypotheses, Ferryman and Thorner
(1981) conclude, "the data are confusing and inconsistent, and no
conclusion is possible at the present time".
Hyperprolactinaemia and Sexual Dysfunction
Miller et_al_. (1980) point out a contradiction in the literature
concerning the incidence of hyperprolactinaemic men complaining of
"impotence" at presentation. Carter et _al_. (1980) reported that 20/22
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of their hyperprolactinaemic men presented with reduced libido and/or
erectile dysfunction, whereas Thorner et _al_. (1977) stated that only
1/17 of their hyperprolactinaemic men presented with the isolated
complaint of impotence. In equating these findings Mi 11er et al.
(1980) state "The disparity between these two groups of patients may be
owing to the confusion arising between impotence and loss of libido".
The present author would like to endorse this point put forward by
Mi 11 er et al_. (1980) and to go further and suggest that erectile
mechanisms per se may not be influenced directly by prolactin levels.
In our case M.J. showed no differences in percentage of morning
erections between bromocriptine and placebo treatments and at no time
during the study did he report experiencing any erectile difficulties.
The present author would propose that the primary behavioural effect of
hyperprolactinaemia in men is one of diminution of sexual appetite,
with erectile failure, when it occurs, being a psychological reaction
to this loss. This hypothesis may account for the contrary data in the
literature concerning sexual problems at presentation in
hyperprolactinaemic men.
Erectile Impotence and Prolactin Levels
A controversy exists regarding the incidence of men complaining
of impotence who have elevated prolactin levels. Rao et _al_. (1981)
claimed that 15/25 men presenting with impotence had elevated prolactin
levels (^.800 mU/1) while Ambrosi _et _al_. (1977) found that 8/30 impotent
men had slightly raised prolactin levels. Miller et_al_. (1980)
reported no significant differences in prolactin levels between
impotent men and controls, and finally Karasek et _al_. (1981) compared
65 impotent men with 18 controls and found the impotent men to have
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mean prolactin levels which were lower than the controls! Obviously
with this contradictory evidence, no conclusions can be made at
present. However, the editorial comment on the Mil 1 er _et _al_. (1980)
paper is worthy of discussion, "This carefully done study shows clearly
that serum prolactin determinations are not cost effective in the
screening of men with erectile dysfunction" (Editorial comment, J.
Urol. p.864, 1980). The present author would rather suggest that in
cases where patients present with loss of sexual interest, a diagnosis
of psychological origin should not be made until an organic cause of
the dysfunction, such as hyperprolactinaemia, has been excluded. A
routine prolactin determination in such individuals would lead to
speedy diagnosis of a sub-group of patients whose sexual dysfunction is
secondary to their elevated prolactin level, and which can be readily
and effectively treated with bromocriptine.
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It is well established that androgen administration to man leads
to a reduction in SHBG levels (Anderson, 1974). Administration of
Testosterone Undecanoate (T.U.), the new orally effective androgen,
leads to (a) a greater proportional elevation of systemic DHT compared
with testosterone (Skakkebaek _et _al_., 1981; Franchimont _et _al_., 1978)
and (b) a highly significant suppression of SHBG levels (Skakkebaek et
al., 1981; Wu et al_., 1982*; Sarris _et _al_., 1977). In these studies,
and the study described in Chapter 4 of this thesis, the method of SHBG
estimation that was used (Anderson et _al_., 1976) is one where DHT is
employed as the ligand, and the amount of exogenous tritiated DHT which
becomes bound to the diluted plasma sample reflects the relative SHRG
binding capacity of the sample. This assay is based on the principle
that SHRG has a higher affinity for binding DHT than other steroids
(Anderson, 1974; Mean et _al_., 1977).
It has been demonstrated that charcoaling of plasma to remove
endogenous steroids prior to assay has no effect on the SHBG values
derived from normal men (Anderson et _al_., 1976; Tulchinsky & Chopra,
1973; Rosner, 1972). However, as DHT levels become elevated following
T.U. administration it is possible that a proportion of the SHBG will
become bound by this circulating DHT, leaving fewer SHBG binding sites
to be filled by the tritiated DHT used in the SHBG assay. Therefore,
it is hypothesised that the degree of reduction in SHBG levels
following T.U. treatment which has recently been reported in the
literature may be an overestimation due to this particular method of






Normal male blood samples were collected from sixteen volunteers
from hospital staff.
As part of a larger series of investigations into the effects of
different androgen preparations and their effects on the endocrinology
of the eugonadal man (described in Chapter 4) four normal men (age
19-40 years, man 29.5 years) were recruited from hospital staff.
Design
After a baseline period of one week, each subject was administered
T.U. at a dosage of 240mg/day for 21 days, capsules being taken in
equal divided doses at 0900, 1300 and 1700 hours. Blood samples were
taken at 0900 and 1300 hours on two days per week throughout the four
week study period, that is prior to and four hours after the morning
dose of T.U.
Hormonal Measurement
The plasma samples were assayed twice to determine SHBG binding;
(a) using the standard procedure of Anderson et _al_. (1976) and (b)
after removal of plasma steroids with Dextran Coated Charcoal (DCC)
treatment. DHT was measured in each of the men receiving T.U.
according to the method of Thorneycroft _et _al_. (1973) after
chromatography on celite columns, as described in Chapter 2.
Charcoaling Procedure
To 0.5 mis plasma, 3.5 mis of assay buffer was added containing
12.5 mg Norit A charcoal and 1.25 mg Dextran T70 (Pharmacia). After an
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incubation with intermittent mixing for 30 minutes at room temperature,
the mixture was centrifuged at 3,000g for 10 minutes. The resultant
supernatant was used directly to determine SHBG binding capacity.
Results
T.U. administration (240mg/day for 21 days) resulted in a highly
significant increase in plasma DHT levels (pretreatment: 1.61 _+ 0.8
nmol DHT/I (mean +S.D.); T.U. treated: 3.77 +_ 2.4 nmol/1; p<0.01,
ANOVAR).
Charcoal treatment of plasma from normal men (n=16) did not affect
the estimated level of SHBG (untreated: 34.3^ 12.3 nmol SHBG/1; DCC
treated: 33.6 +_ 12.4 nmol/1; t=0.425, paired t-test, N.S.). In
contrast DCC treatment resulted in a highly significant increase in the
estimated level of SHBG in plasma samples from men taking T.U.
(untreated: 26.7 + 5.2 nmol SHBG/1; DCC treated: 30.0 +; 6.6 nmol/1;
t=3.05, paired t-test, p<0.01). This effect of DCC treatment is
graphically demonstrated in Fig. II.1.
Piscussion
The results confirm previous findings (Anderson et _al_., 1976;
Tulchinsky and Chopra, 1973; Rosner, 1972) that DCC treatment has no
effect on the estimation of SHBG in plasma from normal men. However,
when samples from men receiving T.U. are assayed, removal of steroids
from plasma by DCC treatment has a highly significant effect on the
SHBG values obtained, in that DCC treatment produces SHBG values which
are significantly higher than those obtained from the same non-charcoal
treated samples. This effect is presumably an indirect result of the











The effect of DCC (charcoal) treatment to remove steroids from
plasma samples prior to SHBG estimations using the DHT-ligand
binding assay method.
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compete with the tritiated assay DHT for binding sites on the protein.
The hypothesis outlined in the introduction suggesting that
elevated DHT level, as a result of the T.U. treatment, act to interfere
with the accuracy of the SHBG assay has thus been confirmed. It is
recommended that samples from men receiving T.U. have steroids removed
from plasma samples prior to SHBG estimation when the DHT-binding
assay is to be used.
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APPENDIX III
AN INVESTIGATION INTO THE RATE OF ABSORPTION OF
TESTOSTERONE UNDECANOATE IN THE EUGONADAL MAN
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INTRODUCTION
The aim of this small study was to investigate the rate of
absorption of testosterone undecanoate (T.U.) in eugonadal men, in
light of recent reports in the literature which suggest that
individuals may vary in the rate at which plasma testosterone levels
peak following T.U. ingestion (Cantrill et aj_. 1983; Schurmeyer et al.
1983).
MATERIALS AND METHODS
Three eugonadal male volunteers aged 46 _+ 13 yrs. agreed to
participate in a study where they were administered T.U. 240 mg/day for
three weeks. T.U. absorption curves were carried out twice, (a) after
taking their first 80 mg dose of T.U. and (b) again following oral
ingestion of 80 mg T.U.; at the end of three weeks treatment with T.U.
240 mg/day. Subjects came into the Edinburgh Royal Infirmary and had
blood samples taken every 30 mins. for seven hours, with 80 mg T.U.
administered after one hour. Blood samples were assayed for
testosterone using the method of Corker Davidson (1978).
RESULTS
The results of the absorption studies are shown in Figure 111.1.
Subject A demonstrated a very gradual and slight elevation in
circulating testosterone levels which appeared to reach a maximum
approximately six hours after ingestion of the T.U. dose.
Interestingly, after three weeks of T.U. administration basal
testosterone levels were lowered, presumably due to decreased
production of endogenous testosterone as a result of the increased
negative feedback effect of the exogenous testosterone administration.





































The effect of oral administration of 80 mg T.U. on circulating
testosterone levels in 3 eugonadal men:
• • after their first dose of T.U.
o o after three weeks treatment with T.U. 240 mg/day.
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the basal condition, but this peak had shifted to four - five hours
following three weeks treatment with T.U. 240 mg/day. Subject C
demonstrated a very slight increase in circulating testosterone levels
one - three hours after the basal T.U. dose, but after three weeks
treatment with T.U. 240 mg/day, plasma testosterone levels were
massively raised (approximately 70 nmol/1) two hours after oral
ingestion of 80 mg T.U.
DISCUSSION
The results of this small study confirm the findings of Cantrill
_et jfl_. (1983) and Schurmeyer et _al_. (1983), i.e. that there is a marked
degree of inter- and intra-individual variation in T.U. absorption
rates. One factor which could possibly contribute to this observed
variation is dietary fat content. As T.U. is fat soluble and is
absorbed via the lymphatic system, changes in the fat content of the
diet could affect the rate of fat absorption and metabolism and hence
affect the rate of absorption of T.U.
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APPENDIX IV
DAILY ASSESSMENT DIARY QUESTION AND ANSWER FORMS
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I Did you awake with an erection this morning? (please tick)
11 Mood Scales
Please place a mark on the mood
scale lines to indicate how you
have felt today. -A mark to the
extreme left means "not at all"
and a mark to the extreme right
means "more so than I can ever
remember"
1. Cheerful and Happy
2. Fatigued and Tired
3. Sociable and Friendly
4. Energetic
5. Tense and Anxious
6. Irritable
7. Changeable or Up and Down
8. Aggressive
9. Depressed and Unhappy
10. Relaxed
III Sexual Activity
If no sexual activity occurred today, please tick box A. If one
of the activities listed below occurred, then enter a number 1-4 in the
appropriate box to indicate how satisfactory you found it.
Activity
M - Masturbation
A.C. - Affectionate intimate contact
with partner, i.e. caressing
genital areas or breasts
S.I. - Sexual Intercourse
Rating
1 = unsatisfactory or even
unpleasant
2 = neither satisfactory nor
unsatisfactory
3 = quite satisfactory
4 = very satisfactory and
pieasant
In the lower box marked Ej, simply insert a tick if you ejaculated on
that occasion.
, please indicate with a tick
(s), partner initiated (p) or
whether the
initiated by




IV A. Please indicate how often you have found yourself thinking sexy
thoughts today by marking the line A in the appropriate place.
A mark to the extreme left means "no sexual thoughts at all" and
a mark to the extreme right means "sexual thoughts frequent".
B. If you have had any sexy thoughts today, please indicate how
often you have found yourself having feelings of sexual
excitement accompanying your thoughts by marking the line R in
the appropriate place. A mark to the extreme left means "sexual
thoughts not associated with feelings of sexual excitement" and
a mark to the extreme right means "sexual thoughts frequently


































1. Frequency of Sexual Activity
"How often have you engaged in sexual intercourse or masturbation in
the last x weeks?"
Record frequency.
2. Level of Sexual Interest
"How often during the past x weeks have you found yourself thinking
about sex with any interest, appetite or desire. Would you say it was
several times a day, a week, once or twice a month, or less?"
0. Thoughts about sex absent, or never associated with desire
1. Rarely (less than once a month)
2. About once a month
3. Less than once a week, more than once a month
4. At least once a week
5. Several times a week
6. At least once a day
3. Negative Feelings During Sexual Contact
"You have made love approximately x times in the last x weeks. On what
proportion of these occasions have you felt, at some stage, any
unpleasant, or anxious, or tense feelings during lovemaking?"
A. 0. Rarely has sexual contact without anxious feelings
1. Unpleasant feelings on about 75% of occasions
2. Unpleasant feelings on about 50% of occasions
3. Unpleasant feelings on about 25% of occasions
4. Rarely has unpleasant feelings
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4. Positive Feelings During Sexual Contact
"What proportion of these occasions did you feel v/ere enjoyable, mainly
pieasurable?"
0. No pleasure from sexual contact at any time
1. Experiences pleasure on about 25% of occasions
2. Experiences pleasure on about 50% of occasions
3. Experiences pleasure on about 75% of occasions
4. Rarely fails to experience pleasure
5. Sexual Arousal (non-genital)
"How often during the past x weeks when you have engaged in sexual
contact have you found yourself getting generally aroused? By that I
mean general excitement, skin or heart rate changes, semi-voluntary




2. On about 25% of occasions
3. On about 50% of occasions
4. On about 75% of occasions
5. Rarely does not become aroused
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B. Strength (show subject rating scale)
0. Calm, no excitement, no general bodily changes
1. Slightly aroused, wanting to continue, little body movement
2. Moderately aroused, feeling excited, less inhibited, moving
body during lovemaking, breathing more rapidly
3. Strongly aroused, very excited, making some noises, moving
involuntarily, not fully aware of things happening around you
4. Highly aroused, out of control of your body, making loud
noises, extremely active bodily movements. Unaware of anything
going on around you, close to "passing out"
6. Orgasm
"On what proportion of occasions have you experienced an orgasm during
1ovemaking?"
A. Frequency
0. Never experiences orgasm in waking state
1. Experiences orgasm on approximately 25% of occasions
2. Experiences orgasm on approximately 50% of occasions
3. Experiences orgasm on approximately 75% of occasions
4. Experiences orgasm on most occasions - rarely not
B. Occasion
0. Never
1. Orgasm in coitus
2. Orgasm during penile stimulation by partner
3. Orgasm during self-stimulation in partner's presence
4. Orgasm during masturbation (alone)
9. Subject does not know if he is orgasmic
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7. Erection
"Do you have any difficulty in getting or keeping an erection
during "1 ovemaking?"
0. Never has an erection whilst awake
1. Only experiences erection on waking
2. Gets erection, but never during sexual contact with partner
3. Gets erection during loveplay, but insufficient for vaginal
intercourse
4. Gets erection sufficient for vaginal intercourse but only v^hen
it is not expected to happen
5. Gets erection sufficient for vaginal intercourse on
approximately 25% of occasions
6. Gets erection sufficient for vaginal intercourse on
approximately 50% of occasions
7. Gets erection sufficient for vaginal intercourse an
approximately 75% of occasions.
8. Rarely unable to have vaginal intercourse
8. Ejaculation - Retarded
"Have there been any occasions when you have been unable to
ejaculate, or it has taken too long to do so?"
0. Ejaculation or emission never occurs
1. Ejaculation or emission only occurs during sleep
2. Ejaculation occurs when awake but not in partner's presence
3. Ejaculation occurs during sexual contact, but not vaginal
intercourse, with difficulty
4. Ejaculation occurs during sexual contact, but not vaginal
intercourse, easily
5. Ejaculation occurs during vaginal intercourse on
approximately 25% of occasions
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6. Ejaculation occurs during vaginal intercourse on
approximately 50% of occasions
7. Ejaculation occurs during vaginal intercourse on most
occasions
9. Premature Ejaculation
"During intercourse, are you able to control your ejaculation as
you would like to?"
0. Always ejaculates before or at time of vaginal entry
1. Nearly always ejaculates within 30 seconds of vaginal entry
2. Can usually delay ejaculation beyond 30 seconds, but not
adequate control
3. Occasionally has adequate control
4. Adequate control on about 25% of occasions
5. Adequate control on about 50% of occasions
6. Adequate control on about 75% of occasions
7. Rarely fails to have adequate control
8. Can be delayed but partner urges rapid conclusion
10. Receptivity
"During the past x weeks, on the occasions that your partner has
initiated sexual contact, how have you responded?"
0. Partner never initiated sexual contact
1. Nearly always refused to continue
2. Responded with a desire to continue on about 25% of
occasions
3. Responded with a desire to continue on about 50% of
occasions
4. Responded with a desire to continue on about 75% of
occasions
5. Nearly always responsed with a desire to continue
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On the following pages are 12 problems. Each problem consists of a
complex design (on the left-hand side of the page) and 5 simple shapes.
One of these shapes is hidden or obtained within the complex design.
Pick out the simple shape and write down its letter in the answer
column. Do the same for all of the problems.
You are allowed ten minutes to complete this test
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